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Summary 
 
Malaria is an important cause of death and illness in children and adults, 
particularly in the tropics. The World Health Organization (WHO) estimated that, 
worldwide, there were 655,000 malaria deaths in 2010, of which 91% were in 
Africa, and 216 million cases, of which 91% were due to Plasmodium falciparum 
(P.falciparum). However, case estimates are particularly uncertain, due to the 
ambiguous definition of a malaria case and methods used for their quantification. 
 
Efficacious interventions against malaria exist, but it is not clear what their full 
impact will be or how they could be most efficiently implemented. A cornerstone 
of malaria strategies is case management, which consists primarily of 
administering drug treatment to cure the disease, and was the focus of this thesis. 
Currently, the aim of most countries in sub-Saharan Africa is to control malaria 
and reduce the disease burden by increasing coverage of effective preventive and 
curative interventions. However, in some places successes in reducing disease 
burden have lead countries to consider whether and how local interruption of 
malaria transmission could be achieved and maintained. In these settings, 
improved surveillance is critical, but it is not clear what it should consist of.  It is 
important to consider the long-term effects of intervention and intervention 
combinations, such as the dynamic effects on population immunity, which are not 
captured within the time frame of intervention trials, and their impact in real health 
systems. Mathematical models can offer guidance in these situations.  
 
In 2006, Smith and colleagues presented individual-based stochastic simulation 
models of the biology and epidemiology of P. falciparum malaria. As part of this 
project, a model for the case management of malaria was developed which 
permitted simulation of the dynamic effects of treatment on transmission. For this 
Summary  
 
x 
thesis, these models were extended to low-transmission settings and used to 
predict the levels of passive case detection and treatment that would be needed to 
prevent local re-establishment of transmission in different settings. We assessed 
the uncertainties in model predictions resulting from stochastic variation and from 
the assumptions in our model formulations. We found that, even at rather low 
levels of receptivity, case management alone could not reliably prevent re-
establishment of P. falciparum malaria transmission in the face of medium to high 
importation rates. Model assumptions regarding rates of decay of natural immunity 
resulted in significantly different odds of transmission re-establishment, 
highlighting the urgent need for research in this area. 
 
We also developed a literature-based estimate of the per-person cost of screening 
an entire population for P.falciparum infection using diagnostic tests. We used this 
cost estimate along with simulation model outputs to analyse the cost-
effectiveness of mass screening and treatment (MSAT) as a burden-reducing 
intervention, relative to the cost-effectiveness of scaling up case management or 
insecticide-treated net (ITN) coverage. We found that MSAT may be a cost-
effective strategy at medium to high transmission levels and at moderate ITN 
coverage. This finding is in contrast to the current focus on MSAT as an 
intervention for low or near-elimination settings. Future analyses comparing the 
cost-effectiveness of case management with that of preventive interventions 
should include both disability and deaths averted (expressed in DALYs) as an 
outcome measure.  The analysis also highlighted the need for alternative measures 
of uncomplicated malaria burden to capture the impact of case management in 
simulation models of its cost-effectiveness. An approach to do this, using data 
available in community surveys, is presented in this thesis. 
 
Finally, the previous case management model was extended to allow a finer-
grained simulation of health systems and a drug action model was integrated to 
Summary  
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allow simulation of the effects of case management on parasite densities. The 
development and parameterization of the new case management model, and its 
potential future uses and limitations, are presented in the last sections of this 
thesis.
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1. Introduction 
 
1.1. Epidemiology of malaria 
 
Malaria results from infection with a protozoan parasite transmitted by species of 
the mosquito genus Anopheles. Five species of the Plasmodium parasite can infect 
humans. The most serious form of the disease, and that which most affects Sub-
Saharan Africa, is caused by Plasmodium falciparum. P. vivax, ovale, and 
malariae cause milder forms of the disease. A fifth species, P. knowlesi, primarily 
affects monkeys but infection in humans has been reported [1].  
 
Malaria parasites, which at this stage are called sporozoites, are inoculated into the 
human host by a feeding female mosquito. After several stages of development 
within the human, sexual-stage parasites, called gametocytes, are taken up by a 
mosquito feeding on an infective person, and the malaria transmission cycle is 
complete. These parasites develop within the mosquito and are injected into 
another person at a subsequent feed. 
 
After a period spent in the liver, the inoculated parasites start to multiply in red 
blood cells of the infected host, often leading to symptoms which include 
headache, fatigue, and muscle and joint aches, usually followed by fever, chills, 
vomiting and worsening malaise. In general, uncomplicated malaria is a curable 
disease if diagnosed and treated promptly and effectively. If left untreated, parasite 
burden continues to increase and may lead to severe malaria, particularly in the 
case of P.falciparum. Severe malaria usually manifests with one or more of the 
following: coma (cerebral malaria), metabolic acidosis, severe anaemia, 
hypoglycaemia, acute renal failure or acute pulmonary oedema. If untreated, 
severe malaria is usually fatal [1].  
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The geographical distribution of malaria has been reduced significantly since 
1900, due both to concerted control efforts and to broader socio-economic 
development.  The estimated area of human malaria risk was reduced by around 
half, from 53% to 27% of the Earth’s land surface [2]. An estimated 3.3 billion 
people were at risk of malaria in 2010, with populations in sub-Saharan Africa 
having the highest risk of acquiring malaria. During 2010, there were 106 
countries in which malaria was considered endemic [3].  
 
Malaria is an important cause of death and illness in children and adults, 
particularly in the tropics. The clinical consequences of malaria infection depend 
to a great extent on the level of the individual’s acquired immunity to malaria. In 
areas of stable transmission, clinical malaria affects primarily children under five 
years of age and pregnant women, as immunity acquired through previous 
exposure renders infections largely asymptomatic in older children and adults. In 
areas of low or unstable transmission, the risk of clinical malaria is high across all 
age groups [1].   
 
Determination of morbidity and mortality from malaria is fraught with difficulty, 
due in part to low health facility use and deficient systems for collection of vital 
statistics. The World Health Organization (WHO) estimated that, worldwide, there 
were 655,000 malaria deaths in 2010, of which 91% were in Africa, and 216 
million cases, of which 91% were due to P. falciparum [3]. Case estimates are 
particularly uncertain, due to the ambiguous definition of a malaria case and 
methods used for their quantification. Using alternative methods, Hay et al 
concluded that there were 451 million cases of P.falciparum malaria globally in 
2007; their distribution is shown in Figure 1.1 below [4]. 
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Figure 1.1 Global clinical burden of P.falciparum in 2007 
(Source:[4]) 
 
Malaria disproportionately affects poor people, who are the least able to afford 
prevention and treatment, and places enormous strain on national resources, those 
of both government and households. There is evidence that it reduces productivity 
and impairs the cognitive development of children, negatively impacting economic 
growth [5]. 
 
1.2.  Case management and integrated malaria control 
 
Effective malaria control requires an integrated approach. Preventive measures 
against malaria include preventive chemotherapy (e.g. intermittent preventive 
treatment (IPT) in pregnancy), prevention of mosquito bites (e.g. distribution of 
insecticide-treated nets (ITNs)), or interventions to reduce the vector population 
(e.g. indoor residual spraying (IRS) of insecticides and ITNs). A malaria vaccine 
has shown promise in Phase 3 clinical trials [6] and could be available as early as 
2015. Curative interventions consist primarily of administering drug treatment 
with the objective of completely eliminating from the body the parasites that 
caused the symptoms. Effective treatment can also curtail malaria transmission by 
reducing the parasite reservoir in the population.  
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Most symptomatic malaria is diagnosed and treated in communities, peripheral 
health facilities, and in informal health structures. Malaria can be diagnosed in one 
of several ways. Historically, most diagnosis of malaria in Africa has been based 
on symptoms, primarily fever. However, the accuracy of malaria diagnosis based 
on clinical symptoms is quite low. Microscopy is an alternative which involves 
collection and staining of a blood smear and examination of the red blood cells 
under a microscope for malarial parasites. Diagnosis using microscopy requires 
laboratory equipment, and its accuracy depends to a great extent on the quality of 
the blood smear and experience of laboratory personnel; therefore, it is only 
available in limited locations in sub-Saharan Africa. The advent of rapid 
diagnostic tests (RDTs) offers the possibility to extend parasite-based diagnosis to 
areas where microscopy is not available. RDTs are immunochromatographic tests, 
often dipsticks, which detect circulating parasite antigens in a finger-prick blood 
sample; they require no electricity or additional equipment and can be performed 
with limited training [7].  
 
In 2010, WHO recommended that all suspected malaria cases receive 
parasitological confirmation where possible [1]. The advantages of confirmatory 
diagnosis are improved management of febrile disease, both parasite-positive and 
parasite-negative, as the correct drugs can be prescribed for the illness; reduction 
of side effects, selection pressure for drug resistance and costs of antimalarial 
drugs; and better public trust in the case management system. The risks of such a 
strategy are primarily that some true malaria cases may be missed due to false-
negative test results and thus antimalarial treatment withheld when it is indicated; 
however, several recent studies suggest that restricting antimalarial treatment to 
parasitologically confirmed cases of malaria is safe, as morbidity and mortality did 
not increase in patients who were not treated with an antimalarial drug following a 
negative RDT result [8;9]. Another concern is whether satisfactory adherence to 
the test result by health workers can be achieved [10]. The use of RDTs also adds 
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costs to case management which may outweigh cost savings from reduced 
antimalarial consumption; these cost savings depend to a large extent on 
prevalence of parasitaemia in the clinical population and adherence of clinicians to 
the test result [11]. 
 
A variety of antimalarial medications are available. Two drugs, chloroquine (CQ) 
and sulfadoxine pyremethamine (SP), were until recently the mainstay of 
treatment for uncomplicated P.falciparum malaria. These drugs, given orally, were 
affordable and widely available [12]. However, resistance to these compounds has 
developed, rendering them ineffective. Fortunately, an alternative exists – 
artemisinin-based combination therapies (ACTs). ACTs are the most effective 
treatments currently available for uncomplicated P.falciparum malaria and in 
2006, the WHO recommended ACTs as the first-line treatment for P.falciparum 
malaria worldwide [13]. ACTs are given orally, and must be taken daily, usually 
for three days. Five ACTs are currently recommended for use by the WHO: 
artemether plus lumefantrine, artesunate plus amodiaquine, artesunate plus 
mefloquine, artesunate plus sulfadoxine-pyrimethamine, and dihydroartemisinin 
plus piperaquine. Artemisinin and its derivatives should not be used as oral 
monotherapies for the treatment of uncomplicated malaria due to their potential to 
foster emergence and spread of drug resistance [1].  
 
Young children and pregnant women are particularly vulnerable to severe malaria. 
Severe malaria requires treatment with parenteral quinine, artesunate or 
artemether, followed by a complete course of an effective ACT as soon as the 
patient is able to take oral medications. Intravenous (IV) artesunate is currently 
preferred to quinine for the treatment of severe malaria in adults and children. If 
complete treatment of severe malaria is not available, WHO recommends that 
patients be given pre-referral treatment with rectal artesunate, quinine 
intramuscular (IM), artesunate IM, or artemether IM and referred immediately to 
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an appropriate facility for further treatment. Intensive nursing care and supportive 
interventions as indicated (such as fluid replacement and blood transfusion) are 
strategies to reduce mortality from severe malaria [1].  
 
1.3. Case management in elimination and pre-elimination settings 
 
Successes in reducing malaria disease burden in some places have placed the 
prospect of eventual malaria eradication back on the international agenda [14] and 
have prompted a consultative process to identify of a set of research and 
development priorities for worldwide eradication of malaria [15]. An estimated 1 
billion people live in areas of low P.falciparum malaria risk, where elimination 
could be epidemiologically feasible [16].  
 
WHO defines malaria elimination as the interruption of local mosquito-borne 
malaria transmission, or zero incidence of locally contracted cases, and eradication 
as the permanent reduction to zero of the worldwide incidence of infection. 
However, the definition of elimination is still shifting, given the recognition that a 
small number of secondary cases will be inevitable as long as eradication has not 
been achieved, since infections will continue to be imported [17]. Malaria 
elimination should also include P.vivax and other strains [15;18], which will be 
more challenging due to the ability of P.vivax to relapse [19]. 
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Figure 1.2 Phases of malaria control through prevention of reintroduction 
(Source: [20]) 
 
WHO has established programme phases and milestones on the path to malaria 
elimination, moving from control, to elimination, to prevention of reintroduction 
(Figure 1.2). The transition from each phase to the next requires a programme re-
orientation and different interventions. In the control phase, the goal is to reduce 
the malaria disease burden to a level at which it is no longer a public health 
problem, through achieving high coverage with current interventions. In the pre-
elimination stage, it is critical to perfect the quality and targeting of case 
management and vector control operations, and to reduce the onward transmission 
from existing cases in residual and new active foci. Establishment of a strong 
surveillance system is essential at this stage. Finally, once elimination is achieved, 
the focus is on preventing onward transmission of imported cases [20].   
 
In programmes which aim at reducing transmission, the WHO recommends that a 
single dose of primaquine (PQ), a drug which kills gametocytes, be added to ACT 
treatment. In addition, PQ is one of few drugs which are effective against 
hypnozoites, or liver-stage parasites, that cause relapse in P.vivax. However, in 
individuals that have glucose-6-phosphate dehydrogenase (G6PD) deficiency, 
1. Introduction  
 
8 
primaquine can cause haemolysis. These risks need to be considered when giving 
PQ; they also make PQ an imperfect tool for mass administration in elimination 
programmes [1].  
 
Where the aim is to interrupt local transmission or prevent its re-establishment, 
prompt and effective diagnosis and treatment of all malaria cases is critical. 
Therefore, in pre-elimination and elimination settings, surveillance is an 
intervention in and of itself which involves detection of infections and includes a 
timely and effective health system response. Although there is consensus around 
the need for improved surveillance for elimination, it is not clear what this 
intervention should consist of.  
 
Individuals can be infected with malaria, and capable of transmitting the disease, 
without showing clinical symptoms. Programmes transitioning to low transmission 
conditions need advice on when and under which conditions it would be optimal 
for them to add active case and infection detection to their response strategies, and 
the effects of combining it with vector control interventions [21;22]. One option 
that is being considered, but has not yet been empirically tested, is mass screening 
and treatment (MSAT), which involves screening the whole population of interest 
and only treating those who test positive, regardless of symptoms. This approach 
could be useful to reduce the parasite reservoir in the targeted area [1]. 
 
Prior to embarking on malaria elimination, countries need to assess the technical, 
operational and financial feasibility of achieving and maintaining interruption of 
malaria transmission. Such an exercise was recently carried out in Zanzibar [14]. 
An understanding of malaria resurgence risks and the interventions that will be 
needed to prevent re-establishment once malaria transmission has been locally 
interrupted,  is of critical importance to malaria control programmes when setting 
objectives and planning malaria strategies. 
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1.4.  Global malaria targets and intervention coverage levels 
 
The Roll Back Malaria (RBM) Partnership comprises hundreds of partners, 
including malaria endemic countries, their bilateral and multilateral development 
partners, the private sector, nongovernmental and community-based organizations, 
foundations, and research and academic institutions. Its overall aim is to provide a 
coordinated global response to the disease. Current RBM Partnership goals and 
targets call for reducing global malaria deaths to near-zero by the end of 2015; 
reducing global malaria cases by 75% from 2000 levels by the end of 2015; and 
eliminating malaria by the end of 2015 in 10 new countries since 2008. These 
targets will be met by achieving and sustaining universal coverage for all 
populations at risk of malaria using locally appropriate interventions for 
prevention and case management, and accelerating the development of 
surveillance systems [23]. 
 
In recent years, disbursements for malaria control have increased dramatically, 
from an estimated US$ 200 million in 2004 to approximately US$ 2 billion in 
2010, much of it from the Global Fund to Fight AIDS, Tuberculosis and Malaria 
(GFATM), the U.S. President’s Malaria Initiative (PMI) and the World Bank [3]. 
This is a great improvement, although it still falls short of the approximately US$ 
6 billion estimated to be needed in 2010 [23].  Concerns about stagnating donor 
aid for malaria have led to calls to donors to sustain funding and to countries to 
find alternative financing strategies to reduce reliance on donor aid [24]. This 
situation also calls for more efficient use of scarce resources [3].  
 
Funding increases have made possible remarkable decreases in morbidity and 
mortality due to P. falciparum malaria in a range of settings across Sub-Saharan 
Africa. These decreases have been achieved primarily by the application of IRS 
and ITNs and the introduction of ACTs [25-27]. Coverage of preventive 
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interventions, primarily ITNs, has increased dramatically in the last decade. It is 
estimated that 50% of all households in sub-Saharan Africa owned at least one net 
in 2011, compared to 3% in 2000 [3]. However, increases in malaria prevalence 
and incidence have been recorded of late, despite increasing intervention coverage, 
in some sub-Saharan African countries ([28],A.Bennett, personal communication).  
This Red Queen phenomenon, in which malaria interventions need to improve 
over time just to maintain the effect on prevalence or incidence they had when first 
introduced, is due to the interaction between transmission and immunity [29]. This 
reality must be considered when planning interventions and predicting their 
impact. Also, in such a situation, increasing access to effective medicines to avert 
severe illness and mortality becomes ever more imperative.  
 
By 2010, ACTs had been adopted as national policy for first-line treatment in 42 
out of 43 malaria-endemic countries in Africa [3]. However, although public 
sector procurement of ACTs has increased greatly in recent years, data suggest 
that case management coverage with effective medicines is still low in many 
countries. The mean proportion of children under five years of age with fever that 
were treated with an antimalarial drug was 32%, and less than 15% received an 
ACT, in 11 of 13 countries for which survey data were available in 2007-2008 
[30].  
 
In 2010, 37 of 43 malaria-endemic countries in the WHO African Region reported 
having adopted a policy of providing parasitological confirmation for all age 
groups.  The percentage of reported suspected malaria cases in the public sector 
receiving a parasitological test has increased from 20% in 2005 to 45% in 2010, 
but overall is still low in most African countries. In 2010, the number of ACTs 
distributed by national malaria control programmes in Africa was more than 
double the number of tests carried out, indicating that a large proportion of the 
suspected malaria cases are treated with ACTs without confirmatory diagnosis [3]. 
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Little data is available about the extent of parasitological testing outside the public 
sector, but in a recent study from six countries, it was found to be less widespread 
in the private than in the public sector [31]. 
 
Limited availability, acceptability and affordability of ACTs are major reasons 
why, following change of national policies to ACTs, use of these drugs remains 
low in many high-burden countries [32]. Problems include high use of the 
informal sector, where first-line drugs, if available, are often unaffordable and 
product quality is low [31;33]; breakdowns in supply chains [34] and poor 
diagnostic and prescribing practices in public health facilities [35;36]; and sub-
optimal patient compliance to treatment regimens [37].   
 
Strategies to improve the quality of malaria case management and increase 
coverage include engaging and training community members and informal 
providers. The Affordable Medicines Facility– malaria (AMFm) is an initiative to 
make subsidized ACTs available in the private sector. Others have focused on 
improving care-seeking and quality of care in the public sector. A systematic 
review of current evidence to identify those provider and user behavior 
interventions that are most effective in improving prompt and effective treatment 
of malaria was published in 2009. It concluded that very little is known about what 
interventions work [38].   
  
1.5.  Integrated models of malaria case management 
 
As noted above, many efficacious interventions against malaria exist, but it is not 
clear what their full impact will be. Intensifying resource constraints make 
increasing the efficient use of resources and demonstration of intervention cost-
effectiveness ever more important. Policy-makers require guidance as they make 
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choices on which interventions to implement in different settings. It is important to 
consider the long-term effects of intervention and intervention combinations, such 
as the dynamic effects on population immunity, which are not captured within the 
time frame of intervention trials, and their impact in real health systems. It is not 
financially or operationally feasible to conduct field studies of a large number of 
interventions and intervention combinations in every possible location, and 
mathematical models can offer guidance in these situations.  
 
For accurate predictions, models of the impact of malaria interventions should 
consider the prevailing level of case management. Effective case management 
modifies disease burden (uncomplicated, severe and death) as well as influencing 
transmission by decreasing host infectivity. In addition, interventions modify the 
demands on the health system, resulting in cost savings from reduced health 
system use that need to be accounted for in cost-effectiveness analysis. Moreover, 
case management is an intervention in its own right and the health and economic 
implications of scaling up coverage are critical questions. 
 
Malaria models in the last few decades of the 20th century focused in large part on 
morbidity and mortality, rather than transmission. These models used empirical 
estimates of the effectiveness of interventions, studies on disease burden, and unit 
costs to quantify morbidity and mortality and likely cost-effectiveness of 
interventions. Impact estimates generally came from field trial results, which 
assess only short-term effects under well-controlled conditions, with no explicit 
consideration of the dynamics of transmission and immunity [39].  
 
To address this gap, in 2006, Smith and colleagues presented individual-based 
stochastic simulation models of the biology and epidemiology of P. falciparum 
malaria, which were developed to study long-term impacts and cost-effectiveness 
of intervention strategies [40] (Figure 1.3). These models simultaneously capture 
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the dynamics of infection, acquired immunity, parasite densities, the consequences 
of infections (morbidity, mortality and infectivity to mosquitoes), the health 
system and economics. The integrated models were formally fitted to numerous 
datasets from different ecologic and epidemiologic settings. As part of this project, 
a model for the case management of malaria was developed  which permitted 
simulation of the dynamic effects of treatment on transmission [41].  
 
 
Figure 1.3 Key causal factors and outcomes in the models of malaria 
epidemiology and interventions. 
Abbreviations: BSV: blood stage vaccine; MSTBV: mosquito stage transmission blocking 
vaccine; PEV: pre-erythrocytic vaccine; ITNs: insecticide treated nets; IRS: indoor residual 
spraying.  
(Source: [39]) 
 
The case management model was appropriate for the purpose of that study, which 
was to predict the impact and cost-effectiveness of a pre-erythrocytic malaria 
vaccine. Case management coverage level was varied resulting in different 
parasitological cure rates, and a model for the costs of case management, based on 
data from Tanzania, was developed. These models, applied to low-transmission 
settings, were also suitable for simulating the effect of varying levels of passive 
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case detection (PCD) on local re-establishment of transmission and were extended 
to enable simulation of MSAT. The results of these studies are described in this 
thesis. 
 
Evaluation of intervention effects requires quantification of the malaria burden in 
the absence and presence of the intervention. Current estimates of uncomplicated 
P.falciparum malaria burden are problematic as a result of imprecise terminology 
and estimation techniques that do not allow for the complexity of the natural 
history of the disease. In practice, and in our models, the definition of a malaria 
episode attempts to capture the illness caused by a single P.falciparum malaria 
infection. However, this definition is deficient as a measure of disease burden 
because the amount of illness that an infection causes depends to a great degree on 
the timing and effectiveness of treatment. The effectiveness of improved case 
management is thus likely to be underestimated if malaria burden is reported in 
this way, and estimates of malaria burden will be biased. Therefore, this thesis 
presents an alternative measure and estimation method for quantifying 
uncomplicated malaria burden using recalls of illness from cross-sectional surveys 
carried out in the community. 
 
Additionally, the Tediosi et al case management model [41] was extended to allow 
a finer-grained simulation of health systems and their impact on coverage for 
predicting the cost-effectiveness of case management interventions, such as 
improved diagnosis. Also, a drug action model was integrated as an additional 
model component to allow simulation of the effects of case management on 
parasite densities, which is needed to simulate sub-curative treatment.  
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Figure 1.4 How interventions lose traction in health systems 
(Source: D. de Savigny) 
 
A number of factors affect the level of case management. Taking the example of 
ACTs in Rufiji, Tanzania, Figure 1.4 shows how apparently very efficacious 
interventions can lose their effectiveness under real-life conditions due to a variety 
of health system factors. Sub-optimal access, targeting accuracy, provider 
compliance and consumer adherence can all reduce the impact of an intervention. 
Evidence suggests that these health system factors are major obstacles to progress 
in a number of malaria endemic countries (unpublished data, INDEPTH 
Effectiveness and Safety Studies of Antimalarials in Africa). Human behaviour is 
shaped by the particular social, economic, cultural and health systems context, 
which can help explain the burden of malaria and inform the design and planning 
of case management interventions [42]. Furthermore, health systems are dynamic, 
and feedback effects of changes to one part of the system can be substantial [43]. 
A P. falciparum malaria case management model, integrated with 
pharmacodynamics, was developed to enable inclusion of these factors.  
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1.6.  Objectives of this thesis 
 
• Use an existing set of models of P.falciparum malaria case management 
and transmission to predict the impact of passive case detection (PCD) and 
treatment (Chapter 2) and cost-effectiveness of mass screening and 
treatment (MSAT) (Chapter 3) in varying transmission and health system 
settings. 
• Present an alternative method for estimation of uncomplicated P.falciparum 
malaria burden (Chapter 4). 
• Develop a model for P.falciparum malaria case management that, when 
integrated with dynamic models of the natural history and transmission of 
the disease, permits simulation of the impact of health system factors on 
treatment coverage, the effects of drug treatment on parasite densities and 
the impact of changes in the case management system (Chapter 5) on 
human behavior and health outcomes. Parameterize this model with data on 
current case management and the costs and effects of alternative delivery 
strategies (Chapter 6).
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2.1.  Abstract 
 
Recent declines in malaria burden in many parts of the world have prompted 
consideration of how interruption of Plasmodium falciparum transmission could 
be maintained, if achieved, and notably whether large-scale vector control could 
be replaced with surveillance. This information is essential for elimination 
feasibility assessments and planning. The risk of re-establishment of transmission 
depends mainly on vectorial capacity (receptivity), likely to rebound once vector 
control is removed, the rate of importation of infections (vulnerability), the 
capacity to detect and treat infections and the level of immunity in infected 
individuals. Timely detection and removal of new infections is likely to be critical 
to prevent re-establishment of transmission. We assess, through mathematical 
modeling and simulation, which levels of case detection and treatment (case 
management) are required to prevent re-establishment of transmission of P. 
falciparum after local interruption of transmission has been achieved, in settings 
with varying receptivity and vulnerability. We find that, even at rather low levels 
of receptivity, case management alone cannot reliably prevent re-establishment of 
P. falciparum malaria transmission in the face of medium to high importation 
rates. Thus, if vector control is to be discontinued, preventing the importations by 
controlling transmission in source areas will generally be necessary for preventing 
reintroduction in such settings, and cannot be substituted by very high levels of 
case management coverage.  
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2.2.  Background 
 
Recent years have seen remarkable decreases in morbidity and mortality due to 
Plasmodium falciparum malaria in a range of settings across Sub-Saharan Africa. 
These decreases have been achieved primarily by the application of effective 
vector control tools, such as indoor residual spraying (IRS) and insecticide-treated 
nets (ITNs), and the introduction of artemisinin combination therapies (ACTs) 
[25-27]. Such successes, which have been made possible by increased donor 
commitment to malaria control, have prompted national health policy-makers and 
their partners to consider how interruption of transmission could be maintained, if 
achieved [14].  
 
Evidence suggests that in some areas with a relatively low endemicity, local 
transmission could be [44], or may already have been [45], interrupted. In such 
places, for example the Kenyan highlands and Zanzibar, vector control was critical 
to bringing about substantial decreases in transmission and continues to be widely 
applied. However, it is likely to be difficult to sustain the will to maintain high 
levels of these interventions, particularly after malaria has ceased to be a public 
health problem [46]. Policy makers will need guidance on when it is safe to scale 
down large-scale vector control operations aimed at achieving interruption of 
transmission and on when to proceed with a policy that relies mostly on 
surveillance. Maintenance of transmission interruption without large-scale vector 
control has been possible in several areas with moderate vectorial capacity, such as 
Reunion Island [47] and Singapore [48]. In other places, such as Mayotte in the 
Comoros Islands, interruption of P. falciparum transmission has proved elusive 
even when it seemed imminent, despite intensive control efforts, and it seems that 
vector control will need to be maintained to prevent resurgence of malaria [49]. 
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Understanding malaria resurgence risks is of critical importance to malaria control 
programmes when setting objectives and planning malaria strategies.  
 
In closed systems, interruption of transmission would be maintained automatically 
once achieved. However, in reality, human populations are connected to each 
other, and as long as local vectors have sufficient capacity to transmit malaria, 
local transmission can be reintroduced through immigration of infected people or 
infective mosquitoes. The greater the magnitude of this immigration, the more 
likely malaria transmission will resurge, all else equal. Evidence indicates that 
current control strategies, even applied at very high coverage, will be insufficient 
to interrupt transmission in much of Sub-Saharan Africa [50], so importation of 
infections will remain a major challenge for the foreseeable future for countries in 
the region which seek to maintain local interruption of transmission. 
 
Health systems which deploy methods for timely detection and removal of 
imported infections can prevent re-establishment of transmission. For instance, 
Singapore, which reported elimination of malaria in 1982, saw a large cluster of 
imported P. falciparum malaria infections in 2005, but local onward transmission 
was prevented through early diagnosis, treatment and screening [51]. Likewise, in 
the United States of America, outbreaks of locally transmitted malaria have been 
detected and contained on several occasions since certification of the country’s 
malaria-free status [52]. 
 
Individuals can be infected with malaria, and capable of transmitting the disease, 
without showing clinical symptoms. Intervention strategies based on case 
detection and treatment target individuals with clinical disease, whereas others, 
such as mass drug administration or screening and treatment, include individuals 
without signs of illness. Although the latter types of approaches may identify a 
larger proportion of infections, screening or diagnosis with methods appropriate 
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for use in the field, notably rapid diagnostic tests or microscopy, may still miss a 
significant number of infections with low or sub-patent parasite densities [53;54]. 
These types of approaches may also be less sustainable long-term, because of their 
costs and organizational requirements, potential to accelerate development of drug 
resistance, and refusal of healthy individuals to participate in repeated screenings 
[55-57]. 
 
After interruption of transmission, individuals’ naturally-acquired immunity will 
decay in the absence of exposure to malaria. Although the mechanisms involved 
are poorly understood, this decay in immunity could be expected to influence re-
establishment of transmission in two ways. First, an infected individual with a 
lower anti-parasite immunity is more likely to be infective to mosquitoes. Second, 
an infected individual with a lowered immunity is more likely to show clinical 
symptoms and thus, given access to appropriate care, to be treated promptly, 
reducing the parasite reservoir. Both these effects need to be considered in 
assessing the likely outcomes of different strategies. 
 
The vectorial capacity is the capacity of the combined vector populations present 
in an area to transmit disease agents, expressed as the potential number of 
inoculations per time unit originating from an infective person with no prior 
immunity. In the absence of major structural environmental or socio-economic 
changes, it is probable that, after withdrawal of large-scale vector control 
operations, the vectorial capacity will revert quickly to the same level as prior to 
control. As the vectorial capacity is difficult to measure, the pre-intervention 
entomological inoculation rate (EIR) may be a good proxy measure for the 
receptivity. 
 
The risk that transmission will re-establish in an area thus depends mainly on the 
local receptivity, or vectorial capacity, the local vulnerability, or infection 
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importation rate (IIR), the capacity to detect and treat infections, and the level of 
immunity in infected individuals. The purpose of this paper is to assess, through 
mathematical modeling and simulation, which levels of case detection and 
treatment (case management) are required to prevent re-establishment of 
transmission of P. falciparum after local interruption of transmission has been 
achieved, in settings with varying receptivity and vulnerability. 
 
2.3. Methods 
 
Individual-based stochastic simulation models of the biology and epidemiology of 
P. falciparum malaria were developed to study long-term impacts and cost-
effectiveness of intervention strategies, and have been described elsewhere 
[39;40]. Briefly, there is a simulated population of humans who are updated at 
each five-day time step via model components representing new infections, 
parasite densities, acquired immunity, uncomplicated and severe episodes, direct 
and indirect malaria mortality, infectiousness to mosquitoes, and case 
management. Simulated immunity to asexual parasites, derived from cumulative 
exposure to both inoculations and parasite densities and maternal immunity, acts 
mainly by controlling parasite densities [58]. The probability of a clinical attack of 
malaria depends on the current parasite density and a pyrogenic threshold [59]. 
Severe malaria comprises two categories of episodes: those that occur as a result 
of overwhelming parasite densities, and those that arise when an uncomplicated 
malaria episode coincides with non-malaria co-morbidity. Mortality can be either 
direct (following severe malaria) or indirect (uncomplicated malaria in conjunction 
with co-morbidity, or during the neonatal period as a result of maternal infection) 
[60]. There is also a model of the dynamics of malaria in mosquitoes [61]. 
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Infectivity of hosts to mosquitoes at a given time point is modeled as a function of 
asexual parasite densities 10, 15 and 20 days previously, allowing for the delay 
resulting from the time course of gametocytemia [62]. Effective treatment 
completely clears parasites by the next time step, ending the infection, while 
ineffective treatment has no impact on asexual parasite densities. By clearing 
asexual parasites, case management renders individuals uninfectious to vectors at 
later time points. Given sufficiently high case management coverage, this lowered 
infectivity translates into a future reduction in EIR. We do not model the effects of 
drug treatment on gametocytemia.  
 
Previous studies using these models [63;64] focused on settings of medium to high 
transmission intensity, for which the model outcomes could be presumed to be 
insensitive to importation of infections. We have now extended these models to 
include importation of infections, and applied them to low and medium 
transmission settings. 
 
We used three different pre-intervention EIRs of two, 20, and 50 infectious bites 
per adult per annum (ibpapa), with a pattern of seasonality as observed in 
Namawala, Tanzania [65]. The infection status and immune status at the start of 
the simulation are determined by exposing the simulated population to the same 
annually recurring pattern of inoculations for a lifetime-long burn-in at the start. 
The level of case management coverage was set at zero during the burn-in period 
in all simulations in order to ensure that the simulated vectorial capacity was the 
same across all scenarios. Case management coverage was changed to the 
appropriate level at the beginning of the main simulation. 
 
We used a population size of 1,000, with underlying demography based on East 
African life tables [66]. In our simulations, to interrupt transmission, we applied 
mass drug administration at 100% coverage and cleared all infections from vector 
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mosquitoes over a period of 30 days at the beginning of year 2. These 
interventions are not intended to be realistic, but were a convenient way to locally 
eliminate malaria in our simulations. Achievement of such high coverage of mass 
drug administration would be nearly impossible in a real-life setting, nor do we 
consider the mechanism by which all infections could be simultaneously cleared 
from vector mosquitoes.  
 
The case management component [41] models a health system using ACT. 
Individuals with uncomplicated malaria were assigned a probability of accessing 
treatment over the next five-day period, expressed as percent coverage, which was 
varied between 0% and 100% at 10% intervals. These probabilities were constant 
over the entire time period of the simulation. We considered only case detection 
and treatment based on clinical symptoms. Compliance to the drug was set at 90% 
[67], and the drug was assumed to be 98% effective. In patients who did not 
comply, the drug was assumed to have an effectiveness of 20%. All severe cases 
were assigned a probability of receiving treatment as an inpatient of 48%, and 
parasites were cleared in all hospitalized cases who survived [41]. 
 
Imported infections were simulated by assigning infections to individuals in the 
population stochastically every 30 days at a constant average rate throughout the 
simulation period. No infected mosquitoes entered the local system. The rate of 
imported infections was Poisson distributed with mean of 0, 0.02, 0.2, 2, or 20 
imported infections per 1,000 persons per annum. These rates compare to 
estimates of infection importation rates in Zanzibar ranging from 2 to 8 infections 
per 1,000 inhabitants per annum in 2008 [14;68] and cases reported as imported in 
South Africa from 1981 to 1999 ranging from about 0.02 to about 0.17 per 1,000 
population [69]. The IIR of 0 was included as a reference scenario to check that 
transmission had indeed been interrupted by mass drug administration and clearing 
infections from vectors.  
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We evaluated the impact of all possible combinations of these scenarios on the 
number of malaria episodes expected over the last 14.75 years of the simulations. 
For each IIR, we chose a threshold number of cases over the 14.75-year period 
after interruption of transmission, above which we considered transmission to have 
re-established. This threshold was calculated by taking the 97.5 percentile of the 
Poisson distribution of the number of imported cases that would be expected over 
the period, and multiplying this by 3, thus allowing each imported infection to give 
rise to a maximum of 2 secondary infections before classifying the simulation as 
one where transmission was re-established. The reason for using the 97.5 
percentile was to establish a very generous threshold for re-establishment. If 
malaria is considered to have re-established under these conditions, it is not likely 
to be kept out under more strict definitions.  
 
We assessed the uncertainties in model predictions resulting from stochastic 
variation and from the assumptions in our model formulations by using 100 
different seeds for the random number generator and an ensemble of 14 model 
variants as described in Table 2.1. The ensemble consists of a base model, used in 
previous publications [63;64], and thirteen variants on that model, with each one 
representing a different set of assumptions about malaria transmission and 
epidemiology. The motivation for using model ensembles is to assess how our 
understanding of a particular phenomenon is affected by uncertainty in model 
assumptions. Our ensemble of stochastic simulation models of malaria 
epidemiology incorporates different assumptions about decay of immunity and 
about heterogeneities in exposure, co-morbidity and access to treatment [70].  
 
While the base model assumes that, in a given transmission setting, entomological 
exposure depends only on age, the model variants for heterogeneities in exposure 
include random variation in the availability of the human host to mosquitoes. 
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Thus, the expected number of entomological inoculations is additionally a function 
both of the individual and of log-normal noise. Three different parameterisations 
were considered - R0063 assigns most variation to be inter-host, R0068 assigns the 
variation predominantly to within host variation, and R0065 is intermediate.  
 
The model for natural immunity used in the base model, developed primarily for 
simulating the epidemiology of malaria in endemic settings, does not allow for any 
decay of immunity in the absence of exposure. To allow for such decay, the base 
model was extended by two alternative algorithms. In both cases, the model 
variants were parameterised so that in the absence of new exposure, the decayed 
value is some fixed proportion of that at the previous five-day time step. The half 
life of the decay is either fixed at 10 or 1,000 years or estimated during the model 
fitting process.  
 
Finally, the model variants for heterogeneities in co-morbidity and access to 
treatment assign each simulated individual a status for each of the two kinds of 
heterogeneity at birth, which they carry throughout their life, structured in each 
case so that 50% of the population are assigned to each of the high and low status 
categories, with the values in the base model multiplied by either 1.8 or 0.2. Two 
of the model variants simulate these heterogeneities singly, while the third 
simulates both, where they are assigned to individuals independently of each other. 
  
Analyses were conducted using R statistical software version 2.11.1 [71].  
 
2.4. Results 
 
Figure 2.1 illustrates the use of model ensembles to simulate clinical episodes over 
time, in a setting with a pre-intervention EIR of 2 ibpapa. Model variant medians 
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for simulated incidence post-intervention were higher at 20% (a) case management 
coverage than at 80% (b), indicating the effect of higher case management 
coverage in reducing transmission. In these scenarios, where IIR=2 per 1,000 
persons per annum, the higher case management coverage level seems to prevent 
the resumption of transmission in most simulations, in contrast to the lower case 
management coverage level. There was a much larger variation among model 
variant outcomes post-intervention at the lower case management coverage level. 
 
Figure 2.1 Simulated clinical incidence by model variant with 20% (a) and 
80% (b) case management coverage 
IIR=2 per 1,000 persons per annum, and pre-intervention EIR=2 ibpapa.  
Black lines: model variant medians; gray shading: 95% probability interval around each median. 
Results are smoothed to remove the effect of seasonality. The arrow indicates the time point 
where transmission is interrupted with mass drug administration and clearing infections from 
vectors. 
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Figure 2.2 depicts the proportion of model variant simulations in which 
transmission remained interrupted as a function of case management coverage at 
different IIRs. In the lowest transmission setting with a pre-intervention EIR of 2 
ibpapa (Figure 2.2a), there was a positive relationship between case management 
coverage and the proportion of simulations in which transmission remained 
interrupted for all IIR levels except at 0.02 imported infections per 1,000 persons 
per annum. At IIR=0.2 per 1,000 persons per annum, 60% case management 
coverage resulted in maintenance of interruption of transmission in 86% of 
simulations of the median model variant. At IIR=2 and 20 per 1,000 persons per 
annum, predicted success was much lower; at IIR=2, at 60% case management 
coverage, transmission remained interrupted in only 66% of simulations of the 
median model variant, while at IIR=20, transmission remained interrupted in only 
15% of simulations of the median model variant at 60% case management 
coverage. At IIR=0.2 and 2 per 1,000 persons per annum, most of the benefits 
from increasing case management coverage seem to be gained at lower coverage 
levels; at 70% case management coverage, the imaginary curve through the 
median model variant results flattens off . As seen from the boxplot, variation in 
probability of success over the model variants was relatively large at the IIR levels 
2.0 and 20. At the lowest IIR, 0.02 per 1,000 persons per annum, case 
management coverage level had little effect on the probability of success; 
however, at this low IIR level, the probability that no infections were imported 
during the observation period in a simulation was 74%. At IIR=0.2 per 1,000 
population per annum, this probability was approximately 5%.  
 
In the higher transmission settings (Figures 2.2b and 2.2c), at IIR= 0.2 per 1,000 
persons per annum, higher case management coverage slightly increased the 
proportion success in preventing re-establishment, but even with perfect passive 
case detection, transmission returned in at least half of simulations of the median 
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model variant. In these settings, at IIR= 2 or 20 per 1,000 persons per annum, 
interruption of transmission was never, or almost never, maintained.  
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Figure 2.2 Boxplot of the proportion of simulations in which transmission 
remains interrupted by model variant at a pre-intervention EIR of 2 ibpapa 
(a), 20 ibpapa (b) and 50 ibpapa (c).  
Fill colours: white: Infection importation rate (IIR) = 0.02, light gray: IIR = 0.2, medium gray: 
IIR = 2, dark gray: IIR = 20 
Boxplot shows the median, maximum, minimum, and interquartile ranges. 
 
Figure 2.2 primarily serves to show the trends among case management coverage, 
IIR, and the proportion of simulations in which transmission remains interrupted, 
and where most model variants agree and where there is a wider range in 
predictions. The median proportion of simulations in which transmission remains 
interrupted may be biased and should not be over-interpreted, as it is unclear how 
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to weight the fourteen model variants to allow for plausibility, goodness of fit 
and correlations both in structure and parameter values. 
 
In general, at low case management coverage, the model variants for 
heterogeneities in exposure resulted in a higher proportion of simulations in which 
transmission remained interrupted. At medium to high case management coverage, 
it was the decay of immunity model variants which resulted in a higher proportion. 
The model variants with heterogeneities in access to treatment usually resulted in a 
lower proportion of simulations in which transmission remained interrupted.  
 
For each pre-intervention EIR, we fitted a logistic regression model to the 
probability of success in preventing re-establishment of transmission, with 
covariates in case management coverage, the natural logarithm of the infection 
importation rate, and each of the fourteen model variants as categorical variables. 
Backward stepwise regression showed that removing any of the independent 
variables from the model was found to significantly decrease the model’s 
goodness of fit at the 95% confidence level, so all covariates were kept. We then 
tested for interaction between case management coverage and the natural 
logarithm of the infection importation rate. From the likelihood ratio test, the 
interaction term was found to be significant (p<0.001), although it has only a slight 
effect.  
 
The fitted relationships between case management coverage and the probability 
that transmission remains interrupted, for the base model and at different IIRs, are 
shown in Figure 2.3 (EIR = 2 ibpapa) and Figure 2.4 (EIR = 20 ibpapa). The 
figure at EIR = 50 ibpapa looks very similar to that at EIR = 20 ibpapa and is not 
shown. At EIR = 2 ibpapa, the odds ratio that transmission remains interrupted 
associated with a tenfold decrease in IIR is 16.6 (95% ci: 15.6, 17.6). At EIR = 20 
ibpapa, the corresponding odds ratio is 23.7 (95% ci: 21.5, 26.3).  
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Figure 2.3 Best-fitting regression model predictions for the probability that 
transmission remains interrupted, as a function of case management coverage 
and infection importation rate, at pre-intervention EIR of 2, using the base 
model 
Thin line: IIR=20, Dotted line: IIR= 2, Dashed line: IIR= 0.2, Thick line: IIR=0.02 imported 
infections per 1,000 per annum. 
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Figure 2.4 Best-fitting regression model predictions for the probability that 
transmission remains interrupted, as a function of case management coverage 
and infection importation rate, at pre-intervention EIR of 20, using the base 
model 
Thin line: IIR=20, Dotted line: IIR= 2, Dashed line: IIR= 0.2, Thick line: IIR=0.02 imported 
infections per 1,000 per annum. 
 
Table 2.1 shows that, at a pre-intervention EIR of 2 ibpapa, the model variants 
which included decay of immunity with a shorter half-life were found to have a 
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relatively large positive effect on the odds that transmission remained interrupted 
relative to the base model. By contrast, model variants R0674, which assumes 
uncorrelated heterogeneity in co-morbidity and access to treatment, and R0678, 
which assumes heterogeneity in access to treatment, were found to have a 
relatively large negative effect on the odds that transmission remained interrupted 
relative to the base model.  
 
At the higher pre-intervention EIRs of 20 ibpapa and 50 ibpapa (not shown), the 
model variants had much smaller effects on the odds that transmission remained 
interrupted relative to the base model. This is evidenced by the much narrower 
range in the odds ratios. Moreover, in these transmission settings, it was the model 
variants that assumed heterogeneity in entomological exposure that had the largest 
positive effects on the odds that transmission remained interrupted.  
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Table 2.1 Descriptions of model variants and predicted odds ratio that transmission remains interrupted for each 
model variant relative to the base model, at pre-intervention EIR of 2 and 20 ibpapa. 
Model 
identifier 
Description Half-life of decay (years) odds 
ratio, 
EIR=2 
95% 
confidence 
interval 
odds 
ratio, 
EIR= 20 
95%  
confidence 
interval 
  
1/2
ln(2)
b
t
α
−
=  1/2
ln(2)
c
t
α
−
=  
   
   
R0125 Fixed decay in immune proxies ∞ 10 a 4.57 4.02 5.21 1.47 1.27 1.71 
R0132 Estimation of decay in immune proxies ∞ 14 4.31 3.79 4.90 1.29 1.11 1.49 
R0115 Fixed decay in effective cumulative exposure 10 a ∞ 4.17 3.67 4.74 1.29 1.11 1.50 
R0133 Estimation of both decay parameters 250 19 3.89 3.42 4.42 1.37 1.18 1.59 
R0131 Estimation of decay in effective cumulative 
exposure 
1187 ∞ 2.42 2.14 2.74 1.36 1.17 1.58 
R0065 Mass action:             varies between and within 
hosts 
∞ ∞ 2.18 1.93 2.47 1.89 1.63 2.20 
R0670 Heterogeneity in susceptibility to comorbidity ∞ ∞ 2.03 1.80 2.30 1.22 1.05 1.41 
R0063 Mass action:            varies mainly between hosts ∞ ∞ 1.86 1.64 2.10 2.04 1.75 2.37 
R0121 Fixed decay in immune proxies ∞ 1000a 1.63 1.45 1.84 1.18 1.02 1.37 
R0068 Mass action:             varies mainly within hosts ∞ ∞ 1.44 1.27 1.62 1.53 1.32 1.78 
R0111 Fixed decay in effective cumulative exposure 1000a ∞ 1.30 1.15 1.46 1.14 0.98 1.33 
R0674 Uncorrelated heterogeneities in access to 
treatment and susceptibility to comorbidity 
∞ ∞ 0.63 0.56 0.71 1.04 0.89 1.21 
R0678 Heterogeneity in access to treatment ∞ ∞ 0.56 0.50 0.63 0.87 0.75 1.02 
Ea (i,t) : the expected number of entomological inoculations, adjusted for age and individual factors . 
α b : decay applied to the two measures of the effective cumulative exposure. 
α c : decay applied to the function representing the immune status. 
 a
 These parameters were fixed, in other models the decay parameters were estimated. Decays shorter than the shortest fixed values gave 
unacceptable fits to the data. 
( , )
a
E i t
( , )
a
E i t
( , )
a
E i t
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2.5. Discussion 
 
Although maintaining interruption of malaria transmission would bring benefits, it 
would also require reorientation of programmatic strategies, significant long term 
financial commitments, and major operational preparations. Therefore, the 
decision to pursue transmission interruption and prevention of re-establishment of 
transmission is not trivial. Prior to embarking on such a course a thorough 
evaluation of the likelihood of success, and what will be required to maintain it, is 
desirable.  
 
Early detection and treatment of infections is critical to prevent onward 
transmission in the face of renewed vectorial capacity. However, our findings also 
suggest that, even where vectorial capacity is low, maintaining interruption of 
transmission is likely to require continued vector control at or above moderate 
levels of vulnerability (IIRs on the order of 0.2 per 1,000 population per annum or 
higher). Even perfect passive case detection will fail to identify imported 
asymptomatic infections, which under these circumstances will be sufficiently 
numerous to result in a considerable probability of resumption of transmission. 
The chances that an imported infection is asymptomatic will depend on the 
immunity profile of the immigrant/visitor, which in these analyses was assumed to 
match that of the simulated population.  
 
Statistical analysis revealed that modeled outcomes were sensitive to several of the 
model assumptions. At low pre-intervention EIR levels, decay of natural immunity 
is an important driver of whether or not interruption of P.falciparum malaria 
transmission can be maintained. This is because, as immunity decays, more 
infections are likely to be symptomatic, and therefore detectable and treatable by 
the passive case management system. Also, in the base model, individuals are 
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assumed to have homogenous access to treatment and to be at similar risk of co-
morbidity. In this analysis, introducing heterogeneities in these factors increased 
the risk of re-establishment. These findings suggest that areas with these kinds of 
differentials among population sub-groups may face specific challenges in 
maintaining transmission interruption.  
 
In higher transmission settings, variations in these assumptions did not have as 
large an effect on the odds that transmission remained interrupted. At higher pre-
intervention EIRs, the vectorial capacity is the dominant determinant of re-
establishment. In these settings, immunity was much higher post-interruption than 
in the low-transmission setting, and thus even with decay, a large number of 
infections remain asymptomatic.   
 
The perhaps counter-intuitive finding that the models assuming heterogeneity in 
force of infection had positive effects on the odds that transmission remained 
interrupted could be explained in several ways. First, if infections are concentrated 
in the same people, a given level of case management coverage will result in a 
higher proportion of infections being treated than if infections are spread more 
evenly across the population (because a single treatment will terminate all co-
infections in that host). Second, this finding may be due to the way we have 
constructed our outcome variable. Where certain individuals have higher 
availability to mosquitoes than others, this may result in a lower number of 
episodes (as multiple infections can give rise to only one episode at a time). 
 
There are several factors that are likely to affect the probability of success in 
preventing re-establishment which were not considered here. Characteristics of the 
population under consideration, for example the size of the population and the 
degree of interaction between individuals, were not studied. Interruption of 
transmission is easier to achieve and maintain in smaller populations than in large 
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ones, ceteris paribus, as re-introduction of transmission is an infrequent, and 
hence highly stochastic, event. Our results, using a population of 1,000, therefore, 
offer an optimistic estimate of the probability for prevention of re-establishment, 
and make predictions at very low IIRs problematic. Also, our models assume 
perfect mixing within each mosquito population across all humans. Patch models 
may offer a way forward to more accurately capture the phenomena of 
heterogeneity in interactions, as well as spatial heterogeneity in transmission.  
 
The probability that transmission remains interrupted or conversely, re-establishes, 
is also likely a function of geographical and temporal heterogeneities in 
importation of infections. We assume that imported infections mix uniformly with 
the simulated population and enter at a constant rate; however, in reality, 
individuals bringing malaria infections into an area may concentrate in a particular 
place. If this effect is important, we expect transmission to spread more slowly, 
and to be easier to arrest, provided that such foci can be located. Also, rates of case 
importation may not be constant over time. Our models could incorporate this, but 
refining these assumptions would require temporal data on human migration 
patterns. This is an important area of further research [49;72].  
 
Our rapid method of interrupting transmission likely had an effect on chances of 
maintaining interruption, as even with the model variants which capture immunity 
decay, immunity levels remained relatively high in the population for a certain 
time. In reality, interruption of transmission would take longer and immunity 
would be lower upon its achievement, resulting in a higher proportion of 
secondary (locally transmitted) infections manifesting clinically. The level of 
immunity in the population at the time of interruption, which drives the proportion 
of infections in the population which are asymptomatic, is an important 
determinant of the probability of success in preventing re-establishment. This may 
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lead our models to overestimate the probability of re-establishment of 
transmission. 
 
On the other hand, our method of importing infections may have led us to 
underestimate the probability of re-establishment of transmission. We assign 
imported infections randomly to individuals in the simulated population, who are 
exposed to the same transmission and therefore have the same immunity profile. 
However, it is likely that transmission in source areas is substantially higher than 
in the simulated population, and thus individuals importing infections would be 
expected to have higher immunity. Our current models do not offer the possibility 
to simulate this immunity differential readily; however, if this were the case we 
could expect a lower probability that imported infections are symptomatic and 
therefore detectable by the case management system.  
 
There is a need to extend these models to capture other features of real health 
systems [73-75]. It would be important to assess the importance of the capacity of 
the system to react to outbreaks by temporarily improving case management 
coverage or by implementing emergency vector control operations when outbreaks 
occur. In countries which succeed in actively interrupting transmission, the health 
system will likely have strong surveillance and epidemic response capacity, which 
could contain outbreaks and reduce local transmission again to zero. Screening of 
potential asymptomatic carriers would likely be a part of this response and was not 
modeled here. It is also possible that, following interruption of transmission, the 
case management system would be strengthened to enable more intensive routine 
detection of cases. Under these conditions, interruption of transmission would be 
more likely to be maintained, but probability of success would, again, depend to a 
great degree on the immunity profile of the population concerned.  
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The case management model offers a very simple description of the health system 
and does not consider diagnosis, provider practices or patient behaviour which 
could alter coverage. For a better understanding of the role of case management in 
achievement and maintenance of transmission interruption, a more realistic case 
management model is needed. 
 
Thus, there remains a significant unfinished research agenda to increase the 
understanding of the relationship between case management coverage, 
vulnerability, receptivity and prevention of re-establishment of P. falciparum 
malaria transmission. Nevertheless, we believe that the results described here 
provide important input into the discussions surrounding the feasibility of 
maintaining interruption of malaria transmission in various contexts.  
 
2.6. Conclusion 
 
Even at rather low levels of receptivity, case management alone cannot reliably 
prevent re-establishment of P. falciparum malaria transmission in the face of 
medium to high importation rates, even if all clinical cases are treated. Thus, if 
vector control is to be discontinued, preventing the importations by controlling 
transmission in areas from which imported cases originate is a precondition for 
preventing reintroduction in such settings. Achieving very high levels of case 
management coverage does not appear to substitute for this. Alternatively, a 
system of active surveillance to prevent importation, including screening of all 
potential carriers at points of entry, could be considered, but in most areas this 
strategy is not likely to be feasible.  
 
Model variants assuming decay of natural immunity resulted in lower odds of 
transmission re-establishment, relative to the base model that assumed no such 
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decay. These findings highlight the urgent need for research into the mechanisms 
and rate at which naturally- acquired immunity to P.falciparum malaria decays in 
the absence of exposure, to inform current and future malaria elimination efforts. 
Certain characteristics of the population, in particular heterogeneities in co-
morbidity and access to treatment, also appeared to influence simulated probability 
of success. There is a need for further analysis of effects of different population 
sizes and patterns of within-population interaction and of geographical and 
temporal heterogeneity of imported infection rates.  
 
A key issue that has not been addressed here is the related economic analysis. 
Interruption of transmission and prevention of re-establishment, whether through 
increased case management coverage or other strategies, will carry significant 
costs, which need to be evaluated together with appropriate outcome measures and 
compared to other possible uses of funds to optimize resource use. A recent study 
found that malaria elimination is unlikely to be cost-saving in most cases, even 
over a time frame of 50 years, but may bring additional benefits that would make 
it a worthy investment [76].  
 
The costs and effects of screening asymptomatic individuals, either in response to 
a detected case or indiscriminately in at-risk populations, will likely need to be 
considered in addition to case management. Data from field studies are needed to 
determine the most cost-effective surveillance and response models in different 
settings and to inform future modeling efforts [22]. Importantly, the costs of 
surveillance are unlikely to increase linearly with coverage; isolated or 
marginalized populations are usually the last to be reached and the most expensive 
to serve, resulting in significant diseconomies of scale at the higher coverage 
levels. In addition, the appropriate outcome measure to use in settings where 
malaria burden is already very low, as would be the case in places which are close 
to or have recently achieved elimination, is unclear. Further methodological 
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developments to quantify the benefits of transmission interruption are needed to 
apply economic evaluation usefully.  
 
The results of these analyses need to be taken into account in global and national 
discourse and in feasibility assessments of and planning for elimination of malaria 
[14]. Failure to plan for prevention of re-establishment could result in loss of the 
last decade’s tremendous gains towards rolling back malaria.  
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3.1. Abstract  
 
Background 
Past experience and modelling suggest that, in most cases, mass treatment 
strategies are not likely to succeed in interrupting Plasmodium falciparum malaria 
transmission. However, this does not preclude their use to reduce disease burden. 
Mass screening and treatment (MSAT) is preferred to mass drug administration 
(MDA), as the latter involves massive over-use of drugs. This paper reports 
simulations of the incremental cost-effectiveness of well-conducted MSAT 
campaigns as a strategy for P. falciparum malaria disease-burden reduction in 
settings with varying receptivity (ability of the combined vector population in a 
setting to transmit disease) and access to case management. 
 
Methods 
MSAT incremental cost-effectiveness ratios (ICERs) were estimated in different 
sub-Saharan African settings using simulation models of the dynamics of malaria 
and a literature-based MSAT cost estimate. Imported infections were simulated at 
a rate of two per 1,000 population per annum. These estimates were compared to 
the ICERs of scaling up case management or insecticide-treated net (ITN) 
coverage in each baseline health system, in the absence of MSAT.  
 
Results 
MSAT averted most episodes, and resulted in the lowest ICERs, in settings with a 
moderate level of disease burden. At a low pre-intervention entomological 
inoculation rate (EIR) of two infectious bites per adult per annum (IBPAPA) 
MSAT was never more cost-effective than scaling up ITNs or case management 
coverage. However, at pre-intervention entomological inoculation rates (EIRs) of 
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20 and 50 IBPAPA and ITN coverage levels of 40 or 60%, respectively, the ICER 
of MSAT was similar to that of scaling up ITN coverage further.  
 
Conclusions 
In all the transmission settings considered, achieving a minimal level of ITN 
coverage is a “best buy”. At low transmission, MSAT probably is not worth 
considering. Instead, MSAT may be suitable at medium to high levels of 
transmission and at moderate ITN coverage. If undertaken as a burden-reducing 
intervention, MSAT should be continued indefinitely and should complement, not 
replace, case management and vector control interventions.  
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3.2. Background 
 
Mass drug administration (MDA), where the entire population is treated with anti-
malarial drugs, was tried on a number of occasions during the malaria eradication 
efforts of the last century, and sporadically since then. Mass screening and 
treatment (MSAT), which involves screening the whole population of interest and 
only treating those who test positive, has not been empirically tested, although an 
upcoming clinical trial in Burkina Faso aims to evaluate it [77]. Another variant 
proposed is “focal screening and treatment”, which involves screening all people 
living in a defined geographical area [78]. This approach is now being used in an 
attempt to contain emerging artemisinin-resistant falciparum malaria in western 
Cambodia [79]. 
 
Unfortunately, MDA has proved disappointing in most instances for the objective 
of interrupting transmission. A review of experiences with anti-malarial drug mass 
administrations was carried out in 2003; these projects undertook MDA with 
varying frequencies and numbers of rounds [80]. The authors found that MDA has 
almost always failed to interrupt transmission, although it often led to a marked 
reduction in parasite prevalence and probably a transient effect on malaria-related 
morbidity and mortality. The authors concluded that direct MDA with a full 
therapeutic drug dose might have a role to play in circumstances such as the 
control of epidemics, or in relatively low transmission areas or in those with a 
short transmission season. However, it is not likely to have a sustained effect in 
most malaria-endemic areas.  
 
These discouraging findings are echoed by several recent model-based 
investigations of MDA and MSAT. Mathematical malaria transmission models are 
useful tools to synthesize data and make predictions about intervention impact 
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where trials are not feasible. One study found that only in areas with low 
transmission of less than 10 infectious bites per adult per annum (IBPAPA) could 
parasite prevalence be reduced to less than one percent with annual MSAT and 
insecticide-treated nets (ITNs) at 80% coverage [81]. Additional investigations of 
the impact of MDA and MSAT using different drugs, at different timings, and 
with correlation in probability of participating in successive rounds, in varying 
initial endemicity settings, were undertaken using a similar model [82]. 
Transmission was found to rebound to previous levels within about two years after 
one round of the intervention in a low-endemicity setting. However, repeating the 
intervention or combining it with vector control enhanced and extended the 
impact. 
 
Even if it could be achieved, a major challenge to maintaining local transmission 
interruption would be the importation of Plasmodium falciparum infections. 
Human populations are connected to each other, and as long as local vectors have 
sufficient capacity to transmit malaria, local transmission can be sustained or re-
introduced through immigration of infected people or infective mosquitoes. A 
recent modelling study [83] found that, even at relatively low receptivity levels, 
case management alone could not reliably prevent P. falciparum transmission re-
establishment in the face of medium to high importation rates. These findings 
suggest that achieving and maintaining local transmission interruption without 
large-scale vector control across most of sub-Saharan Africa will be difficult for 
the foreseeable future. 
 
Although MDA or MSAT rounds can be expected to have only an ephemeral 
effect on prevalence, it may be a viable strategy to reduce malaria disease burden 
if carried out regularly. Intermittent preventive treatment in pregnant women, 
children and infants are targeted, continuous MDA forms that have been found to 
reduce burden in specific population groups [84;85]. To evaluate the potential role 
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of MDA or MSAT for burden reduction, it is important to consider both the 
expected effectiveness and intervention cost. 
 
The effectiveness of both MDA and MSAT strategies may be compromised by the 
difficulty of achieving sufficient coverage due to refusal of populations to 
participate in repeated screenings and/or treatments and population movements. A 
further disadvantage of MSAT is that sub-patent parasitaemia will be missed, and 
if this contributes significantly to the infectious reservoir, the intervention effect 
will be limited. Experience indicates that the success of these approaches is 
predicated on the ability to deploy them multiple times at high coverage levels and 
together with vector control measures [78]. Mass treatment is thought likely to be 
more effective if introduced following reductions in transmission due to other 
interventions, such as distribution of ITNs and indoor residual spraying (IRS) [86]. 
 
Due to concerns about the potential for MDA to contribute to the spread of drug 
resistance [80], MSAT is currently preferred to MDA, as it avoids the massive 
over-use of drugs [57]. However, it is bound to be more difficult and costly to 
organize and implement than MDA. There is no known evaluation to date of the 
possible cost-effectiveness of MSAT for reducing malaria disease burden.  
 
This paper’s objective is to predict the incremental cost-effectiveness of well-
conducted MSAT campaigns as a strategy for P. falciparum malaria disease-
burden reduction in sub-Saharan African settings with varying receptivity (ability 
of the combined vector population in a setting to transmit disease) and access to 
case management, compared to the same setting in the absence of MSAT.  
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3.3. Methods 
 
Simulation model 
 
A dynamic, individual-based, stochastic model of malaria biology and 
epidemiology was used. The model corresponds to the base model in an ensemble 
of stochastic simulation models that has been developed recently [70]. Briefly, a 
simulated human population was updated at each five-day time step via model 
components representing new infections, parasite densities, acquired immunity, 
uncomplicated and severe episodes, direct and indirect malaria mortality, 
infectiousness to mosquitoes, and case management. Simulated immunity to 
asexual parasites, derived from cumulative exposure to both inoculations and 
blood stage parasites and transferred maternal immunity, acted mainly by 
controlling parasite densities [58]. The probability of a clinical malaria attack in a 
simulated individual depended on the current parasite density and a pyrogenic 
threshold [59]. Severe malaria comprised two episode categories: those that 
occurred as a result of overwhelming parasite densities, and those that arose when 
an uncomplicated malaria episode coincided with non-malaria co-morbidity. 
Mortality could be either direct (following severe malaria) or indirect 
(uncomplicated malaria in conjunction with co-morbidity, or during the neonatal 
period as a result of maternal infection) [87]. Malaria dynamics in mosquitoes was 
also modelled [61;88]. 
 
Transmission settings 
 
The vectorial capacity, or receptivity, is the ability of the combined vector 
population in a setting to transmit disease, expressed as the potential number of 
inoculations per time unit originating from one infective person with no prior 
immunity. A setting has a baseline vectorial capacity, which can be altered by 
interventions undertaken by the health system, such as vector control. The 
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effectiveness of MDA and MSAT in terms of burden reduction is likely related to 
the actual vectorial capacity (the baseline modified by interventions), which co-
determines, together with immunity, the parasitaemia prevalence in the population 
and the proportion of asymptomatic infections. An infected individual with lower 
immunity is more likely to show clinical symptoms and thus, given access to 
appropriate care, to be treated promptly by the health system, reducing the parasite 
reservoir to be addressed by MSAT. 
 
The pre-intervention entomological inoculation rate (EIR) was used as a good 
proxy for the baseline receptivity. Three pre-intervention EIRs of two, 20 and 50 
IBPAPA were simulated, with a seasonality pattern as observed in Namawala, 
Tanzania [65]. These EIRs correspond to parasite prevalence in children under 
five years of age of approximately 16%, 50%, and 62% [58]. The infection status 
and immune status at the start of the simulation were determined by exposing the 
simulated population to the same annually recurring pattern of inoculations for a 
lifetime-long burn-in at the start. The case management coverage level was set at 
zero during the burn-in period in all simulations in order to ensure that the fitted 
vectorial capacity was the same across all scenarios. Case management coverage 
was changed to the appropriate level at the beginning of the main simulation. 
 
ITNs were distributed at 40%, 60% or 80% population coverage at the beginning 
of years 1, 4, 7 and 10. Imported infections were assigned to individuals in the 
population via a Poisson process every 30 days at a constant average rate of two 
imported infections per 1,000 population per year throughout the simulation 
period. This rate was chosen because it is on the lower end of the infection 
importation rate range (two to eight infections per 1,000 inhabitants per annum in 
2008) estimated in Zanzibar, one of the few places from which preliminary data 
are available [14;68]. No infected mosquitoes were imported. 
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Case management models 
 
The effectiveness of MSAT is probably related to case management coverage, 
which determines the proportion of symptomatic infections that gets treated. The 
case management component [41] models a health system using artemether-
lumefantrine (AL), an artemisinin-based combination therapy (ACT), as treatment 
for uncomplicated malaria. Individuals with uncomplicated malaria fevers were 
assigned a probability of accessing treatment over the next five-day period of 20, 
35 or 55%. These probabilities were constant over the entire simulation period. 
They represent the fever treatment-seeking behaviour range recorded in children 
under five years of age, using 14-day recall, in nationally representative surveys 
conducted in malaria endemic countries in sub-Saharan Africa [89;90], converted 
to five-day probabilities for use in the model. Compliance to the treatment regimen 
was set at 90% [67], and the drug was assumed to be 85% effective [91]. In 
patients who did not comply with the full regimen, the drug was assumed to have 
20% effectiveness [92]. All severe cases were assigned a 48% probability of 
receiving treatment as an in-patient [93], and parasites were cleared in all 
hospitalized cases who survived. 
 
Infectivity of hosts to mosquitoes at a given time point was modelled as a function 
of asexual parasite densities 10, 15 and 20 days previously, allowing for a delay 
resulting from the time course of gametocytaemia [62]. Effective treatment 
completely cleared parasites by the next time step, ending the infection, while 
ineffective treatment had no impact on asexual parasite densities. By clearing 
asexual parasites, treatment rendered individuals un-infectious to vectors at later 
time points. Given sufficiently high treatment coverage, this lowered infectivity 
translated into a reduction in EIR. Neither drug treatment effects on 
gametocytaemia nor prophylactic drug effects were modelled, but as AL has a 
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relatively short half-life, and few treatments were given after the first MSAT 
round, this is likely to be of limited consequence. 
 
MSAT timing, coverage and compliance 
 
Five different timings for MSAT were simulated, according to the seasonal 
transmission pattern – at the month before the peak of EIR, at the peak of EIR, at 
the month before the trough of EIR, at the trough of EIR, and at the month after 
the trough of EIR. The intervention was conducted annually in years 5 to 12, for a 
total of eight rounds. In the base case, MSAT was applied at 85% coverage, which 
is the level that was achieved in a well-conducted mass drug administration for 
malaria in the Gambia [56]. ACT was given simultaneously to all individuals with 
a level of parasitaemia at or above 40 parasites/µl. A detection limit of 40 parasites 
per µl corresponds to the nominal value for standard microscope procedures that 
count parasites against 200 leukocytes, assuming a white cell count of 8,000 
leukocytes per µl. Therefore, rapid diagnostic tests (RDTs) were assumed to have 
about the same level of detection as microscopy. All those who were screened and 
tested positive by RDT took the drug and complied fully with the regimen, while 
none of those who tested negative took the drug. Correlation among individuals in 
participation in different MSAT rounds was not considered. 
 
The optimal day of the calendar year to conduct an MSAT campaign was defined 
as the one, among the days considered, which minimized the number of episodes 
from the beginning of the intervention year to the end of the simulation period. 
This occurred one month before the trough in transmission, defined as the lowest 
EIR, consistent with other modelling studies [81]. This timing was used to 
evaluate the MSAT cost-effectiveness in settings of varying baseline receptivity, 
ITN and case management coverage.  
 
3. Cost-effectiveness of mass screening and treatment  
 
51
All scenarios had a population size of 100,000, with underlying demography based 
on East African life tables [66], and were run 10 times, each time with a different 
seed for the random number generator.  
 
Estimating the cost of MSAT 
 
Methods used to estimate the costs per person screened are described in detail in 
supplementary information (see Additional file 1). 
 
For costing purposes, MSAT was assumed to be conducted through house-to-
house visits by village volunteers or community health workers (CHWs). Two 
situations were considered: 1) a village of 1,000 inhabitants where a cadre of 
CHWs, trained to manage fever presumptively, existed and 2) a similar village 
where volunteers were newly selected from the local population and had no 
previous training or experience with managing illness. In situation 2, the MSAT-
attributable costs of selecting and training village volunteers for the MSAT 
intervention may be lower if the volunteers proceed to take on roles beyond that of 
the MSAT intervention; however, this was not considered 
 
The marginal cost consists of the additional costs that would be incurred when 
undertaking an MSAT campaign, based on new resources that would need to be 
used to deliver the intervention. When spare capacity in the health system exists, 
the use of that spare capacity is not included in the marginal analysis. By contrast, 
the average cost includes all those costs involved in delivering a health 
intervention, whether resources are shifted away from other activities, or whether 
spare capacity is used. In a generalized costing, an average cost analysis is 
problematic, as countries differ in their level of infrastructure, structure of the 
health system and capacity use. Therefore, other than the two starting points 
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considered (with (situation 1) and without (situation 2) an existing network of 
CHWs), only the marginal intervention cost was estimated.  
 
Based on a literature review of similar interventions, costs included in the estimate 
were household enumeration, social mobilization, delivery (comprising volunteer 
or CHW remuneration and supplies), training and supervision of village volunteers 
or CHWs. For the delivery, training and supervision costs, an ingredients approach 
was used, which involved building up a cost estimate by considering the quantity 
and value of each resource used. For the other costs, per-person costs were 
borrowed from similar interventions described in the literature.  
 
Systems costs from the district level upwards and in health facilities were not 
included. A functioning health system was assumed to be able to accommodate an 
annual MSAT intervention without hiring additional staff or making further 
investments at these levels. Clearly, if the health system were poor, further 
investments might be needed in order for MSAT to be successful, and this could 
greatly increase the costs. 
 
In this analysis, costing was conducted from a provider perspective. It was 
assumed that there were no direct costs to individuals and that indirect costs were 
negligible, since the intervention was infrequent and conducted at individuals’ 
homes.  
 
Some of the costs presented here are relatively fixed and thus sensitive to the scale 
at which the intervention is conducted. For example, the average costs of a 
sensitization campaign would likely decrease as more people are included in the 
target population. However, for the MSAT intervention, most of the costs are 
variable and significant economies of scale are unlikely. Therefore, economies and 
diseconomies of scale were not explicitly considered in this analysis.  
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The intervention was undertaken over a period of six days, with the first five days 
for initial visits and one additional day for return visits to cover those not found at 
the first visit. During initial visits, each team, which consisted of three volunteers 
or CHWs, could complete on average one household visit per hour, at an average 
household size of five people [94]. This included time for administering a 
questionnaire, conducting RDTs, waiting for the results, and prescribing ACT to 
any who tested positive. At this rate, eight household visits could be done in a day 
during initial visits (assumption 1), allowing five teams to cover a population of 
1,000 in a five-day period if every member of the population were present during 
the first (and only) visits. The first drug dose was assumed to be taken under 
supervision by the CHW, and the remaining doses were left with the households to 
be taken without supervision. 
 
In the absence of data relating coverage to number of follow-up visits, 40% of 
target households were assumed to have at least one member absent on the first 
visit, with 20% having all members missing and 20% having one member missing. 
A repeat visit was thus required to 40% of the households. Fifty percent of 
members missing on the first visit were assumed to be found on the second visit. 
Return visits were assumed to take half the time, as some of the houses would 
already have been screened and there would be fewer people to screen and treat. 
Thus, five teams would be needed for the second visits to achieve approximately 
85% population coverage.  
 
Nv, the number of volunteers or CHWs needed, is dependent upon factors like the 
population density, infrastructure, and the time it takes for a household visit. 
Therefore, an alternative, assumption 2, was considered, where only five 
household visits could be accomplished in a day during initial visits. In this case, 
eight teams would be required for the first and second visits. 
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Per diems were assumed to be given to volunteers or CHWs as incentives and to 
cover transport. The role of incentives in improving performance and encouraging 
sustainability of interventions is a subject of debate; in a number of settings, 
interventions relying on community volunteers have suffered from a lack of 
financial and non-financial support [95]. Salaries that may be paid to CHWs for 
performing their roles were not included as this was not considered an incremental 
cost incurred by the MSAT intervention. 
 
Each supervisor was assumed to be able to supervise three volunteer or CHW 
teams and received per diems according to the length of the intervention. Training 
costs in situation 1 comprised only the cost of an additional training on using and 
interpreting RDTs, while in situation 2, volunteers needed to be recruited and 
trained in all aspects of the intervention.  
 
All costs were converted to 2007 US$, using the US$ average market exchange 
rate in the study year and the US$ GDP deflator for the appropriate year [96].  
 
The total cost per person screened per MSAT campaign was approximately 2007 
US$5–11, depending on different health system scenarios and assumptions about 
the number of houses that could be visited per day. These costs were added to the 
age-dependent ACT presented in Table 3.1.  
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Table 3.1 Estimated costs per person screened by cost category and ACT 
costs by age group 
Screening cost category Costs per person screened (2007 US$) 
Household enumeration (Ep) 0.29 
Social mobilization (Mp) 0.27 
Delivery (Dp)  
Remuneration (Wp)  
Assumption 1 1.06 
Assumption 2 1.70 
Supplies (Up) 1.78 
Supervision (Ip)  
Assumption 1 0.48 
Assumption 2 0.76 
Training (Tp)  
Situation 1, Assumption 1 1.20 
Situation 1, Assumption 2 1.92 
Situation 2, Assumption 1 3.92 
Situation 2, Assumption 2 6.28 
Total costs (Sp)  
Situation 1, Assumption 1 5.08 
Situation 1, Assumption 2 6.72 
Situation 2, Assumption 1 7.80 
Situation 2, Assumption 2 11.08 
ACT costs Cost per course + 25% wastage (US$) 
Age  
<3 years 1.260 
3–9 years 1.960 
10–14 years 2.660 
15+ years 3.360 
 
The model for the cost of MSAT is separate from the epidemiological and case 
management models. Case management coverage may be higher where a network 
of trained CHWs exists. However, in this analysis the MSAT cost model was used 
to develop a plausible range for MSAT cost, and these costs were applied to all the 
health system scenarios. Clinical cases were costed as treated in health facilities 
using the case management model [41], and the proportion of episodes treated in 
facilities was presumed unaffected.  
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Incremental cost effectiveness ratio 
 
The health care costs for malaria episodes were calculated for each intervention 
scenario and its comparator, where MSAT was omitted. The case management 
cost inputs are described in detail elsewhere [41], and were updated with the costs 
of an ACT, artemether-lumefantrine (AL), as first line treatment for 
uncomplicated malaria [97]. Case management costs included direct costs for 
patient care, but not patient indirect costs (notably loss of productive time due to 
illness) since inclusion of these in cost-effectiveness analysis remains 
controversial and methods for valuing them vary widely [98]. The cost savings to 
the case management system associated with adding MSAT to the comparator 
scenario were computed as DCcmnoMSAT -  DCcmMSAT, where DCcmnoMSAT are the 
direct costs of case management in the scenario without MSAT and DCcmMSAT are 
the direct costs of case management in the case of MSAT.
 
These cost savings were 
subtracted from the direct MSAT intervention cost, DCMSAT, to give a net MSAT 
intervention cost, NCMSAT, computed as follows: NCMSAT=DCMSAT – (DCcmnoMSAT- 
DCcmMSAT). The savings to the case management system constituted only the 
marginal cost of averted cases, and fixed costs remained constant.  
 
Table 3.2 Determinants of intervention costs 
Determinant of cost 
Intervention cost 
category 
ITN 
coverage 
MSAT Case management 
coverage 
Vectorial 
capacity 
 
ITN X    
MSAT X X X X 
Case management X X X X 
 
 
Table 3.2 shows the determinants of total health system costs in each scenario. . 
ITN costs were fixed per person costs, assuming single occupancy, and therefore 
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were determined only by the ITN coverage level in the population. MSAT costs 
constituted primarily the fixed cost of screening individuals, but also depended on 
patent parasitaemia prevalence in the population, which in turn was driven by the 
vectorial capacity and ITN and case management coverage levels. Case 
management costs were a function of the health system use by the population (case 
management coverage) as well as the disease burden, which was determined by 
the vectorial capacity, ITN coverage, MSAT coverage and case management 
coverage itself (through its effect on recurrences and transmission).  
 
The net intervention effects were expressed as the number of episodes averted, i.e. 
the difference in the number of episodes between intervention and comparator 
scenarios. An incremental cost-effectiveness ratio (ICER), expressed as dollars per 
case averted, was calculated for each scenario with MSAT compared to the same 
scenario without MSAT, as the net cost (NC) of the intervention divided by the net 
effects (NE) of the intervention: ICERMSAT= NCMSAT/ NEMSAT. If the ICER is 
lower, the intervention is more attractive.  
 
The ICER value is sensitive to the time horizon over which it is calculated [99]. 
Therefore, to investigate how the ICER changed over the time period of the 
intervention, an annual ICER was calculated for each year of the intervention as 
ICERMSATn=NCMSATn/NEMSATn, where n is the year of intervention, beginning from 
the time the intervention starts.  
 
The cost-effectiveness of scaling up case management coverage or ITN coverage 
from a given level to one level higher was assessed in each health system, in the 
absence of MSAT. The objective of this analysis was to compare, roughly, the 
relative cost-effectiveness of undertaking one or another intervention, in different 
settings. Cost per ITN distributed was set as US$7, which is similar to the 
US$7.03 median financial cost per ITN distributed reported in a recent cost and 
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cost-effectiveness review of malaria control interventions [100]. Case management 
costs were as previously described; fixed infrastructure costs remained constant 
and scale-up costs included only the marginal costs of treating additional cases. 
 
Costs and effects were both discounted at an annual rate of 3% in the analysis 
[101]. The practice of discounting adjusts the value of future costs and effects to a 
present value, according to the timing at which they are incurred or occur. This is 
done to reflect the individual and societal preference to have resources and money 
now rather than in the future [102]. 
 
3.4. Results  
 
Figure 3.1 illustrates how all-age parasite prevalence evolved in a selected 
scenario. In this scenario, the pre-intervention EIR was 20 IBPAPA, case 
management coverage was 20% and ITN coverage was 40% at each distribution 
round. Prevalence began to decrease after the first ITN distribution, dropped 
considerably after the first MSAT round, and reached near zero by the fifth MSAT 
round. However, it returned to and exceeded pre-intervention levels about three 
years after all interventions were discontinued; the higher post-intervention 
prevalence is due to reduced immunity in the population. Prevalence never 
reached zero in any of the simulations, even during the time when MSAT was 
conducted. An analysis of the probability of interruption of transmission is outside 
the scope of this paper.  
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Figure 3.1 Median all-age parasite prevalence over the simulation period 
MSAT was conducted annually one month before the trough of transmission in years 5–12, at a 
pre-intervention EIR of 20 ibpapa, case management coverage of 20%, two imported infections 
per 1,000 population per annum, and ITN coverage of 40%. Circles indicate ITN distributions and 
arrows indicate MSAT campaigns. 
 
In Figure 3.2, the average number of episodes averted by MSAT is plotted against 
the average number of episodes per 1,000 population per year in the comparator 
scenario, for each factorial combination over the intervention time period. The 
number of episodes in the all age population in the comparator scenario with no 
ITNs or case management was greatest at the intermediate transmission level (EIR 
of 20 IBPAPA). Although infection prevalence increased with increasing 
transmission over almost all of the age range, the incidence of acute malaria 
attacks in older children and adults was substantially greater at lower transmission 
levels than at higher ones. This is because immunity levels rise with increasing 
transmission, so a smaller proportion of infections are symptomatic than at lower 
transmission levels. Therefore, reductions in transmission may actually lead to an 
increased incidence of disease due to P.falciparum [59].  
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The three panels combined show a bell-shaped curve; MSAT averted the most 
episodes where the number of episodes in the comparator was intermediate. This 
level was reached with different combinations of interventions at each pre-
intervention EIR. At a pre-intervention EIR of two IBPAPA, MSAT averted the 
most episodes when the coverage of the other interventions, ITN and case 
management, was zero. As case management coverage increased, MSAT averted 
fewer episodes since transmission was lower and some episodes had already been 
averted by case management. With any non-zero level of ITN coverage, 
transmission was so low that there was essentially no disease for MSAT to avert. 
At pre-intervention EIRs of 20 and 50 IBPAPA, the number of episodes averted 
by MSAT was maximized at ITN coverage of 40% and 80% in each distribution 
round, respectively, without case management. These levels of ITN coverage 
reduced transmission sufficiently to allow MSAT to have a sustained effect. 
MSAT was more effective if this optimal transmission level was reached via ITNs 
rather than case management because MSAT and ITNs have different modes of 
action and thus complement rather than duplicate each other. Without ITNs, 
vectorial capacity remained high and individuals became re-infected very soon 
after treatment with MSAT, limiting the intervention’s effectiveness.  
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Figure 3.2 Number of episodes averted as a function of number of episodes in 
the comparator scenario  
Number of episodes averted per 1,000 population per year over the 12.75 years from the 
beginning of the simulation period until one year after the last MSAT campaign are plotted 
against the number of episodes in the comparator scenario over the same time period, for each 
factorial combination averaged over 10 unique seeds. Colors indicate levels of case management 
coverage: Yellow: 0%, Pink: 20%, Blue: 35%, Black: 55%. Plotting characters indicate levels of 
ITN coverage: Squares: 0%, Stars: 40%, Circles: 60%, Triangles: 80%. 
 
The natural logarithm of the ICER for adding MSAT to scenarios with varying 
levels of case management and ITN coverage at different pre-intervention EIRs is 
shown in Figure 3.3. The average ICER over the 10 seeds for each factorial 
combination is plotted against the average number of episodes in the comparator 
scenario over the same time period. This figure suggests that MSAT was most 
cost-effective in settings with a moderate disease burden. At a pre-intervention 
EIR of two IBPAPA, this level of disease burden was achieved without case 
management and ITNs. MSAT was least cost-effective where case management 
and ITN coverage were at their highest levels. The lowest (best) ICER at pre-
intervention EIR of 20 IBPAPA occurred where ITN coverage was 40% at each 
distribution round, and the number of episodes was approximately 700 per 1,000 
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population per year. At the highest pre-intervention EIR, 50 IBPAPA, the lowest 
(best) ICER was achieved where case management and ITN coverage levels were 
at or near their maximum, and the disease burden level was similar to that of the 
best-ICER scenarios in the other pre-intervention transmission settings. MSAT 
was never cost-saving in any of these scenarios. 
 
0
2
4
6
8
10
0 500 1000 1500
2
0 500 1000 1500
20
0 500 1000 1500
50
Number of episodes per 1,000 pop. per year in the comparator scenario
Ln
(IC
ER
($ 
pe
r 
e
pi
so
de
 
a
ve
rte
d))
Entomological inoculation rate
 
Figure 3.3 Logarithm of MSAT ICER as a function of number of episodes in 
the comparator scenario 
Costs and effects were aggregated over the 12.75 years from the beginning of the simulation 
period until one year after the last MSAT campaign, using the high MSAT cost estimate. The 
natural logarithm of the MSAT ICER was plotted against the number of episodes in the 
comparator scenario over the same time period, for each factorial combination averaged over 10 
unique seeds. Colors indicate levels of case management coverage: Yellow: 0%, Pink: 20%, Blue: 
35%, Black: 55%. Plotting characters indicate levels of ITN coverage: Squares: 0%, Stars: 40%, 
Circles: 60%, Triangles: 80%. 
 
Figure 3.3 is a close, inverted, reflection of Figure 3.2, demonstrating that the 
variation in ICER was driven in large part by the net effects of the intervention. 
However, the ICER considers, in addition to the net effects, its net costs, or the 
difference between the MSAT intervention costs and the case management savings 
due to the intervention. In some scenarios, particularly at the lowest pre-
intervention EIR, increased case management reduced the net effects of MSAT but 
also its net costs, so the difference in ICERs was smaller than the difference in net 
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effects. Thus, the curves of ICERs in Figure 3.3 are less linear than those 
representing numbers of episodes averted in Figure 3.2.  
 
Figure 3.4 illustrates the average ICER in each year from the start to the end of the 
intervention, for each health system and transmission setting. At a pre-intervention 
EIR of two IBPAPA, with no ITNs and the lowest three case management 
coverage levels, the ICER showed a decreasing trend, indicating that the 
intervention became more cost-effective over time. The same was true at a pre-
intervention EIR of 20 IBPAPA and ITN coverage of 40 to 80%, and at a pre-
intervention EIR of 50 IBPAPA with ITN coverage of 80%. The opposite was 
observed in the other scenarios; at an EIR of 50 IBPAPA and without ITNs and 
case management, there were actually more episodes in scenarios with MSAT than 
in the comparator scenarios in later years. This resulted in a negative ICER (not 
plotted), and suggests that under these circumstances, doing MSAT would be more 
costly and less effective than not doing it. This is probably because MSAT 
interfered with acquired immunity in this fairly high transmission setting. The 
bumps in the curves observed in scenarios with ITNs are due to reductions in the 
number of episodes averted by MSAT in years 3 and 6 of the intervention, with 
ITNs distributed several months before. As in Figure 3.3, the net effects of the 
intervention were the main driver of the year to year variation in the ICER, 
including through their effects on case management costs. 
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Figure 3.4 Logarithm of MSAT ICER in each year of the intervention 
The natural logarithm of the annual MSAT ICER was calculated using the high MSAT cost 
estimate and averaged over 10 unique seeds, in different transmission and health system settings. 
Lines indicate levels of case management coverage: Yellow: 0%, Pink: 20%, Blue: 35%, Black: 
55%.
3. Cost-effectiveness of mass screening and treatment  
 
65 
Table 3.3 Incremental cost-effectiveness ratio (ICER) for different interventions 
 
Annual EIR in the absence of interventions Baseline 
interventions  2 20 50 
CM 
coverage 
(%) 
ITN  
coverage 
(%) 
MSAT 
11$ 
MSAT 
5$ CM ITN  
MSAT 
11$ 
MSAT 
5$ CM ITN  
MSAT 
11$ 
MSAT 
5$ CM ITN  
0 0 9.5 4.3 2.9 0.9 56.3 26.6 11.2 2.8 177.1 84.1 14.9 7.0 
20 0 12.4 4.7 1.0 -0.3 42.0 19.2 15.3 1.3 105.2 49.3 22.1 4.1 
35 0 18.0 6.7 -0.6 -0.8 37.3 16.5 22.2 0.4 91.0 42.1 39.2 2.9 
55 0 34.4 13.6 – -0.8 33.1 13.9 – -0.6 78.4 35.6 – 1.7 
0 40 523.6 238.0 2.3 22.8 12.5 5.7 5.0 5.1 30.9 14.4 7.6 11.7 
20 40 1932.3 877.4 2.4 41.3 12.5 4.9 5.8 3.6 25.0 10.9 10.0 8.8 
35 40 3276.3 1487.8 2.8 51.2 12.9 4.6 5.9 2.8 22.5 9.3 13.5 7.5 
55 40 4668.5 2120.1 – 61.6 13.6 4.4 – 1.9 19.9 7.6 – 6.2 
0 60 1817.6 826.3 2.9 76.7 14.1 6.4 3.0 6.0 17.7 8.1 5.7 12.3 
20 60 5496.8 2497.7 2.9 120.8 20.0 8.2 2.6 6.2 15.4 6.3 6.9 9.8 
35 60 7654.3 3477.7 3.8 153.7 25.4 10.2 2.2 6.8 14.2 5.3 8.4 8.8 
55 60 11003.4 4999.7 – 178.4 34.2 13.8 – 7.8 13.3 4.4 – 7.4 
0 80 3565.8 1620.9 3.1  – 27.7 12.6 2.0 –  13.4 6.1 4.1 –  
20 80 9669.7 4394.5 4.0  – 68.3 30.2 2.1 –  14.1 5.6 4.6 –  
35 80 14505.9 6592.2 4.6  – 111.7 49.5 2.9 –  14.8 5.5 4.2 –  
55 80 17126.3 7782.7 –   – 165.6 73.5  –  – 16.0 5.5 –  –  
 
Comparison of ICERs of conducting MSAT with ICERs of increasing case management or ITN coverage in different baseline health system 
settings (two leftmost columns), at different pre-intervention EIRs. ICERs for case management and ITNs refer to scaling up coverage from the 
baseline to the next highest coverage level, holding coverage of the other intervention constant. Negative ICERs indicate that the intervention is 
cost-saving due to reductions in case management costs. Bold figures represent settings where MSAT may have comparable or lower ICERs to 
either scaling up ITNs or case management coverage to the next level. 
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Table 3.3 compares the ICERs for the three interventions undertaken separately in 
each baseline health system setting, using high and low estimates for the per-
person cost of the MSAT screening component (see Additional file 1). At a pre-
intervention EIR of two IBPAPA MSAT was never the most cost-effective 
intervention. Increasing ITN coverage from 0 to 40% appeared to be the most 
cost-effective intervention and in fact, was cost saving where a health system was 
in place (hence the negative ICER). From a baseline of 40% ITN coverage and 
above, scaling up case management coverage was the most cost-effective option 
and, as expected, the MSAT ICERs became very large. 
 
At a pre-intervention EIR of 20 IBPAPA, scaling up ITN coverage to the next 
level was the most cost-effective intervention in settings of 0 and 40% ITN 
coverage. At 60% ITN coverage, scaling up case management coverage became 
the most cost-effective intervention. However, at 40% ITN coverage, the MSAT 
ICER was in a similar range to that of scaling up ITN and case management 
coverage. At a pre-intervention EIR of 50 IBPAPA, the ICERs of scaling up ITN 
coverage from 0 or 40% were the lowest. Interestingly, at an ITN coverage of 
60%, MSAT was similarly cost-effective to scaling up ITN coverage further.  
 
3.5. Discussion 
 
To date, MSAT for malaria has been considered almost exclusively as an 
intervention to interrupt local transmission of the parasite, or as a response to an 
epidemic in a previously malaria-free area. Even if MSAT does not result in 
sustained interruption of transmission, it may be a cost-effective strategy to reduce 
the malaria burden in some areas that are pursuing disease control. If used in this 
way, MSAT should be continued indefinitely, similar to ITN distribution.  
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Where prevalence is very low, infections are more likely to be symptomatic and 
thus detected by the passive case management system. The addition of mass 
treatment, therefore, will probably not have a large effect on the incidence of 
disease, particularly where case management coverage is high. Where prevalence 
is high, a greater population proportion will harbour asymptomatic infections, 
increasing the effectiveness of mass treatment relative to passive case detection. 
However, under these circumstances, individuals may become re-infected very 
soon after treatment through MDA or MSAT, limiting the intervention impact in 
averting disease. Of course, the effectiveness will also depend on characteristics of 
the intervention itself, such as the frequency with which it is carried out, 
population coverage and compliance to diagnostic tests and treatment regimens.  
 
These results suggest that, in all the transmission settings considered, achieving a 
minimal level of ITN coverage is always a “best buy”, and in low transmission 
settings, MSAT is probably never worth considering for burden reduction from a 
cost-effectiveness perspective. This finding is in contrast to the current focus on 
MSAT as an intervention for low transmission or near-elimination settings. 
Instead, MSAT may be more suitable at medium to high transmission levels and at 
moderate ITN coverage. In these settings, the cost-effectiveness of MSAT may be 
comparable to that of scaling up case management and ITN coverage.  
 
An interesting finding from this preliminary analysis, and one that merits further 
investigation, is that achieving 80% ITN coverage across all settings, as per 
current global malaria strategies [23], may not be an efficient use of resources, 
particularly in low-transmission settings. Given stagnating donor funding for 
malaria, and the fact that ITNs account for the largest share of most malaria 
programme expenditure [3], this finding may be important for malaria programme 
managers’ decisions. 
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The judgment as to whether or not an intervention is cost-effective rests upon the 
decision maker’s valuation of a unit of health gain, or the ceiling ratio. Values 
used in practice are usually quoted per disability-adjusted life-year (DALY) 
averted, and are based on affordability expectations (such as $US150 per DALY), 
some multiple of gross national income or gross domestic product, or preference-
elicitation methods [103]. This study’s results, presented in 2007 $US per episode 
averted, do not refer to a ceiling ratio and thus do not allow assessment of whether 
MSAT is cost-effective or not. Rather, they provide an initial indication of the 
conditions under which this strategy may be worth pursuing.  
 
The effects of correlations in intervention coverage, either between repeat 
distributions of the same intervention or between receiving MSAT, ITNs and case 
management, have not been analysed. In principle such correlations may result in 
either under- or overestimation of the effects of the interventions. Positive 
correlation between interventions is similar to adding new interventions 
preferentially into population subgroups with relatively high pre-existing 
coverage. This may be efficient when effectiveness is greater at low transmission, 
but in general might be expected to make the intervention package overall less 
cost-effective. 
 
The estimate of the cost-effectiveness of MSAT relies on the per-person cost of 
the intervention, which was estimated from secondary data on costs for similar 
interventions. To account for this uncertainty, a high and a low cost estimate were 
used. All campaign costs incurred were attributed to the MSAT intervention. 
However, MSAT could be more cost-effective if delivered jointly with other 
interventions, since household visits constitute most of the intervention costs. 
Notably, the MDA costs for neglected tropical diseases have been shown to be 
reduced where programmes are integrated in places where diseases co-exist [104] 
and evidence suggests this integration can be effective [105]. An ITN distribution 
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programme was successfully integrated with MDA for lymphatic filariasis and 
onchocerciasis in Central Nigeria [106]. Also, costs per person screened were 
assumed constant and incentives to community health workers were included; this 
cost might vary depending on the implementation stage, the use of volunteers, or 
the programme scale [107] 
 
On the other hand, achieving good MSAT implementation may incur costs that 
were not considered in the cost estimate and presupposes a fairly strong health 
system capable of organizing such an endeavour; otherwise, control programmes 
for other diseases may suffer. In this analysis, MSAT population coverage in each 
round was assumed to be 85% and compliance to be perfect. A well-conducted 
MSAT campaign will require careful planning, social mobilization, community 
involvement, and improvement of health care infrastructure, as was documented in 
Vanuatu [108]. This is not trivial; for example, the difficulties of maintaining an 
effective census record in a past MDA campaign in Tanzania have been described 
[109]. While achieving these high levels of MSAT compliance and coverage may 
be challenging, the aim of this study was to predict the cost-effectiveness of the 
intervention under optimal conditions; future analyses could explore the sensitivity 
of ICERs to reduced coverage and compliance. 
 
The estimate of cost savings from averted case management due to MSAT 
comprised only the marginal costs, assuming that the fixed costs remained 
unchanged. However, a much lower malaria burden may free up capacity for other 
interventions, boosting the cost-effectiveness of MSAT. If this spare capacity can 
be used, it could have significant benefits for the control of other diseases.  
 
In these simulations, MSAT was conducted using existing diagnostic and 
pharmaceutical tools. Microscopy and the current generation of RDTs fail to 
detect many low-density infections, thus a number of sub-patent infections is 
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missed. More sensitive diagnostic tools appropriate for use in the field are a target 
for future development [110], and if these become available, the MSAT impact 
could be enhanced. There could be benefits of other drug regimens, for example 
adding primaquine (PQ) to ACT regimens, which would make MDA/MSAT more 
effective in reducing transmission [22], although a recent study found that addition 
of PQ to ACT did not improve elimination of parasitaemia and prevention of 
gametocyte carriage in carriers with low-density parasitaemia in the dry season in 
Sudan [111]. 
 
As in the case of MSAT, economies or dis-economies of scale were not considered 
in the costs of scaling up case management and ITN coverage. The model for the 
costs of scaling up case management coverage does not account for investments in 
infrastructure that would need to be made when increasing coverage. In reality, 
scaling up case management may be more costly than it appears in this analysis. 
Moreover, a single estimate of distribution cost per ITN (with single occupancy) 
was used; these vary depending on scale, mode of distribution and other factors 
[112]. This analysis could be extended by varying unit costs at different coverage 
levels and assessing the sensitivity of results. Also, if each ITN were assumed to 
cover more than one person, the cost-effectiveness of ITNs would increase.  
 
In addition, the model used for ITNs, where the killing effect of the net decayed 
exponentially with a half-life of 2.64 years, is quite simple. Estimating the cost-
effectiveness of ITNs and case management was not this paper’s focus, and it 
aimed only to compare ICERs in orders of magnitude. Understanding of the cost-
effectiveness of ITNs and case management relative to each other and to other 
interventions could be improved using more complex models; one such model for 
ITNs is currently being developed [113].  
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The comparison of MSAT ICERs with those of scaling up ITN and case 
management coverage should not be construed as pitting the interventions against 
one another, as combinations of the interventions may well be an appropriate 
strategy. Improvements in case management, in particular, represent investments 
in the wider health system; they are valuable on that basis alone and cannot be 
directly compared with preventive interventions such as ITNs and MSAT. 
Furthermore, the use of episodes as the measure of effects resulted in a biased 
ICER for case management relative to the other two interventions. Case 
management’s impact was considered only in terms of reduced host infectivity 
(and thus reductions in future transmission) and decreased recurrences of illness 
due to one infection. However, as a curative intervention, the most important 
effect of case management is to reduce severe disease and mortality, and this was 
not captured in the ICER denominator presented here. Scaling up case 
management is thus likely to appear much less cost-effective in this analysis than 
it would be in reality. Future analyses comparing the cost-effectiveness of case 
management with that of preventive interventions should include both disability 
and deaths averted (expressed in DALYs) as an outcome measure.   
 
3.6. Conclusion 
 
Mass screening and treatment (MSAT) for malaria may be worth considering as a 
burden-reducing intervention in certain areas that possess adequate resources and 
health system capacity to implement it well. If undertaken, it should be as a 
complement, and not a replacement, for case management and vector control 
interventions, like insecticide-treated nets (ITNs). Also, policy-makers and 
planners should be prepared to continue it indefinitely, until new interventions 
become available or other developments make local transmission interruption a 
real possibility.  
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MSAT is at the high end of a case management continuum that goes from passive 
case detection, to screening only febrile or clinically suspected malaria in a small 
radius around a confirmed case, to screening all individuals at a large radius 
around a confirmed case, to MSAT and mass drug administration (MDA). One or 
another of these options may ultimately be a better use of resources than MSAT. 
More data is needed to determine the most cost-effective surveillance and 
response strategies in different settings. 
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3.9. Additional file 1. Estimating the cost of MSAT 
 
This Additional file presents a literature-based costing of MSAT campaigns for 
malaria, delivered through house-to-house visits via a community-based approach. 
Intervention delivery through house-to-house visits by village volunteers or 
community health workers (CHW) is likely to achieve high coverage rates. This is 
how mass drug administration (MDA) for malaria was usually done during the 
historic eradication campaigns [109],  
 
In Vanuatu, communities were enlisted to conduct MDA and community-based 
surveillance and self-monitoring [114]. In Zanzibar, the success of the MDA 
campaign against lymphatic filariasis (LF) has been attributed to the drug 
distributors, or “filarial prevention assistants”, who were selected based on their 
experience, residence in and acceptance by the communities where they worked 
[115]. 
 
Literature on operations and cost of similar interventions was reviewed to identify 
major cost items, variables, and assumptions needed, and to get an idea of the 
order of magnitude of per-person cost that has been estimated for these 
interventions. Total cost per person screened was built and its range explored in a 
sensitivity analysis. Limitations of the methodology were explored as well. 
 
Previous studies on the costs of community-based interventions 
 
Home-based management of malaria 
 
Delivery of treatment for suspected malaria through home-based management of 
malaria (HMM) has been applied in sub-Saharan Africa [116]. The average net 
intervention cost to promote HMM in rural Burkina Faso, including training, 
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purchase of the first drug stock, bags, labels and packing of drugs, incentives to 
CHWs, and supervision and drug distribution, was 1994 US$ 0.06 per resident 
child [117]. The cost of HMM in a trial in urban Ugandan children, including the 
cost of artemether-lumefantrine, was estimated at about US$ 34 per child per year 
[118]. In a study in Nigeria, the cost of design and implementation of a strategy on 
use of CHWs for HMM of malaria, including consumer and provider costs, was 
between US$ 1.40 and US$ 1.70 per villager. Recruitment and training of CHWs 
contributed the highest proportion of these costs [119]. Unfortunately, these 
studies are not directly comparable due to differences in the intervention design, 
collection and inclusion of cost data, and size and composition of the study 
population. Furthermore, HMM is quite different from MSAT in that it does not 
involve household visits; instead, individuals generally visit the CHW when they 
are ill.  
 
Recently, interest in whether CHWs can use RDTs prior to prescribing 
antimalarial treatment has increased. Since parasitological testing with RDTs 
would be an integral MSAT component, literature on this topic was reviewed. A 
cluster randomized trial in Zambia found that CHWs were able to successfully use 
RDTs, ACTs and amoxicillin to manage both malaria and pneumonia in the 
community [120]. A study of a 3-hour training course for CHWs in Zambia on 
how to use and interpret RDTs estimated that the course cost approximately 2006 
US$ 175 per CHW, including supplies (job aids), transportation, lodging, salaries, 
and per diems for CHWs, trainers, observers and MOH personnel. If only supplies, 
transportation, and lodging for CHWs were included, the cost was 2006 US$ 66 
per CHW trained. Significantly more trained CHWs conducted and read the test 
results correctly compared to CHWs who had received only the manufacturer’s 
instructions or job aids [121].  
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Neglected tropical diseases 
 
Preventive chemotherapy is used as a key approach in control and elimination 
programmes for neglected tropical diseases (NTDs), notably LF, schistosomiasis, 
onchocerciasis, soil-transmitted helminths and trachoma [122]. These diseases are 
often found in areas which are co-endemic for malaria. Many components of 
MDA programmes against these diseases could be quite similar to those of MSAT 
programmes against malaria. Therefore, the costing literature for MDA for these 
NTDs were reviewed, with a focus on African settings. A major difference 
between the costs of MDA for NTDs and malaria is that drugs for MDA are often 
donated, and thus incur zero financial costs to the control programme. In addition, 
distribution often relies on unpaid volunteers, which are also not included in 
estimates of financial costs.  
 
LF is currently targeted for elimination by the World Health Organization (WHO), 
and the principal strategy relies on concurrent administration of a drug 
combination, albendazole with diethylcarbamazine or albendazole with 
ivermectin, once-yearly for four to six years. A multi-country cost analysis of 
MDA for LF published in 2007 revealed that financial costs per person treated per 
round (not including drugs or volunteer time) in the sub-Saharan African 
programmes ranged 2002 US$ 0.06 – 0.54, with coverage rates ranging 65% – 
91%. However, when the cost of donated materials, notably drugs, was included, 
cost per person treated was around US$ 5 [107].  
 
All of these programmes involved house-to-house visits by volunteers, with or 
without additional distribution through distribution posts. Cost categories were: 
training, mapping, mobilization and education, drug distribution, adverse reaction 
monitoring, surveillance/laboratory (e.g. tracking of community members in MDA 
area, laboratory work for case identification, testing, etc.), and administration. 
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Input categories were: medications and laboratory supplies, personnel, transport, 
general supplies, and recurrent and capital costs for facilities and equipment. The 
analysis was conducted from a national program perspective and, as many inputs 
were shared among multiple programmes, costs were apportioned accordingly. 
Drug distribution generally represented the largest proportion of financial 
expenditures. The principal determinants underlying variability in the lymphatic 
filiariasis costing appeared to be the number of years that the programme had been 
running; the use of volunteers; and the size of the population treated [107]. 
 
Mean financial cost of the African Programme for Onchocerciasis Control was 
2008 US$ 0.58 per person treated, not including volunteer time, which was valued 
at 2008 US$ 0.16. Again, drugs were donated so are not included in the cost. The 
scale and stage of the program made a large difference to unit costs [104].  
 
MDA for malaria 
 
Only one article with information on the cost of MDA for malaria was found in a 
literature search. A weekly MDA in Vanuatu, conducted by trained village 
volunteers for nine weeks (together with ITN distribution and implementation of 
larvivorous fish), cost US$ 9 per person: US$ 5.6 for the impregnated bednets, 
US$0.7 for antimalarials, US$0.4 for materials for microscopical diagnosis, and 
US$2.3 for transportation and travel allowances for the staff and volunteers. About 
90% coverage was achieved in the first three rounds [108]. This MDA was 
conducted on a small island at short intervals, which is quite different from annual 
MSAT scenarios in mainland Africa.  
 
Some other studies contained useful information about the operational 
considerations when undertaking MDA for malaria, such as on how the 
intervention was carried out, on the number of households that could be visited in 
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a day, and on realistic coverage levels. For example, a report from an MDA in 
Tanganyika (present-day Tanzania) described the detailed individual census 
system that was drawn up before the trial and continually updated, and noted the 
need for repeated household visits and community participation to achieve high 
population coverage [109]. One study gave an indication of the time that would be 
needed to cover a particular population with MDA in an area of north Nigeria with 
reasonably good accessibility [123]. A report on the Garki project in northern 
Nigeria stated that in compact villages, each two-person team covered between 
150 – 180 people per day, whereas in scattered villages, they covered around 90 – 
100 persons per day [124]. Of course, these interventions did not involve 
screening prior to treatment. 
 
Although these costs give a useful indication of what could be expected with 
MSAT for malaria, the interventions are so different that they cannot be applied 
directly to MSAT for malaria; screening prior to treatment, as in the case of 
MSAT for malaria, is a more complex and time-intensive intervention than mass 
treatment alone and will require additional training of volunteers or CHWs.  
 
Algorithm 
 
The screening cost per person screened (
pS ) in an MSAT campaign round was 
estimated according to the formula: 
p p P p p pS E M D I T= + + + +  
 
where 
pE  is the household enumeration cost per person screened, PM  is the social 
mobilization cost per person screened, 
pD  is the delivery cost per person screened, 
pI  is the volunteer or CHW supervision cost per person screened, and pT  is the 
volunteer or CHW training cost per person screened.  
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For those that test positive and receive a drug, the drug cost needs to be added. 
These costs will depend on the total prevalence level in the population and the 
relationship of prevalence to age.  
 
Household enumeration 
 
Costs of surveying and conducting a census of the target population were assumed 
to be borne every time that a mass treatment campaign was planned. In reality, 
costs in subsequent years might be lower if only updating of an existing census 
were required.  
 
Household enumeration costs were borrowed from a study which estimated the 
per-person cost of conducting a national census in Tanzania [125] (Table 3.4).  
 
Social mobilization 
 
Costs for social mobilization are programme costs which are relatively fixed 
irrespective of the covered population size; as such the per-person costs are quite 
sensitive to the intervention scale. Social mobilization costs were borrowed from a 
cost study of introducing ACTs [126] (Table 3.4). This study reported the costs of 
development and production of information, education and communication 
materials and communication and publicity in a rural Tanzanian district of 
approximately 200,000 population over three years. While the ACT introduction 
study assumes that the cost of these activities declines in subsequent years, for the 
MSAT programme, a constant per person cost per round (as in year 1) was 
assumed, given the more intense communication efforts that would be required 
with a MSAT programme (owing to the need to achieve high coverage and the fact 
that the target population is not ill).  
 
3. Cost-effectiveness of mass screening and treatment  
 
79
Delivery costs 
 
Delivery costs per person screened per round was estimated as the sum of the 
volunteer or CHW per diem per person screened per round, 
pW , plus the cost of 
supplies per person screened per round, 
pU . The cost of transport of volunteers or 
CHWs was assumed to be negligible, as they would be based in the community 
and would travel only short distances, and in any case this could be covered by the 
per-diem remuneration.  
 
p p pD W U= +  
 
Remuneration 
 
Remuneration per person screened per round, 
pW , was estimated as: 
, ,
1
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dv vt d r t r
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⋅ ⋅ ⋅
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Where 
dvW  is the daily per diem for the volunteers or CHWs, vtN  is the number of 
volunteers or CHWs in each team, Np is the number of people screened, 
,d rN  is the 
number of days for visit r  of the MSAT campaign, and 
,t rN  is the number of 
teams participating in visit r , with 
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,
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Where P  is the total population targeted for the intervention, hS  is the average 
household size, 
,h rN  is the number of households that a team of volunteers or 
CHWs can visit per day in visit r , and 
,a rp  is the proportion of households with at 
least one member (still) absent on visit r , with 
,0 1ap = . 
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Assumptions made in the calculation of remuneration costs are summarized in 
Table 3.5 and per-person costs under assumptions 1 and 2 are presented in Table 
3.1. 
 
Supplies  
 
The cost of supplies per person screened per round, pU , is estimated as 
p p p p p pU R L G A Y= + + + +  
where pR  is the cost of an RDT, pL  is the cost of a lancet, pG  is the cost of a pair 
of gloves, pA  is the cost of an alcohol swab, and pY  is the cost of paper and 
printing per person. Sources for these prices are given in Table 3.4. 
 
RDT costs were calculated with an additional 12% added for transport, insurance 
and delivery [97] and another 25% for wastage [127]. For the other supplies, we 
did not cost delivery but did assume the 25% wastage rate. 
 
Per-person cost of supplies is presented in Table 3.1. 
 
Supervision 
 
Cost of supervision per person screened per round, pI , was estimated as 
, ,
1
r
ds d r t r
p
p ts
W N N
I
N N
⋅ ⋅
=
⋅
∑
 
 
where dsW  is the daily remuneration of the supervisor, pN  is the number of people 
screened, tsN  is the number of teams per supervisor, here taken to be three, ,d rN  is 
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the number of days for the visit r of the MSAT campaign, and 
,t rN  is the number 
of teams participating in the visit, as given under delivery costs, remuneration. 
 
Per-person cost of supervision under assumptions 1 and 2 is presented in Table 
3.1. 
 
Training 
 
Training of volunteers or CHWs is needed before each round. In situation 1, the 
CHWs have already been trained in presumptive management of febrile illness. 
However, they need to be instructed in the MSAT intervention and trained in 
conducting and interpreting RDTs and record-keeping. RDT training costs were 
borrowed from a study in Zambia [121].  
 
In situation 2, where no network of community health workers yet exists, 
volunteers need to be recruited and trained in all aspects of the intervention (RDT, 
ACT administration, etc). Recruitment and training costs were borrowed from a 
study of a community health worker strategy in Nigeria [119].  
 
Training costs per person screened per MSAT round for situation 1 are thus 
estimated as  
v p
p
p
N C
T
N
⋅
=  
 
where vN  is the total number of CHWs participating in the campaign, pC  is the 
cost of the RDT training course per CHW, and pN  is the number of people 
screened.  
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Training costs per person screened per MSAT round for situation 2 are estimated 
as  
2 1
v pt
p p
p
N C
T T
N
⋅
= + .  
where vN  is the total number of CHWs participating in the campaign, ptC  is the 
cost of recruiting and training per CHW, and pN  is the number of people screened.  
 
Training costs per CHW or volunteer are sensitive to the scale of the training 
programme. Costs for recruiting and training in situation 2 were modified in an 
attempt to adjust for this (see Table 3.4), but this remains a source of uncertainty 
in our costing estimate.   
 
Sources for training costs are presented in Table 3.4 and per-person cost of 
training in situations 1 and 2 and under assumptions 1 and 2 is presented in Table 
3.1. 
 
Artemisinin-based combination therapy 
 
Prices for ACTs were as described in a previous publication [97]. Costs were 
calculated with an additional 12% added for transport, insurance and delivery [97] 
and another 25% for wastage [127]. ACT costs are presented in Table 3.1. 
 
Calculation of total costs 
 
The cost estimates are summarized in Table 3.1. In situation 1, cost per person 
screened per round is estimated as US$ 5.08 under assumption 1, and US$ 6.72 
under assumption 2. In situation 2, cost per person screened per round is estimated 
as US$ 7.80 under assumption 1, and US$ 11.08 under assumption 2.  
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Discussion  
 
To date, MSAT has not been implemented anywhere, so there were no actual costs 
that could be used for this analysis. However, it is encouraging that the estimate of 
roughly US$5–11 per person screened (including RDT costs but excluding drug 
cost) is in a similar range to the cost per person treated in a once-yearly MDA for 
LF (US$5, including drug cost, no screening) [107]. This analysis suffers from the 
inevitable limitations of a generic costing based on secondary data. First, the cost 
of non-tradable inputs (e.g. personnel) could be expected to vary significantly 
among countries, for example according to level of income [128], which was not 
considered. Second, this cost estimate included primarily the marginal costs of 
MSAT, assuming that the health system could accommodate the intervention 
without, for example, hiring additional staff in health facilities or expanding the 
drug supply system. The validity of that assumption will depend very much on 
whether there is spare capacity in the health system. Two situations were 
considered; one where CHWs were already managing febrile illnesses and another 
where a system of village volunteers needed to be set up. Since training costs for 
volunteers or CHWs constitute about a quarter of the total costs of the 
intervention, this is likely to be a major component of the costs of investing into 
the health system. As mentioned above, efficiencies of scale or scope that could be 
achieved by expanding MSAT or integrating MSAT with other disease control 
programmes were not considered. However, as the majority of costs are variable, 
this is unlikely to change the estimate significantly. 
 
It is not clear how the costs of an intervention involving household visits would 
vary with population density: e.g. the difference between rural and urban settings. 
Distances between households are shorter in cities so transport and time costs will 
likely be lower, but it may also be harder to find people at home in large cities 
than in villages [129] and thus more repeat visits may be necessary in cities. Two 
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different assumptions about the number of household visits that could be 
accomplished in a day were made in an attempt to account for this. Transport for 
the village volunteers or CHWs was assumed to be negligible, since they live 
within the community, but for very spread-out villages these could be more 
substantial.  
 
More data is needed on the operations and costs of interventions involving 
household visits in sub-Saharan Africa, as these may be necessary to reach the 
high levels of intervention coverage called for in global malaria control targets. It 
is hoped that the work described here contributes to discussions about the costs, 
feasibility and efficiency of these types of interventions.  
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Table 3.4 Cost parameters, values and sources 
Cost Parameter Symbol Cost 
(2007 US$) 
Source 
Household enumeration  
 
 
Household enumeration cost 
per person  
 
Ep 0.29 
[125] 
Social mobilization  
 
 
Social mobilization cost per 
person 
 
Mp 0.27 
[126] 
Remuneration Wp   
Daily remuneration of 
volunteers or CHWs 
 
Wdv 10 
[130]; G. Ferrari, personal 
communication 
Supplies Up   
Price of 1 pair of sterile gloves  
Gp 0.23 
G. Ferrari, personal 
communication 
Price per lancet Lp 
0.03 
G. Ferrari, personal 
communication 
Price of 1 alcohol swab Ap 
0.19 
G. Ferrari, personal 
communication 
Price of black ink printer 
cartridge 
 
115 
G. Ferrari, personal 
communication 
Price per ream of paper   
2.39 
http://eetd.lbl.gov/paper/coun
ting/html/purchasing.htm 
Price of Paracheck RDT per 
test 
 
Rp 0.61 
[131] 
Supervision  
 
 
Daily remuneration of 
supervisors 
 
Wds 40 
G. Ferrari, personal 
communication 
Training Tp   
Situations 1 and 2: Cost of 
RDT training course per 
volunteer or CHW 
 
Cpr 
68 
[121] 
Situation 1: Cost of recruiting 
and training village volunteers 
per volunteer 
Cpt 
154 
[119]; estimate is half of the 
cost due to assumed 
economies of scale 
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Table 3.5 Input parameters, values and sources 
Input Parameter Symbol Assumption 
1 
Assumption 
2 
Source 
Total population targeted for MSAT P 1000  Assumption 
Number of people screened Np 850  [56] 
Average household size Sh 5  [94] 
CHWs or volunteers per team Nvt 3  G. Ferrari, personal 
communication 
Number of CHWs or volunteers - 
first and second round 
Nv,1 
Nv,2 
 
15 24 Calculation 
Number of households visited per 
team per day - first round 
Nh,1 8 5 Assumption 
Number of houses visited per team 
per day - second round 
Nh,2 
 
16 10 Assumption 
Number of days per MSAT 
campaign 
Nd 6  Assumption 
Number of days - first round Nd,1 5  Assumption 
Number of days - second round Nd,2  1  Assumption 
Proportion of households with at 
least one member missing on first 
visit pa,1 
0.4  Assumption 
Proportion of households with all 
members missing on first visit 
 
0.2  Assumption 
Proportion of households with only 
one member missing on first visit 
 0.2  Assumption 
Proportion of members missing on 
first visit that are found on second 
visit 
 0.5  Assumption 
Number of teams per supervisor Nts 3  Assumption 
Number of printer cartridges used 
per MSAT campaign 
 2  Assumption 
Number of reams of paper per 
MSAT campaign 
 5  Assumption 
Distribution costs as percentage of 
the RDT price 
 12%  [97] 
Wastage rate of drugs and supplies  25%  [128] 
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4.1. Summary 
 
Malaria disease burden is modified by treatment.  While this is the primary reason 
for treating malaria, the dynamic effects of treatment are generally ignored in 
estimates of burden of disease, which is usually presented in terms of numbers of 
clinical cases or episodes [3] with the main sources of data being reporting of 
clinical cases from health facilities and parasite prevalence surveys.  The failure to 
include the dynamic effects of treatment in estimates of burden leads to 
misunderstanding of measures of burden.  It also leads to bias in both empirical 
estimates of the impact of changes in case management, and in simulation models 
of cost-effectiveness of malaria interventions. 
 
This paper examines these challenges in detail, and considers how they can be 
overcome.   
It proposes an approach for measuring burden of disease that recognizes the 
distinction between burden and counts of episodes.  This technique makes use of 
data available from standard designs of community surveys, together with analyses 
of patterns of fever in malaria therapy patients and data on recall bias from 
Asembo, Kenya.  Application of this approach to data from Zambia for 2010 gave 
an estimate of 2.6 (1.5, 3.8) malaria attributable fever days per child-year.  To 
obtain valid estimates of the overall malaria burden using these methods, there 
remains a need for surveys to include the whole range of ages of hosts in the 
population and for patterns of seasonality in confirmed cases to be available.   
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4.2. Introduction 
 
Malaria continues to be a major cause of disability and death in countries where it 
is endemic.  Accurately estimating the burden of morbidity due to the disease1  is 
critical for guiding programmatic strategies and resource allocation, and 
evaluating the impact of malaria control measures. However, commonly-used 
approaches for estimating malaria burden are problematic as a result of imprecise 
terminology and estimation techniques that do not allow for the complexity of the 
natural history of the disease.  
 
When promptly and effectively treated, malaria illness is of short duration, but if 
untreated a single P.falciparum malaria infection can last for many months, 
causing recurring clinical attacks interspersed with asymptomatic periods [132] 
during which parasitaemia is often sub-patent.  This can be clearly seen in the time 
courses of parasitaemia and fever observed when malaria was used for treating 
neurosyphilis (Figure 4.1).  
 
 
 
                                                 
1
 Here we consider only the morbidity burden, though most of the malaria burden, measured in terms of 
disability-adjusted life years (DALYs) or quality adjusted life years (QALYs) is  contributed by mortality 
[41] 
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Figure 4.1 Pattern of parasitaemia and febrile illness in a malaria-therapy 
patient (Patient S-519) 
○—○: Parasite densities; ■indicates a day on which fever (core temperature >=103. °F) was 
recorded. 
 
The full histories of many untreated malaria infections were recorded when 
artificial inoculations of malaria parasites were used for treating neurosyphilis 
[133]. Figure 4.1 shows the time pattern of parasitemia and fever in a 
neurosyphilis patient treated with P.falciparum. In this figure, this single 
(untreated) infection gives rise to five periods of high parasitaemia. The first two 
of these are each associated with several bouts of fever indicated by the black bars 
at the top (see definitions in Table 4.1). 
 
This sporadic pattern of clinical symptoms of untreated disease complicates the 
definition of clinical incidence. For many infectious diseases, for instance 
influenza, each incident infection leads to one and only one period of illness, or 
episode. Burden can thus be estimated from the incidence of disease and the 
duration of episodes, with an appropriate weighting used to convert numbers of 
episodes into DALYs or QALYs. By contrast, with malaria, one incident infection 
may lead to multiple periods of illness (or may be asymptomatic throughout, 
though this may be infrequent [134]). Malaria burden is often expressed as 
numbers of episodes, but it is not clear whether one episode is intended to refer to 
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(i) all illness resulting from a single infection event; (ii) one uninterrupted period 
of illness; or (iii) all malaria illness within a given period.  Infections that are 
treated promptly and effectively when they first lead to symptoms unambiguously 
contribute one episode to this total, but when treatment is delayed, or if the 
infection remains untreated, it is unclear how many periods of illness can result 
from a single infection event.  This matters because the disability caused by the 
disease (and the risk of life-threatening complications) are clearly less when it is 
treated promptly, but these benefits may be invisible, depending on how incidence 
is calculated.  The term episode clearly refers to some of set of bouts, but just how 
many and which bouts make up an episode is not clear.  In Table 4.1 we propose a 
definition that captures this ambiguity.  
 
Statements about incidence of malaria disease are consequently often vague or 
misunderstood. For instance, the World Health Organization (WHO) estimate of 
225 million cases in 2009 [135] is widely interpreted as the number of people 
infected although it is intended to refer to the total number of clinical episodes. 
Confusion is not limited to lay interpretations, for the relationship between a 
malaria infection and the amount of illness it causes is far from straightforward.  
 
In many countries, mostly outside Africa, burden is reported using passive case 
detection data, and in WHO statistics, estimates of morbidity rates for these 
countries are corrected for reporting completeness, diagnostic error, and 
attendance rates [3;136]. In most of sub-Saharan Africa, presumptive treatment 
has been the norm, so that reporting of the numbers of treatments has not been 
used to estimate disease burden.  Instead, maps of P.falciparum prevalence 
determined from surveys have been combined with information on climate 
suitability for malaria transmission and population density in order to classify 
populations into different endemicity levels.  Estimates of clinical incidence for 
different endemicity levels have been derived primarily from longitudinal surveys 
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of febrile malaria episodes in children, detected either actively or passively 
[30;137;138]. The estimates of populations at risk and endemicity-specific 
estimates of disease rates have together been used to produce national and 
continent-wide estimates of the number of clinical malaria episodes [4]. 
 
Longitudinal studies of malaria must always involve treating the acute episodes 
that are discovered, and thus all the burden of disease subsequent to effective 
treatment of an infection is averted2. In several longitudinal studies [65;139], 
dramatic decreases in fever rates over time have been observed, presumably for 
this reason. Intensive research studies are therefore likely to substantially 
underestimate clinical attack rates in the general population.    
 
An alternative to these approaches is to use recalls of illness from cross-sectional 
surveys carried out in the community.  An increasing body of data is available 
from Demographic and Health Surveys (DHS), Multiple Indicator Cluster Surveys 
(MICS), and Malaria Indicator Surveys (MIS), which include ask respondents to 
provide a recall of illness during the previous two weeks for each of their children.  
We show here how these data can be used to estimate the burden of malaria 
disease, and suggest how improved estimates might be obtained.  
 
 
 
 
 
 
 
 
                                                 
2
 Treatment also reduces onward transmission to mosquitoes, but this effect is not relevant to the present 
discussion. 
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 Table 4.1 Definitions used in this paper 
Term Meaning in this paper 
Malaria 
infection 
Those parasites descended from a single inoculation of 
sporozoites3 
Incidence of 
infection 
The number of new infection events in a population in unit time 
Bout of illness An uninterrupted set of days during which a patient is 
considered, or considers themselves, to be ill for at least part of 
each day  
Malaria episode A set of bouts of malaria illness considered by the patient or 
carer to be of common malaria aetiology* 
Incidence of 
clinical malaria 
The number of malaria episodes in a population in unit time 
(Point) 
prevalence of 
clinical malaria 
The proportion of the population suffering from symptoms of 
malaria aetiology at any one time 
Malaria burden The morbidity or disability associated with malaria (ideally 
measured by days of illness, DALYs, or QALYs) 
*This definition is intended to capture the way in which the word episode is used, whereby 
intermittent fever bouts, within a period of continual high parasitaemia characteristically lasting a 
few weeks (Figure 1), are likely to be thought of as part of a single episode.  
 
4.3. Methods 
 
Data sources  
 
The method involves using four distinct sources of data for different quantities 
required in the overall estimate of burden. 
 
1. Incidence of disease in the community: Malaria Indicator Survey data from 
Zambia 
 
Data on history of fever in the last fourteen days from the 2010 Malaria Indicator 
Survey from Zambia [140] were used. Just over 34% of children under five 
                                                 
3
 It is debatable whether co-inoculated but genetically distinct parasites should be considered part of the 
same infection. 
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reported a fever in the last two weeks. This is period prevalence of fever, biased by 
recall. Of these 34% took an antimalarial drug. 
 
2. Recall bias in community surveys of incidence: daily prevalence of fever, 
Asembo, Western Kenya 
 
For analysis of recall bias in recalls of fever, data of Feikin et al [141] for children 
from Asembo, Kenya were used.  These comprise recalls of fever, elicited 
separately for each day in a 14-day recall period, in a survey of approximately 
25,000 people in Asembo, Bondo District, Kenya (Figure 4.2). (We found a 
similar pattern in the data of Genton et al [142] from Papua New Guinea.) 
 
Figure 4.2 Daily prevalence of fever calculated as percentage of persons 
reporting symptoms on each day in the 2 weeks prior to home visit, Asembo, 
Western Kenya  
Source: [141]   
 
3. Seasonality of fever: Health Management Information System (HMIS) records 
of Malaria Indicator Survey data from Zambia 
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4. Patterns of fever in untreated hosts: malaria-therapy data 
 
Patterns of fever in untreated and inadequately treated malaria patients were analysed 
using the data of 330 neurosyphilis patients treated with P. falciparum in the National 
Institutes of Health laboratories in Columbia, South Carolina and Milledgeville, Georgia 
in the United States of America [132]. For each of these patients, the days on which fever 
(core temperature >=103. °F) occurred was recorded. 
 
 
Estimation of recall bias as a function of recall period 
 
Two-week morbidity recalls do not elicit complete information about illness 
during the reference period, and the usual survey procedures do not directly 
provide any information about recall bias.  However recall bias can be estimated 
when respondents are asked individually about illness on each distinct day during 
the recall period.  This is because independence of the timing of the survey and the 
illness justifies the presumption that variations in fever rates by recall period 
reflect recall bias.   
   
The relative frequencies of fever reports by day of recall in the Asembo data 
provide a direct estimate of the recall bias associated with a specific period of 
recall. Assuming that a fever on the previous day is reported with 100% 
sensitivity, an estimate of the recall probability for a fever i days prior to interview 
is 1ˆi ir F F=  where Fi is the fever prevalence recorded in the survey for the single 
day, i days prior to interview. ( 0 0 1ˆ 1r F F= <  because surveys are usually carried 
out early in the day, before all fevers are yet evident.) 
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Estimation of recall bias in two-week morbidity recalls 
 
The probability that a survey respondent reports fever, conditional on fever having 
occurred during a two week recall period, differs from ˆir  because fever bouts 
extend over multiple days (Figure 4.4a), and there may be multiple bouts during a 
single recall period (Figure 4.1).  The overall recall probability for a two week 
period, allowing for these effects, was estimated by applying the estimates of ˆir  
obtained from the Asembo study to simulated interviews of malariatherapy 
patients.  
 
The recorded follow-up periods were divided into fourteen-day intervals during 
which there was daily monitoring, leading to a total of 3715 fourteen-day 
intervals, during 755 of which there was one or more day of fever.  Data were 
discarded for days that could not be included in these intervals because of gaps in 
or termination of the monitoring of the patients.   
 
For the analysis of recall in the absence of treatment, each day of follow-up 
(j=1,2..14) in each of these intervals was evaluated as though the patient had been 
interviewed at j=14.  Each day of fever was assumed recalled with probability 14ˆ jr −  
so that the probability that any fever was recalled in the simulation was 
( )14 14
1
ˆ1 1 j j
j
r I r
−
=
= − −∏ɶ  where 1jI =  if there was fever on day j and 0jI =  if there was 
no fever on day j.   
 
The true treatments administered to the malaria-therapy patients (predominantly 
sub-therapeutic doses) were ignored in this analysis.  To estimate the effects of 
treatment on survey recalls, simulated treatments were assigned stochastically to 
each day of fever with probability t0 corresponding to the probability of prompt 
and effective treatment.  Where treatment was assigned, it was assumed that this 
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would be reported, so that intervals with treatment were always reported in the 
simulated surveys as including fever days. To estimate the values of t0. in Zambia, 
the simulations were repeated with different values of t0. The proportion of recalls 
reporting treatment, among those reporting illness, tɶ , was plotted as a function of 
t0 and the value of t0 corresponding to the observed proportion in the Zambian 
MIS, was read off the graph, thus providing an estimate of the daily treatment rate 
in Zambia.   
 
 
Estimation of period prevalence of clinical malaria from survey data 
 
MIS use two week recalls to elicit histories of both illness and of treatment.  The 
signs and symptoms of malaria are common to those of other diseases, so 
interviews alone perform poorly in assigning malaria as the cause of illness. To 
determine the proportion of recalled illness that is due to malaria, parasitological 
testing is needed. Using 14-day recalls, individuals with reported fever may not be 
parasitaemic at the time of the survey, however Rapid Diagnostic Tests (RDTs) 
based on the presence of the P.falciparum Histidine Rich Protein 2 (PfHRP2) to 
determine the prevalence of malaria infections.  As PfHRP2 persists in the 
bloodstream for up to a month following parasite clearance [143;144], PfHRP2 
positivity (unlike blood slide positivity) can be used to estimate the malaria-
attributable fraction of the recalled fevers and hence the period prevalence of 
clinical malaria. 
 
The processes determining both questionnaire and RDT outcomes can be 
represented by the branching process shown in Figure 4.3, where the columns 
RDT, Fever, Treated indicate the outcomes recorded at the survey, and the 
branches correspond to a classification of respondents according to whether they 
are parasite positive by RDT, whether they suffered a malaria or non-malaria fever 
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in the reporting period, whether they received treatment, and whether the fever 
was reported at the survey.    
 
 
Figure 4.3 Events underlying cross-sectionally recorded outcomes 
p is the RDT positivity; m is the probability of clinical malaria during any two week period, 
conditional on infection; n is the probability of non-malaria fever during any two week period; t is 
the probability of treatment with an antimalarial conditional on being both infected and febrile 
during the two-week period; and r is the probability that an untreated fever is reported. 
 
Malaria fevers and non-malaria fevers are not distinguishable at the individual 
level in field data, so the ten branches shown in Figure 4.3 correspond to five 
observable categories of outcomes, with probabilities 1 2 3 4 5{ , , , , }P P P P P P=  as in 
Table 4.2.  We use a Bayesian approach to estimate the parameters p; m; n; t by 
fitting these probabilities to the data from Luangwa, Zambia (Table 4.2).  t is 
slightly lower than tɶ , the reported proportion of RDT positive febrile children 
who had been treated, because of the under-reporting of untreated fevers.  Because 
the available data from Luangwa did not provide a precise estimate of tɶ  we use 
data from the national MIS survey to estimate the distribution of this variable, and 
incorporate this distribution into the Bayesian model, noting that the expected 
value of tɶ  is:   
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( ) ( ) ( ) ( )
1
1 1 1 1
mt m nt
mt m nt m t r m n t r
+ −
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The reporting probability, r, is not identifiable from the field data.  By making a 
series of assumptions we can use the distribution of  rɶ  estimated from the 
malariatherapy data, as a prior distribution for r in the Bayesian analysis.  This 
makes all the parameters in the decision-tree identifiable.  In addition to assuming 
the same duration and frequency of bouts of fever in untreated individuals in the 
two datasets, we also consider treatment with anti-malarial drugs only in parasite 
positive individuals, assume that treatment never occurs in the absence of illness, 
and that respondents who fail to report illness are otherwise indistinguishable from 
those that report.  We further assume that recall bias in treatment is negligible, but 
that untreated fevers are recalled with some probability, r<1.   
 
To complete the specification of the Bayesian model we use uninformative 
( (0,1)Uniform ) priors for p, m, n, and t.  A Markov chain Monte Carlo method was 
then used to estimate these parameters assuming the probabilities 
1 2 3 4 5{ , , , , }P P P P P P=  to follow a multinomial distribution. 
 
Estimation of numbers of days of illness  
 
The same analyses of malaria-therapy patients, with simulation of surveys and 
treatments, were used to estimate the numbers of days of illness associated with 
each recall of fever, conditional on the proportion of recalled fevers reporting 
treatment, tɶ .  For this analysis, days of fever in the true malaria-therapy dataset, 
subsequent to the simulated treatments, were not counted in the total days of 
illness, thus simulating effective therapy that truncated the illness on the date of 
treatment. Since the MIS surveys were conducted only at one time of the year, the 
incidence estimates needed to be adjusted for the effect of seasonal variation in 
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clinical incidence. This was achieved by scaling the estimate of the clinical 
incidence recorded in the HMIS data during the survey period to the annual 
average incidence. 
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Table 4.2 Outcomes at survey and their probabilities 
RDT 
positive 
Reports 
fever 
Reports 
treatment 
Probability Frequency in 
district 
survey 
Frequency in 
national 
MIS* 
No No No ( ) ( ) ( )( )1 1 1 1P p n n r= − − + −  355 
No Yes No ( )2 1P p nr= −  131 
Yes No No ( )( ) ( ) ( ) ( ) ( )( )( )3 1 1 1 1 1 1P p m t r m n n t r= − − + − − + − −  35 
 
Yes* Yes No ( ) ( ) ( )( )( )4 1 1 1P p m t r m n t r= − + − −  686 
Yes* Yes Yes ( )( )5 1P p mt m nt= + −  
46 
353 
*The report of the national MIS does not distinguish antimalarial drug used by RDT positive children from use by RDT negative children.  Since 
only 16.7% of children with fever reported use of a diagnostic test, we assume for the present analysis that antimalarial drug use was independent 
of RDT positivity.  
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4.4. Results 
 
Duration of bouts and recall bias 
 
The daily prevalences of fever reported by Feikin et al [141]  clearly indicate the 
fevers a few days prior to survey are much less likely to be recalled than those the 
previous day.  If each recalled period with illness only entailed only day of fever, 
then a simple mean of the recall-day specific probabilities, 14ˆ jr − , could be used to 
estimate the overall recall bias, which would be substantial.  However, bouts of 
fever in malaria-therapy patients (as defined in Table 4.1) frequently last several 
days (Figure 4.4a), and if these are not treated, there may be several bouts in one 
recall period, so that, while the proportion of days with fever is 5.4%, only 17.8% 
of two week periods include one or more days of fever (Figure 4.4b).    
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Figure 4.4 Effect of bout length on period prevalence in the malaria-therapy 
data 
a: distribution of durations of bouts of fever in the malaria-therapy data; b: period prevalence of 
fever in the malaria-therapy data, as a function of the duration of the period. 
 
Each additional day of fever adds to the probability that the illness will be 
recalled, leading to a recall probability that is much higher than the daily recall 
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probabilities reported in the Asembo study, so that when we apply the recall 
probabilities from the Asembo study to the patterns of fever occurrence in the 
malaria-therapy data, we estimate that 612 out of 755 (81%) of 14-day intervals 
with fever days would have been recalled, corresponding to 19% underreporting 
and a value of rɶ =0.81 (Figure 4.3).We use this as the value of r in the estimation 
of tɶ  (see above). 
  
The probability that fever will be recalled is further complicated by the effects of 
treatment.  While Figure 4.4 provides a description of the actual malaria-therapy 
data, simulation of treatments under the assumption that a treated fever will 
always be recalled increases the simulated probability that morbidity will be 
recalled, while decreasing the corresponding number of days of fever (Figure 4.5).  
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Figure 4.5 Proportion of recalls of fever also reporting treatment 
The plots were constructed by simulating effective treatments applied to malaria therapy data (see 
Methods) with 14 day morbidity recalls, with recall bias based on the Asembo data.  The arrows 
correspond to the observed proportion of morbidity recalls reporting treatment in the Zambian 
MIS survey. 
 
The proportion of recalls mentioning treatment has a non-linear relationship with 
the daily probability of treatment, because recurrent fevers provide multiple 
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opportunities to treat, so even a modest rate of prompt treatment will result in a 
very high proportion of recalled fevers being treated. The 34% of recalls in the 
Zambian MIS data that reported treatment (Table 4.3) thus corresponds to only 
about 7% treatment per day of fever (Figure 4.5a). The proportion of treatments 
delivered promptly on the same day is also not the same as the daily probability of 
treatment because prompt treatment (as defined in the MIS questionnaire) may 
occur on either the same day, or the day after onset of fever.  A 7% daily 
probability that a fever will be treated consequently corresponds to a probability 
almost twice as high as this that treatment will occur in the first two days, which is 
comparable with, though somewhat lower than, the 18.7% of fever reports that 
indicated receipt of prompt anti-malarial treatment in the survey, te.   
 
Numbers of days of fever associated with each recall 
 
As the treatment rate increases, the number of fever days corresponding to each 
report decreases (Figure 4.5b).  In the absence of treatment, the 755 two-week 
periods of malaria-therapy with at least one day of fever averaged 4.3 days of 
fever each.  Allowing for the estimate of 19% underreporting of two-week periods 
with untreated fever in the model of ascertainment, each report of fever 
corresponds to 5.3 days of fever in this model.  As treatment rates increase, the 
number of days of fever corresponding to each report decrease, since an increasing 
proportion is averted by the treatments, until in the limiting case of 100% prompt 
and effective treatment, each report corresponds to exactly one day with fever 
(Figure 4.5b).   
 
Estimation of total burden of uncomplicated malaria 
 
Table 4.2 gives the numbers of respondents in the Luangwa district malariological 
survey in each of the four classes categorized by RDT positivity and reports of 
fevers.  The recalled treatment rate by RDT positivity is estimated from the 
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national level data (right hand column of Table 4.2).  The Bayesian estimation 
procedure provides interval estimates for p, m, and n, conditional on the 
distribution for rɶ  assembled from the Asembo and malaria-therapy data (Table 
4.3).  
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Table 4.3 Parameter estimates and their origins 
 Name Source of 
estimate 
Estimate (95% 
credible interval)* 
p Period prevalence of malaria 
infection 
Bayesian model 0.14 (0.12, 0.17) 
m Probability of malaria fever 
conditional on infection 
Bayesian model 0.48 (0.29, 0.67) 
pm Period prevalence of malaria 
fever 
Bayesian model 0.07 (0.04, 0.10) 
n Period prevalence of non-malaria 
fever 
Bayesian model 0.33 (0.29, 0.39) 
rɶ  Probability that fever is recalled  Asembo and 
malaria therapy 
data 
0.81 (0.78, 0.84) 
t Proportion of periods with 
malaria fever that were treated 
Bayesian model 0.29 (0.27, 0.32) 
tɶ  Proportion of malaria positive 
recalls where treatment was 
received 
MIS data 0.340 (0.31, 0.37) 
t0 Daily probability of treatment Asembo and 
malaria therapy 
data and MIS data 
0.07 
te Probability of prompt and 
effective treatment 
MIS data 0.187 
d Days of malaria fever during 
recall period among those who 
report malaria fever 
Read from Figure 
4.5b as a function 
of t 
3.7 
I  Annual average incidence of 
confirmed clinical malaria at 
health facility (cases per month) 
HMIS data from 
Luangwa District 
(Figure 4.6) 
102.3 
I  Incidence of confirmed clinical 
malaria at health facility (cases 
per month) during period of MIS 
survey 
HMIS data from 
Luangwa District 
(Figure 4.6) 
258.0 
b Days of malaria fever per person-
year at risk  
365
14
Ib dpm
I
=  
2.6 (1.5, 3.8) 
*Bayesian credible intervals for data derived quantities were computed assuming (0,1)Uniform  
priors for proportions.  For derived quantities, the credible intervals were computed by sampling 
from the joint posterior densities of the individual parameters.  Where no interval estimates are 
shown, fixed values were included in the calculations, so the uncertainty in these variables is not 
included in the final estimate. 
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Of the 14% of children with evidence of malaria parasites, half of them (7%) are 
estimated to have suffered malaria fevers during the interval.  Only 29% of 
children with fever were treated at some point in the interval.  This is lower 
(because of recall bias in the fever data) than the observed proportion of recalls 
mentioning treatment (34%) among those who mentioned fevers.  
Figure 4.6 Average number of confirmed cases by month in Luangwa District 
Zambia 2009-2010 
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The dashed line corresponds to the annual average incidence and the double headed arrow to the 
survey period and the corresponding average incidence. 
 
Figure 4.6 shows the seasonality in confirmed malaria cases at all health facilities 
in Luangwa district, Zambia.  The MIS surveys in Luangwa were typically 
conducted during peak transmission season (April-May) and thus the annual 
burden estimate needs to be scaled by the ratio of malaria fever incidence over the 
whole year, relative to the incidence during this period (Table 4.3). It is assumed 
that this district is representative in terms of the degree of seasonality, and the 
targeting of the MIS surveys to the peak season of incidence.  This provides an 
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estimate of the average days of malaria fever per person-year in Zambian children 
of 2.6 (1.5, 3.8) days of malarial fever per person at risk per year. 
 
This estimate seem plausible, though the credible intervals (which capture most of 
the uncertainties in the data) do not capture the full level of uncertainty implied by 
the assumption that patterns of fever in Zambian children may be similar to those 
in malaria-therapy patients, or that recall patterns in Kenya can be applied to 
Zambia.  
 
4.5. Discussion 
 
Definitions and methods for estimating rates of uncomplicated malaria morbidity 
depend on the purposes for which the information is needed. Thus, WHO 
estimates of malaria burden refer in principle to the amount of disease that is 
eligible for anti-malarial treatment4.  This is different from the level of 
transmission (which is addressed in a companion paper)5, and from the amount of 
disease that would be averted by eradicating the infection.  The economic burden 
of the disease includes the costs of diagnosing malaria negative patients, of 
preventive measures in visitors, and of investments lost because of concerns about 
the disease. These considerations lead to the conclusion that proliferation of 
measures is unavoidable. This paper focuses specifically on measures of health 
burden, defined in terms of the experience of the sick individual.   
 
                                                 
4
 Under this definition, all febrile illness with incidental parasitaemia should be included in the burden 
calculations.  This, however, leads to double-counting in overall disease burden statistics, since much of 
this illness should also be recorded as respiratory infections 
5
 A variety of methods are being developed for measuring transmission, in particular serological 
approaches [145] and model-based approaches combining parasitological and clinical data [146]. MIS 
provide data relevant to many of these approaches and may well prove key to measuring transmission as 
well as disease burden, but the two objectives should be clearly distinguished. 
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Unfortunately, current practice in measuring burden in this sense is not 
satisfactory.  From the clinical perspective, it is good enough to identify an 
“episode” or “case” when an individual presents to a health facility with febrile 
illness and detectable parasitaemia. This is also useful for commodity forecasting 
and managing clinical workloads.  It may also be suitable for use in intervention 
trials where the goal is simply to detect a difference between two or more arms.  It 
is suboptimal as a measure of health burden, because it ignores what is going on in 
the infected people who are not reporting to the health facility or reporting late.  
When such data are used for managing resource allocation between interventions 
they can be seriously misleading because: (i) they can give a quite false idea of the 
importance of malaria relative to other illnesses, and (ii) they substantially 
understate the impact on health burden of improvements in case management 
practice.  Strikingly, the roll-out of ACT as first-line therapy across Africa barely 
impacts official estimates of burden, which show only a modest improvement over 
time, driven by scaling up of vector control. 
 
The proxy indicators generally used to indicate trends over time in disease rates 
can be fundamentally misleading. The Global Fund to fight AIDS, TB and Malaria 
(GFATM), in its Monitoring and Evaluation (M&E) toolkit for countries, 
recommends parasite prevalence and anaemia prevalence as morbidity indicators 
for national malaria control programs [147]. These indicators are frequently 
collected in Malaria Indicator Surveys (MIS) and a recent study from Zambia used 
them as evidence of health impact of interventions [148]. However, they are not 
direct measures of malaria morbidity, they are multifactorial [149] and they may 
change at different rates from clinical malaria incidence [150]. 
 
Reported histories of fever in the previous two weeks collected through 
community-based surveys provide a more direct measure of morbidity, and at least 
in some situations have been validated as comparative morbidity measures [151]. 
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However, to obtain health burden estimates, corrections must be made for the 
benefits of treatment on duration of illness, for recall bias, and for diagnostic error. 
Correction for levels of incidental parasitaemia is critically important when the 
malaria situation is changing, since the diagnostic performance depends on the 
level of asymptomatic parasitaemia and may also change over time. 
 
In this paper, we have incorporated all these considerations into an approach for 
estimating the number of days of illness due to malaria as a percentage of all days 
of observation and applied this to a specific set of surveys in Zambia.  The 
approach uses outcomes assessed in MIS surveys, recall data from Kenya, and 
data on the natural history of malaria fever from malaria-therapy patients.  Clearly 
the appropriateness of combining these datasets can be questioned, especially the 
assumption that the patterns of fever in African children parallel those in malaria 
therapy patients.  However the approach does lead to parameter estimates (Table 
4.3) with at least face validity, and unfortunately these are the only datasets we 
have available that provide all this information.  Estimates of burden, based on this 
approach, would be a substantial improvement on current practice in cost-
effectiveness analysis.  The Appendix discusses the implications of this for 
simulation modeling of case management, and how this relates to previous 
practice. 
 
Some of the data limitations could be addressed by improvements in survey 
design.  First, cross-sectional surveys of malaria illness and treatment-seeking 
need to include questions on history of fever and measure parasitaemia in all age 
groups, not just children under five. As malaria control efforts are scaled-up and 
transmission falls, malaria illness shifts into older age groups [28] due to slower 
acquisition of immunity. Burden will thus fall harder on older children and adults, 
and monitoring systems need to allow for this reality in order to capture the full 
burden of malaria illness.  Second, there is a need for more data like those from 
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Asembo to estimate recall bias. Ideally, 24-hour recalls would be used but this 
would reduce the size of available databases.  Finally, the current practice of 
carrying out MIS surveys at approximately the same time across whole countries 
means that there are limited data available on seasonality in either parasitological 
or clinical indices.  Data for each period of the year are essential for unbiased 
estimates of annual burden, and could in principle be obtained by carrying out 
rolling surveys visiting different clusters in a random order throughout the year.  
 
4.6. Conclusion  
 
Measurement of malaria burden is fraught with complexity mainly due to the 
natural history of the disease and to sub-optimal health facility utilization which 
means that treatment is often delayed or not sought. Definitions of malaria 
episodes are either ambiguous or difficult to use because we rarely have good 
information about patterns of infection, recurrence of fever or asymptomatic 
infection. 
 
This paper suggests that the point prevalence of malaria attributable disease, or 
equivalently, the days of malaria fever in unit time, should be used as a measure of 
burden.  This avoids the problem of defining a malaria episode, and we contend 
that it can in principle be estimated in an unbiased way from data that is already 
collected in national MIS combined with data on seasonality.  Estimates of recall 
bias and duration of bouts that we use in this paper could be applied more 
generally. 
 
It is hoped that this work will stimulate a dialogue on how to improve 
measurement of the burden of uncomplicated malaria, for the benefit of all those 
who are suffering from or are involved in the fight against the disease.   
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4.8. Appendix:  Burden of uncomplicated malaria in simulation 
models   
 
Studies of likely long-term impacts and cost-effectiveness of novel intervention 
strategies are often best carried out by simulation modeling.  Measures of disease 
burden in such studies need to be aligned with the data that can be obtained from 
field studies, and should use the same terminology and definitions.  Simulation 
modeling disciplines the practitioner into using explicit definitions.   
 
We previously developed individual-based stochastic simulation models of the 
biology and epidemiology of P. falciparum malaria [39] and applied these to 
estimating the cost-effectiveness of scaling up case management [41]. These 
models went beyond previous static models (such as those published by the Global 
Forum for Health Research [92]) by including the effect of treatment in truncating 
an infection and the dynamic effects of treatment on transmission.  However in 
modeling scaling up effective case management the model of Tediosi et al [41] 
assumed a constant duration of illness for episodes of clinical malaria.  This was 
taken from the Global Burden of Disease (GBD) study [152] without critically 
evaluating the GBD meaning of a malaria episode. 
 
A further criticism of the Tediosi et al [41] case-management model was that 
assumed treatment rates were very low in relation to clinical incidence.  The 
clinical incidence rates were fitted to data from the villages of Ndiop and Dielmo 
in Senegal [59;153]. These data were from daily surveillance carried out with the 
explicit intention of detecting and treating every clinical malaria attack, and 
reported higher rates than other studies.  
 
The Tediosi et al [41] model is an individual-based discrete time representation of 
the dynamics of malaria using five-day timesteps.  Bouts of illness (see Table 1) 
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are represented by classifying each time step according to whether it included any 
days of malaria fever.  In publications based on these models [41;63;64], numbers 
of episodes are calculated by grouping together bouts occurring within 30 days of 
each other in the same individual, following an approach used in some field 
studies [154]. This period can be justified by reference to prophylactic periods 
associated with treatment and the duration of standard in vivo tests for drug 
resistance.  It can be thought of as the period over which the patient or health care 
system considers the bouts of illness to be part of the same illness (Table 4.1). 
 
Treatment coverage in such models, defined as the proportion of sick intervals 
where treatment is applied, maps non-linearly onto the data available from 14-day 
recalls in MIS, MICS, or DHS surveys. This is because if treatment coverage is 
perfect and treatment completely effective, each episode is treated, and the 
infection causing it removed, during the first bout. There is therefore one bout per 
episode. As treatment coverage decreases, the number of bouts per episode 
increases. The amount by which bouts and episodes diverge across settings with 
different treatment coverage will depend on how many bouts each new infection is 
expected to generate in the absence of treatment and on their severity.   
 
Coverage values for input to the models can however be inferred from the 
mapping of model predictions of 14 day treatment rates as a function of the time-
step specific treatment rate.  The relationship depends on the details of the 
epidemiological model.  Figure 4.7 provides calibration results for a family of 14 
different models with 5-day time steps, all variants on the original model used by 
Tediosi et al [41], and applied in recent simulations of the likely impact of malaria 
vaccines on clinical incidence [70] . 
 
That can be used to estimate the amount of under-reporting of bouts if surveys are 
undertaken with different recall periods. For example, to estimate this with a 
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fifteen-day recall period (approximating , we set the health system memory to 15 
days and surveyed the population every 15 days, recording the number of 
treatments given and the number of episodes). Figure 4.7 shows that in our model, 
the probability of seeking treatment in any 5 day period is lower than the 
corresponding 15-day probability, because individuals can be sick multiple times 
in a 15-day period, and some fevers go untreated. Figure 4.7 also shows how this 
relationship is model-dependent.  
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Figure 4.7 Five- vs 15-day treatment-seeking probabilities 
Simulation of a setting where EIR=20, with a population size=2000. Lines are sub-model 
medians.  
 
We used an ensemble of 1 4 model variants. The ensemble consists of a base model, used in 
previous publications [63;64], and thirteen variants on that model, with each one representing a 
different set of assumptions about malaria transmission and epidemiology. Our ensemble of 
stochastic simulation models of malaria epidemiology incorporates different assumptions about 
decay of immunity and about heterogeneities in exposure, co-morbidity and access to treatment 
[70].  
 
R0674 (uncorrelated heterogeneities in access to treatment and susceptibility to comorbidity) and 
R0678 (heterogeneity in access to treatment) are not shown since at high treatment coverage 
levels, there is a limit to the amount of heterogeneity possible. Above about 55%, heterogeneity 
in treatment-seeking starts to decrease, since the upper half cannot go above 100% probability of 
accessing treatment. The ratio of upper to lower treatment-seeking probability thus starts to 
change. Overall 15-day treatment-seeking probabilities of above that level cannot be simulated 
with the R0674 and R0678 sub-models.  
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5. Development of a P. falciparum malaria case 
management model integrated with 
pharmacodynamics 
 
5.1. Background 
 
In 2006, Smith and colleagues presented individual-based stochastic simulation 
models of the biology and epidemiology of P. falciparum malaria, which were 
developed to study long-term impacts and cost-effectiveness of intervention 
strategies [40]. Models of health system effectiveness in intervention delivery are 
an important part of the simulation of any preventive and curative intervention, as 
the prevailing health system modifies the disease burden and thus the gains 
expected from an intervention. Therefore, as part of this project, a decision tree 
model for the case management of malaria was developed, based on data from 
Tanzania [41]. This model was novel for its consideration of the effect of 
treatment on malaria transmission. In addition to averting severe morbidity and 
mortality, treatment reduced burden by reducing recurrent clinical attacks due to 
one infection and by reducing infectivity of the population. In simulations using 
this model, the reduced burden on the health system resulting from preventive 
interventions and case management were considered. 
 
The Tediosi et al [41] model for case management of uncomplicated malaria 
consisted of three parameters – treatment-seeking (from the formal sector, self-
treatment, or no treatment-seeking), patient compliance to the drug regimen, and 
treatment cure rate in the presence and absence of compliance. An uncomplicated 
malaria case that was treated in the last 30 days was assumed to either seek 
treatment in the formal sector or not seek treatment. The model for severe malaria 
assumed that it could either be treated as an in-patient or not treated, and there 
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were three possible outcomes – death, full recovery, or recovery with neurological 
sequelae. In-patient case fatality rates were taken from a study in Tanzania while 
corresponding community case fatality rates were estimated. Algorithms were also 
developed to estimate the cost of case management [41]. 
 
This model was adequate for predictions of the cost-effectiveness of other 
interventions in the presence of different levels of treatment coverage. However, it 
did not allow simulation of the multiple factors which determine the treatments 
given in real health systems. In particular, alternatives to the public sector or self-
medication as sources of treatment were not considered, and neither was the 
response to diagnostic tests, imperfect provider compliance with treatment 
guidelines, or sub-optimal drug quality. The model also failed to consider the 
impact of malaria case management on management of non-malarial febrile 
disease. Increased use of confirmatory diagnosis offers the potential to improve 
treatment and therefore reduce morbidity and mortality from other causes, and 
should be considered in estimations of the cost-effectiveness of case management 
interventions. Second, there was no drug model, so clinical and parasitological 
outcomes were predicted within the case management model, and treatment either 
completely cleared parasites or had no effect. In reality, drug treatment should act 
to reduce parasite densities, and the outcome is not dichotomous. Drug treatment 
may cure clinical symptoms but not eliminate parasites, with implications for 
recurrences of illness, infectivity, and development of drug resistance; this could 
not be simulated with the previous model.   
 
There was agreement that the Tediosi et al model needed to be revised to 
incorporate improved simulations of the contribution of the informal sector, 
diagnosis, referral and drug action. This motivated the development of a case 
management model integrated with a model for malaria pharmacodynamics. 
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Alongside development of the model, potential interventions to be simulated were 
identified (see Table 5.1). Criteria for selecting interventions were primarily 1) 
potentially high impact and 2) broad applicability. Intermittive preventive 
treatment in infants, children and pregnant women was explored separately.
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Table 5.1 Interventions to simulate using the case management model integrated with pharmacodynamics 
(Source: A. Schapira, 2009) 
 
 
 
 
Strategic variants Intervention 
Technical Operational including targeting 
Secondary questions 
CHEMOTHERAPY 
Case management 
uncomplicated: 
treatment 
 
Schizonticidal 
 ACTs 
 Mono-artemisinins 
 SP 
P.falciparum gametocytocidal 
(primaquine) 
Integrated Management of Childhood Illness 
Differentiation by risk group, e.g.: <5 
Public 
 Facility-based free or paid  
 Community (home) -based) 
Formal private paid/SM 
 Franchises 
Informal private paid/SM 
 Improved drug vendors 
Global subsidy 
Secondary questions: Sequential ACTs 
vs multiple 1st line ACTs 
Higher than standard dose of drugs like 
chloroquine 
AIDS interactions 
Pregnancy specific protocols 
Case management 
uncomplicated: 
diagnosis 
Presumptive (clinical) 
Microscopy 
P.falciparum  RDTs 
Differentiation according to risk group, e.g. 
presumptive diagnosis in <5s and confirmatory in 
others in high transmission settings  
 
Active case detection 
(screening fever cases) 
 
For elimination 
In epidemic 
To compensate case management 
Mass screening 
Mass treatment 
Schizonticidal 
 ACTs 
P.falciparum gametocytocidal For elimination 
In epidemics 
 
Case management 
severe malaria 
Artemisinin suppositories as 
stand-by or complete  
Parenteral artemisinin or 
quinine 
Children/All  
Community/facility-based standby/ 
Only hospital-based parenteral  
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5.2. Overview of new simulator and fitting to data 
 
As previously, the new case management model works in conjunction with other 
model components to predict impact and cost-effectiveness of interventions. 
Briefly, there is a simulated population of humans who are updated at each time 
step via model components representing new infections, parasite densities, 
acquired immunity, uncomplicated and severe episodes, direct and indirect malaria 
mortality, infectiousness to mosquitoes, and case management. Simulated 
immunity to asexual parasites, derived from cumulative exposure to both 
inoculations and parasite densities and maternal immunity, acts mainly by 
controlling parasite densities [58]. The probability of a clinical attack of malaria 
depends on the current parasite density and a pyrogenic threshold [59]. Severe 
malaria comprises two categories of episodes: those that occur as a result of 
overwhelming parasite densities, and those that arise when an uncomplicated 
malaria episode coincides with non-malaria co-morbidity. Mortality can be either 
direct (following severe malaria) or indirect (uncomplicated malaria in 
conjunction with co-morbidity, or during the neonatal period as a result of 
maternal infection) [155]. The models which simulate the clinical consequences of 
malaria infection are collectively termed “pathogenesis” model.  
 
While the previous models used five-day time steps, the new simulator works on a 
one-day time step. The previous within-host model, which used a statistical 
description of parasite densities, was replaced with a mass action model of P. 
falciparum asexual parasite densities fitted to malariatherapy data [156]. The 
published model used a discrete time-step of two days. Our implementation 
adapted this to a one-day time-step by interpolating the parasite multiplication 
rate. Drug effects and natural immune effects of previous exposure were 
represented by further modifying the parasite multiplication rates. The models for 
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pharmacodynamics [157] and for case management were also implemented on a 
one-day time step. The ability to predict parasite densities each day allows a finer-
grained simulation of the action of drug treatment that people receive, since potent 
antimalarial drugs generally act to significantly reduce parasite densities within 
hours of being administered. It also allows a more realistic simulation of people’s 
response to illness and treatment.  
 
An overview of the new simulator and its components is presented in Figure 5.1. 
The pathogenesis models determine if an individual becomes sick, and whether the 
sickness is uncomplicated or severe. The case management model, which 
comprises the clinical scheduler and clinical decisions modules, determines 
whether, when and how the sickness is treated and how long it lasts. The case 
management model works together with the models for drug action, severe 
outcomes, and within-host dynamics to predict clinical and parasitological 
outcomes. The other components are as described in previous publications [40], 
with the addition of a model for the dynamics of malaria in mosquitoes [61]. The 
code for these models can be downloaded on openmalaria 
(http://code.google.com/p/openmalaria/). 
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Malaria infection of 
the human
Infectivity to 
vectors
Clinical Scheduler 
Entomology & 
transmission 
model
Drug Action
• PK/PD 
Severe 
Outcomes
• Malaria Mortality
• Sequelae
• Recovery
Pathogenesis
•Uncomplicated malaria
•Severe malaria
•Non-malaria fever
•Indirect mortality
Within-host model
Clinical decisions 
• Care-seeking, testing and 
treatment decisions
Case management
interventions
 
Figure 5.1 Module overview of new simulator 
 
The parameter values for each of the components of the one-day time step model 
were estimated by fitting to data from a total of 61 malaria field studies of 
different aspects of malaria epidemiology [39]. However, efforts so far to validate 
this model by comparing results from the five-day and the one-day models lead to 
the conclusion that the predictions of the force of infection model for incidence in 
older age groups were far too high. The force of infection model was thus replaced 
with an alternative [158] and the whole model is currently being re-fitted. 
 
5.3. Presentation of case management model 
 
Each day, the within-host model generates a parasite density, Y(t), which is a 
function of the parasite density at the previous time point and a drug factor, if 
relevant.  For each individual, the pathogenesis model is then called to determine 
the individual’s new state. Given Y(t) and the patient’s history, the pathogenesis 
model calculates the individual’s pyrogenic threshold and the probability that an 
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event occurs [59] and the event type [155]. The pathogenesis model also generates 
indirect deaths and non-malarial fevers according to age-specific functions. 
 
To avoid confusion of terms while adapting the clinical model for a one-day time 
step, we developed the following notation (see Chapter 4):  
• Bout: a "bout of sickness" describes a fever, malarial or otherwise, or 
period of severe illness, usually lasting no more than five days. This is the 
main unit of interest for the purposes of the case management model. 
• Episode: the health-system's reporting unit; each bout is either considered 
the start of a new episode, or, if occurring within the health system memory 
(currently 30 days) of the start of the last episode, considered part of that 
episode.  
 
Thus, at least in low transmission settings, an episode should roughly correspond 
to one malaria infection (which can cause multiple bouts). An episode's severity is 
considered to be that of its worst bout.  
 
Each individual is assigned a clinical state which lasts until the next event. At any 
given time point, there are five possible states: healthy (including asymptomatic 
infections), uncomplicated malarial fever with or without a recent history of 
treatment, severe malaria, and dead. The corresponding events are start of an 
uncomplicated malarial fever from a healthy state, start of severe malaria (from 
healthy or uncomplicated malaria states), direct death (from a severe malaria state) 
and recovery (from uncomplicated malaria or severe malaria states). Transitions 
from severe malaria to uncomplicated fever, or from uncomplicated malaria to 
direct death, are not allowed. If the non-malarial fever option is enabled, an 
additional state of uncomplicated non-malarial fever is also possible. 
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Since state changes are not possible at every time-step, the clinical scheduler 
component of the case management model (see Figure 5.2) decides and tracks the 
clinical state of the individual and allocates individuals to the clinical decision and 
severe outcomes models, based on the state as determined by the pathogenesis 
model and recent illness and treatment history.  
 
Figure 5.2 Clinical scheduler module 
 
A bout commences with a morbidity event and concludes with a recovery or 
mortality event (stressing terminology used). When the bout first occurs, the 
clinical scheduler calls the clinical decision model. At the start of an 
uncomplicated fever, a potential treatment-seeking delay is modeled. The bout 
duration of uncomplicated malarial fevers and non-malarial fevers is fixed at three 
days from the time of seeking treatment, or from the start of illness (if treatment is 
not sought). If an individual delays seeking treatment for one or two days, bout 
duration becomes four or five days, respectively. During this time, the clinical 
scheduler maintains the individual in the same state, unless the pathogenesis 
models indicate that the illness has progressed to severe or the individual has died 
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from a non-malarial illness. After this time period, it is assumed that parasite 
densities have been reduced by treatment or immunity, or that the individual has 
recovered from the non-malarial illness, and the individual is returned to the 
healthy state.  
 
While healthy or during an uncomplicated bout, a severe bout may commence. In 
this case, the clinical scheduler calls the clinical decision model, cancels any 
recent drug treatment, and allocates the individual to the severe case management 
decision tree. The severe bout is fixed at six days long when the patient enters 
hospital immediately or not at all; a one-day delay to hospital entry is also 
considered possible which increases the bout length to seven days.  
 
Mortality due to malaria is possible during severe malaria bouts, and considered as 
a stochastic function of the proportional reduction in parasite density each day of 
the case (Hardy et al, unpublished). Each day during the severe illness, the clinical 
scheduler calls the severe outcomes model, which applies the appropriate case 
fatality rate to determine whether or not the individual died that day. For delayed 
hospital entry, the community death rate takes effect on the first day. Mortality 
events are always modeled as happening at the end of the associated severe 
episode.  
 
The clinical decision component of the model consists of stochastic decision trees 
concerned with determining the treatments given (including the actual schedule 
followed and dose sizes taken), along with whether the patient was hospitalized 
and whether treatment or hospitalization delays occurred. The decision trees also 
provide information necessary for calculating costs, derived from treatment-
seeking behaviour, drugs administered, and diagnostic tests used.  
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The decision tree for uncomplicated fever is shown in Figure 5.3. The simulated 
individual has a fixed chance of seeking treatment immediately, or, if yet to do so, 
on the following two days. Delays to treatment-seeking are modeled by starting 
the drug curve (of parasite density versus time) on the second or third day after the 
occurrence of the episode. If treatment is not sought on all three occasions, the 
individual reverts to the healthy state.  
 
Figure 5.3 Uncomplicated fever decision tree 
 
The first decision branch is whether and where to seek care. In health facilities, 
patients can be tested with a rapid diagnostic test, by microscopy, or not be tested 
at all; at community health workers, we assume that only RDTs are possible, 
which may or may not be used. Each test has a sensitivity and specificity which 
are functions of parasite density. To model this, we looked for a function to relate 
parasite densities to the probability of a positive outcome. Methods for doing so 
are described below. 
 
Based on the results of the test, the simulated individual can receive one of several 
antimalarial drug regimens, or no antimalarial treatment. Providers may respond to 
a given test result by prescribing or not prescribing antimalarials. The drugs can be 
given at various levels of quality. We also consider three possible adherence 
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options: good adherence, missing the first dose of the drug (common when 
patients vomit upon taking the drug), or missing the last day (as when treatment is 
stopped before the end of the recommended regimen). The individual is deemed to 
recover three days from the time of treatment-seeking (or, from the onset of 
illness, if treatment is not sought). 
 
If a bout of uncomplicated malarial fever occurs in an individual who has been 
treated with antimalarials within the last 14 days, it is assumed this would be 
considered as a treatment failure [13] which should be treated with the second-line 
drug. The decision tree is identical but the values of treatment-seeking, quality of 
care and compliance parameters are modified.  
 
In the case of severe malaria, the path through the case management decision tree 
is determined at the start of the episode. The tree may determine that a one-day 
travel-time delay occurs, in which case in-hospital decisions are not determined 
until the next day.  
 
The decision tree for severe malaria is shown in Figure 5.4. Individuals can 
initially either seek treatment from a lower-level source, in hospital, or not at all. 
There is a possibility of pre-referral treatment with referral to hospital on the same 
or next day; pre-referral treatment reduces parasite densities on the first day of 
illness. Diagnostic testing is considered for costing purposes but is assumed not to 
affect treatment received. The treatment schedule is found and applied in the same 
way as with an uncomplicated case. Entry to hospital temporarily removes the 
individual from the transmission cycle.  
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Figure 5.4 Severe malaria decision tree 
 
In both severe and uncomplicated cases, the relevant case management decision 
tree determines treatments given. For each drug and age group, the standard 
regimen is specified– dose size (in milligrams), and times given (in hours), and 
then modified, based on the decision tree outputs, by reduced drug quality, 
adherence and delays to taking treatment.  
 
The treatment schedule is applied to the individual as a list of pending medications 
that are given over the next time points. Any previously pending medications are 
cancelled when new treatments are prescribed, and drugs are only costed when 
taken, so that if an individual progresses to severe after receiving treatments for an 
uncomplicated case, remained unconsumed medications are not costed.  
 
Parasite diagnostics  
 
Data from [159] were used to model the outcome of RDTs for P. falciparum, 
which show the percent sensitivity (and the 95% confidence interval) found for the 
RDT BinaxNOW Malaria in a rigorous field trial, at different levels of 
parasitaemia. This assay is based on detection of the antigens HRP-2 for P. 
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falciparum and aldolase for generic Plasmodium. The sensitivities listed for P. 
falciparum were associated with the mid-points of the parasite density ranges 
listed, and one minus the specificity for a density of 0 parasites.  
 
To model microscopy, the data shown in Table 5.2 were assumed. This was 
sourced from expert opinion (personal communication, A. Schapira), backed by 
the observation that microscopy diagnostic errors are noted more commonly for 
low-density parasitemias of 10 to 100 parasites/µl [160].   
 
Table 5.2 Sensitivity and specificity of microscopy (P.falciparum) by parasite 
density 
(Source: A. Schapira, 2009) 
Parasite density (parasites / µl) Sensitivity of microscopy (P. 
falciparum) 
>100 90% 
0–100 75% 
Specificity 75% 
 
 
A sigmoidal function was found to be a good match for this data. Since the 
probability of obtaining a positive outcome when testing a sample with no 
parasites is non-zero, the sigmoidal had to be scaled. With a parasite density of Y, 
probability of a positive outcome with zero parasites α, and parameter β, this gives 
us the probability of a positive test outcome as a function of parasite density:  
( ) (1 ) Yf Y
Y
α α β= − + +  
and thus the diagnostic test’s output can be modelled as Bernoulli (f(Y)).  
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The parameters in Table 5.3 were used to model RDT and microscopy diagnostics.  
 
Table 5.3 Parameters used to model diagnostic sensitivity and specificity 
Parameter Description RDT Microscopy 
α  Specificity 0.942 0.75 
β  density at which sensitivity is half given 
α =1 
50  
 
5.4. Model of incidence and management of non-malarial fevers 
 
Clinical decisions on management of fevers affect health outcomes and costs for 
both malarial and non-malarial illnesses. Correct targeting of antimalarials to 
malarial fevers and antibiotics to those non-malarial fevers (NMF) that need them 
is desirable. The use of malaria diagnostic tests to confirm the presence or absence 
of malaria parasites could help to achieve this; where fever is often treated 
presumptively as malaria, they might be expected to result in reduced mortality 
from non-malarial illnesses, as well as lowering malaria treatment costs and 
slowing the spread of antimalarial drug resistance. This is because a negative 
malaria diagnostic test result would likely prompt consideration and treatment of 
alternative causes of fever, while a positive test would increase the certainty that 
the symptoms are indeed due to malaria. These benefits and costs should be 
included when evaluating the cost-effectiveness of varying levels of 
parasitological diagnosis. We therefore present a model for the management and 
clinical outcomes of NMF. 
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Non-malarial fever (NMF) incidence and severity 
Table 5.4 Estimated incidence of non-malarial fevers 
(Source: A. Schapira, 2009) 
Age-group All fever pppy RR 
Estimated non-malarial fevers 
pppy 
0-11 mo. 9.1 
12-59 mos 9.8 9.66 1 6.08 
5-9 vrs. 6.06 6.06 0.63 3.81 
10-14 yrs. 4.16 4.16 0.43 
 2.62 
15-59 yrs. 6.43 6.43 0.67 4.05 
60 yrs + 8.6 8.6 0.89 5.41 
 
 
To model age-based incidence of non-malarial fever, the data shown in Table 5.4 
were used. In order to transform this into a continuous function for frequency 
given age, we interpolated linearly on the data-points generated as follows: 
• For each age group, we added a data point centred on the age axis with 
frequency as given in the age group. 
• We added data points at ages 0 and infinity, taking frequency from that of 
the youngest and oldest age groups. 
 
The incidence of NMF was modeled as an interpolated linear function. NMFs can 
only start at a given time point if it has been determined that a malarial fever is not 
starting at that time point. If both a NMF and a malarial fever occur within the 
health system memory, only the malaria episode is reported.  
 
Each NMF has a certain age-based probability of needing antibiotic treatment, 
which was assumed to be independent of parasitological status. 
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Model for the probability of antibiotic administration 
 
We assumed that each individual has a probability of antibiotic administration, 
( )P AB , which varies according to treatment-seeking location. For NMF seeking 
treatment in a health facility, ( )P AB  is a function of the average probability of 
being prescribed an antibiotic in the absence of a malaria test; whether the 
individual had a negative or a positive malaria diagnostic test result; and whether 
the individual needs or does not need an antibiotic (this latter captures signs and 
symptoms that would indicate to a health worker need for antibiotics, in the 
absence of knowledge of malaria parasitological status).  
 
Thus: 
0 1 2 3logit(P( )) * ( ) * ( ) *( )AB I MD I MD needβ β β β= + − + + +  
and 
0 0 3log it( ) *P( )nP Nβ β= −  
 
where 0β is the log odds of receiving an antibiotic in the absence of need and of a 
malaria test; 1β  and 2β  are the effect of a negative and positive test, respectively, 
on the log odds of receiving an antibiotic; and 3β   is the effect of needing an 
antibiotic on the log odds of receiving it. ( )I X  is 1 when event X  is true and 0 
otherwise; event “need” is the event that death may occur without treatment, and 
"MD-" and "MD+" are the events that a malaria parasite diagnostic was used and 
indicated no parasites and parasites respectively. 0P  is the average probability of 
being prescribed an antibiotic in the absence of a malaria test, and ( )nP N  is the 
probability that a NMF needs an antibiotic. 
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For a NMF seeking treatment in the informal sector,  
0 4logit( ( ))P AB β β= +   
where 4exp( )β  is the effect of seeking treatment in the informal sector on the odds 
of getting antibiotics. In general, it is not known how the chance of getting an 
antibiotic depends on health facility attendance. Therefore, for the purposes of this 
model, 4β was set to 0, assuming that the overall probability of getting an 
antibiotic is not affected by seeking in the informal sector but targeting of 
antibiotics to those in need is improved in health facilities both by malaria 
diagnosis and additional diagnostic procedures (e.g. measuring respiratory rates, 
examining for symptoms of viral infection, etc). 
 
For NMF seeking treatment from community health workers (CHWs) who are 
trained in malaria diagnostic testing and management of non-malarial fevers, 
( )P AB  is assumed to be the same as in formal sector. If treatment is sought from 
community health workers (CHWs) trained to administer only presumptive 
treatment for malaria, or if no treatment is sought, ( ) 0P AB = . 
 
For malaria fevers,  
0 1 2 3logit(P( )) * ( ) * ( ) *( )AB I MD I MD needβ β β β= + − + + +  
and 
0 0 3logit( ) * ( )mP P Nβ β= −  
 
where ( )mP N  is the probability that a malarial fever needs antibiotics. This is 
assumed to be zero, as NMF are only assumed to occur in the absence of malaria 
fevers.  
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NMF case fatality rates 
 
The case fatality rate of fevers that do not need antibiotics is assumed to be 0.  
 
0 (1 * ( ))a ABaCFR need I ABγ ε= −  
where aCFR need  is the age-based case fatality rate given need for antibiotics, 0aγ  
is the age-based case fatality rate in the absence of antibiotics, given need, and ABε  
is the efficacy of the antibiotic on the case fatality rate. ( )I AB  takes the value 1 if 
the individual receives an antibiotic and 0 if s(he) does not. 
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6. Parameterization of a P. falciparum case management 
model integrated with pharmacodynamics 
 
6.1. Background 
 
To parameterize the one-day time step case management model integrated with 
pharmacodynamics, we collected and analysed evidence on patient and provider 
behaviour that influences the level of effective case management coverage.  This 
was divided into two sets of data: 1) levels of treatment-seeking for fever or 
malaria, quality of care and patient use of medicines under usual practice; and 2) 
the impact and cost of interventions to improve treatment-seeking, quality of care 
and use of antimalarial drugs. Usual practice was defined as ACTs policy but with 
limited interventions above and beyond what was available under previous first-
line antimalarial drug policies. We also aimed to gain an understanding of the 
relative importance of determinants of these variables.  
 
 
Health system classification 
  
Successful ACTs-based malaria case management requires considerable health 
system capacity, which includes human resources, infrastructure, health 
commodities, logistics, tracking progress and effective financing. In order to 
provide general cost-effectiveness results for different health system settings, we 
planned to group countries by health system type and assign each group a common 
set of parameters in the case management model that determine baseline case 
management coverage. In simulations of intervention effectiveness, we would also 
match estimates of cost and impact from intervention studies to health system 
groups.  
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Recently, there is increased global recognition of the need to invest in health 
systems while working towards disease-specific targets [161;162]. WHO-
CHOICE (Choosing interventions that are cost-effective) has undertaken to 
improve costing of health systems interventions [163] and through the Alliance for 
Health Policy and Systems Research, WHO is promoting the generation and use of 
health policy and systems research as a means to improve health and health 
systems in developing countries. 
 
In 2000, the Commission on Macroeconomics and Health (CMH) classified 
countries by the need for additional health systems investments [164]. Following a 
review of work on classifying health systems, we found that, more than 10 years 
on, the CMH remains the reference for this type of work. A recent analysis on the 
intervention and health system costs of scaling up to reach the health Millennium 
Development Goals (MDGs) used the CMH classification, adjusting it to take 
account of specific constraints related to maternal health [165]. A 2009 attempt to 
create a health system typology for the 41 countries and 5 Indian states estimated 
to have the highest child mortality was unable to find variables upon which 
countries grouped. Scarce data for comparison of health systems in low-income 
countries was identified as a major problem [166].  
 
Our work ran into a similar problem, as we found that countries did not cluster 
easily according to all of the variables in our case management model – access, 
provider compliance, and patient adherence. The complexity of health systems and 
the state of malaria case management therein lead us to conclude that the results of 
simulating case management in generic health systems using our model would 
have limited utility. Instead, data on case management from a particular place can 
be input into the model for geographically-specific predictions of cost-
effectiveness; alternatively, it makes more sense to define several levels for each 
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parameter and investigate what effect varying each has on the results, without 
referring to particular health system types.  
 
6.2. Methods 
 
We undertook a review of published literature using the keywords in Table 6.1. 
Table 6.1 Literature review search strategy 
 
Key words used in search: 
 
Location Disease/conditions 
Treatment 
Diagnosis 
Case Management 
Treatment-seeking 
Care-seeking 
Demand 
Access  
Equity 
Coverage of poor 
Health services performance 
Quality of care/of health 
services 
Prescribe 
Adherence 
Compliance 
Use of drugs/medicines 
Cost 
Cost-effectiveness 
Health services efficiency 
Community health 
Performance improvement 
Informal sector 
Shopkeepers/Drug vendors 
Global ACTs subsidy 
Affordable Medicines 
Facility for Malaria 
Franchising/accreditation 
Africa 
 
Malaria 
Fever 
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We considered primarily material published from 2001 onwards, as this is the year 
that South Africa changed its first-line treatment policy to ACTs and WHO 
recommended them as first line treatment for uncomplicated malaria. The last 
database search was conducted in late 2009, although efforts were made to update 
this with key additions to the literature thereafter. Searches were limited to 
material published in the English language.  
 
The electronic databases used were PubMed and African Journal Online, and 
manual search for relevant references. We also attempted to include gray literature 
by searching the sites of World Bank, WHO, the UK Department for International 
Development, Partnerships for Health Report project, Quality Assurance Project, 
Health Systems Resource Centre, Population Services International, Management 
Science for Health, Malaria Consortium, DHS, MICS, GFATM, MIS, and 
BASICS.  
 
Criteria for inclusion as data for the parameter estimates were as follows:  
 
1. Studies with original quantitative data on actual treatment-seeking for 
fever/malaria, quality of care for fever/malaria, or use of antimalarial drugs 
where the sample is representative of the population under study. 
2. Studies of interventions specifically undertaken to improve these variables, 
where there is a quantifiable change in patient or provider behaviour from 
the introduction of an intervention.  
3. Both types of studies had to present both numerator and denominator 
information for outcomes.  
4. In the case of intervention studies, they had to be either RCTs, time series 
measurement, pre-post design with or without a control, and post design 
with a control. 
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When assessing the strength of the study, we considered whether it was a peer-
reviewed study, the sample size, and whether the study reported statistical 
significance of results. 
 
Providers were defined as anyone responsible for dispensing antimalarials and 
were categorized as formal/informal, public/private and community-based. Self-
treatment was defined as not consulting a provider.  
 
We excluded studies conducted in populations where malaria is not endemic; 
studies on chemoprophylaxis or mass treatment; studies which were not 
representative of the underlying variable to be estimated (for example, studies of 
treatment-seeking behaviour conducted at health facilities, or studies of adherence 
in a supervised population); studies of knowledge and perceptions with no data on 
actual patient or provider behaviour for recent illness episodes experienced or 
treated; and general reviews with no original data. 
 
6.3. Main findings 
 
Care-seeking 
 
There is a large body of literature on care-seeking for febrile illness across sub-
Saharan Africa, particularly among children under five in rural areas. Many of the 
studies use household survey methodology, interviewing caretakers about actions 
taken for recent childhood fevers (usually the last two weeks). The majority of 
these found high treatment rates (most over 90%), and that multiple treatments 
were common (most over 40%). Self-treatment was the first response to fever in 
about half of all cases, often with inappropriate drugs and dosages. Often, febrile 
children were given an antipyretic only. In most studies around half of fever cases 
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received some treatment in the official health sector, and this was higher in urban 
areas and for cases of higher perceived severity [93;167-171].  
 
Varying definitions of treatment sources are used, particularly for self-treatment. 
For example, studies differ in their definitions of “self” and “home” treatment, and 
in whether they consider treatment-seeking from a shop or pharmacy to be self-
treatment [172]. Definitions seem to be shifting to differentiating between the 
public/ not-for-profit sector, which includes public health facilities, community 
health workers, and non-profit health facilities, and the private sector, which 
encompasses outlets with or without qualified health workers [31].  
 
Whereas earlier studies focused more on describing treatment-seeking behaviour, 
more recent work seeks to understand why people make the choices they do [173]. 
Baume et al found that mothers seem to be very aware of start of fever and its 
course, suggesting that caretaker recognition of fever is not a major impediment to 
care-seeking [174]. Several studies have assessed the accuracy of mothers’ 
diagnoses of malaria in their children, often finding quite a low sensitivity [175]. 
The availability of drugs, perceived quality of provider, distance from health 
center, perceived severity of illness, duration of sickness, and costs/ability to pay 
have all been found to influence choice of provider [174;176;177]. Some evidence 
indicates that smaller children are more likely to be taken to a health centre, 
suggesting that mothers recognize the advantages of seeking care in the public 
sector and are deterred by other factors such as cost or convenience [178].  
 
Recent work in medical anthropology seeks to place access to health care within 
the broader context of livelihood insecurity to better understand the many 
dimensions that influence access. This work highlights the importance of 
understanding how people mobilize household and community assets to access 
care [179]. 
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Findings indicate that delays in treatment seeking from the formal sector are 
substantial, even where physical access to care is relatively good [180]. A study in 
Ghana conducted in 2002-2004 found that only 11% and 33% of children 
consulted a trained provider within 24 and 48 hours, respectively [181]. A study 
from Kenya reported a median waiting time of 2 days to any treatment, and that 
only <3% of fevers were treated within 24 hours using the nationally-
recommended 1st line drug, sulfadoxine-pyremethamine (SP), obtained largely 
through the public formal sector [182]. In a study of children presenting to health 
facilities and drug shops in Uganda, the mean duration of illness was 3.6 days; for 
those with no prior treatment it was 2.16 days [183].  
 
Previous work suggested that convulsions, a symptom of severe malaria, were 
associated with supernatural causes and prompted treatment-seeking from 
traditional healers [174;184-186]. However, more recent research indicates that 
this seems to be no longer the case. 57% of respondents in a rural Tanzanian 
community said that malaria was a cause of convulsions [187]. De Savigny et al 
found that of malaria-attributable deaths in Tanzania, nearly 79% used modern 
biomedical care as first resort [188] This suggests that in this population, 
something broke down in the transaction to obtain that care or in the quality of 
care at the point of contact. 
 
Treatment-seeking for adult febrile illness has been a relatively neglected area of 
research. Guyatt and Snow attempt to fill this gap, extending their household 
survey to treatment-seeking in three age groups (under 5, 5-14, 15+). Surprisingly, 
the study found that, in a rural, low-transmission area of Kenya, there were no 
significant differences in prevalence of reported fever or treatment-seeking for 
recent fever by age. Overall, only 33% of all fevers were treated with an anti-
malarial drug, due to the large proportion of visits to the informal sector where 
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anti-malarials were infrequently prescribed, with no significant difference by age 
[189].  
 
Rapid urbanization across much of sub-Saharan Africa has prompted inquiries into 
the differences between malaria/fever care-seeking patterns of rural and urban 
populations. A study in coastal Kenya found that urban care-seeking for malaria 
was surprisingly similar to rural care-seeking; 52% of lifelong rural resident 
mothers and 47% of urban resident mothers used only shop-bought drugs for 
recent (2 week recall) episodes of childhood febrile illness. Urban mothers were 
more likely to contact a private clinic (24% vs. 15%) and less than half as likely to 
consult a government service (22% vs. 10%). Urban mothers had better access to 
prescription-only drugs such as SP or amodiaquine (AQ), which were stocked 
more frequently in shops  [178]. A study in Kenya found that, for adults and 
children with acute illness, in a rural area 80% received some treatment (of which 
55% was self-treatment), while in an urban area 91% received some treatment (of 
which 50% was self-treatment) [190]. The high prevalence of self-treatment in 
urban areas begs the question of whether community-based initiatives would be 
cost-effective in these settings. Time before action taken was significantly shorter 
in urban (1.05+- 1-67 days) than rural (2.32 +- 0.82 days) areas in a study in 
Nigeria [191] 
 
Are national policy changes from chloroquine to newer, more effective 
antimalarials having an impact on treatment-seeking and access? Several studies 
suggest that treatment-seeking patterns are relatively consistent [192-194], and 
that access to ACTs remains very low in settings from Tanzania and Kenya to 
Burkina Faso [195;195;195-197]  
 
Recently-conducted household surveys investigating treatment-seeking for febrile 
children in six Africa countries highlighted the continuing dominance of the 
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private sector as a source of fever treatment for children [31]. Coverage with an 
ACT was found to be low although variable across countries, with Uganda and 
Zambia having relatively higher rates.  
 
By contrast, in another study from Tanzania, self-treatment seems to have 
decreased following the policy change from chloroquine (CQ) to SP [198]; this 
may be because CQ was no longer available in shops and was not replaced with 
SP [199]. In North A district, Zanzibar, care-seeking for fever by children at 
public health facilities increased by two-fold following the introduction of free 
ACTs. The authors hypothesize that these two are related, but note that there were 
no stock-outs of ACTs during this period, and that physical access to health 
facilities is quite good in the area [26].  
 
For nationally representative estimates of treatment-seeking for febrile illness, the 
Demographic and Health Surveys (DHS) and the Malaria Indicator Cluster 
Surveys (MICS) represent the most geographically complete and directly 
comparable source. Indicators are the percentage of children under five with fever 
in the two weeks preceding the survey and of those, the percentage who took 
antimalarial drugs the same or next day. These are disaggregated by background 
characteristics. There is also data on the percentage of children who took specific 
antimalarial drugs, and the percentage who took them the same or the next day.  
Given the large variation among countries in treatment-seeking patterns [3], it 
would be advisable to use household survey data to simulate specific settings.  
 
Quality of care 
 
Quality of care is multidimensional. For our purposes, adequate care can be 
defined as performing a diagnostic test on a febrile patient and prescribing an 
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antimalarial to a test positive patient with sufficient active ingredient, in the 
appropriate dosage, and not prescribing an antimalarial to a test-negative patient.  
 
With regard to diagnostic testing, recent developments to ensure RDT quality 
[200;201] and evidence that restricting antimalarial treatment to parasitologically 
confirmed cases of malaria is safe [8] have allayed some of the early concerns that 
RDTs were not sufficiently accurate to justify withholding life-saving drugs. 
Studies have shown that increased use of parasitological diagnosis can improve 
the management of febrile disease [202]. However, concerns with moving to a 
test-based strategy for young children include doubts about the sensitivity of the 
test under field conditions and satisfactory adherence to the test by health workers 
[10]. This issue is not completely resolved and some have called for additional and 
larger studies that include severe outcomes. This would include studies on 
etiologies of non-malarial fevers, antibiotic prescribing and thus clinical benefits 
of improved treatment of alternative fever causes [203]. 
 
Availability and affordability of drugs and diagnostics in places where people 
access treatment are prerequisites for adequate quality of care. Outlet surveys 
conducted in six countries in the frame of the ACT Watch project found that 
availability of quality-assured ACTs, at affordable prices, is very low, particularly 
in the private sector where most antimalarials are distributed. Availability of 
diagnostic tests also varied considerably by country but in general was quite low, 
particularly in the private sector [204]. Stock-outs in public health facilities are a 
major problem [34;205]. However, treatment guidelines often are not followed 
even when the first-line drug is in stock [206]. 
 
Quality of care in the public sector has been found to be higher, in general, than in 
the informal sector. In a study in Tanzania, care-seeking from a government health 
facility was the main predictor increasing the likelihood of prompt access to ACT 
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[195]. However, recent household surveys suggest that case management practices 
in the public sector are far from ideal – fewer than half of children managed in the 
public sector received a blood test for malaria, and between 7 and 47% received an 
ACT [31].  The high use of the informal sector for fever treatment in Africa is in 
part a response to perceived poor quality of services offered in the public sector 
[177].  
 
Prescription of the correct drug in the appropriate dose is often sub-optimal. 
Hetzel et al found that, despite high health facility usage rates in rural Tanzania, 
only 23% of children and 11% of adults received timely treatment with an 
appropriate and correctly dosed antimalarial; inappropriate dosing of antimalarials, 
including in public health facilities, was documented as a problem [207]. In four 
Kenyan districts three years after SP replaced CQ as first-line treatment, SP was 
only prescribed in the correct dosage in 34% of pediatric prescriptions. Counseling 
and observation of taking treatment were also poor [208]. Another study, with a 
small sample size, found that children were never prescribed second line treatment 
(SP) even if it was a repeat treatment-seeking visit [174]. Nine months after 
introduction of artesunate-amodiaquine (AS-AQ) in public facilities in Burundi, 
AS-AQ prescription was only 14.1% [194] Zurovac et al examined prescribing 
practices in health facilities 4 to 6 months after the policy change from SP to 
artemether-lumefantrine (AL). The study found that only three-quarters of children 
with fever (and a positive test or no test) were prescribed an antimalarial, and only 
28% got AL. Many were prescribed the second line drug (AQ). The presence of a 
positive test did made a child more likely to get AL  [209].  It seems that health 
workers may prescribe AL for cases perceived as “more urgent” while using other 
antimalarials for other cases [210] 
 
Two additional problems are low diagnostic testing rates, and prescription of 
antimalarials to test-negative patients. Even when available, diagnostic tests are 
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often not used or their results ignored [211;212], even in areas of low-
.transmission [213]. Hamer et al found that only 28% of febrile patients were 
tested in facilities where diagnostics were available, and many who tested negative 
(58% by blood slide, 36% by RDT) still got antimalarials. 72.6% had no test 
performed and 66% were prescribed antimalarials anyway [214]. Overdiagnosis 
may lead health workers to miss other serious causes of febrile illness, as found in 
Tanzania, where 66% of slide-negative patients were not treated with antiobiotics, 
of which 7.6% died [215]. In 2009, Kenya initiated a new policy of universal 
parasitological diagnosis and targeted treatment with AL. Nation-wide surveys in 
Kenya found that, in health facilities where AL and malaria diagnostics were 
available, about half of patients with fever were tested, and about half of test-
negative patients were treated with an antimalarial, even following exposure to 
implementation activities to promote the new policies [205]. 
 
Zurovac et al reported that in four districts in Kenya, actual treatment practices 
differed dramatically from the national guidelines, which stated that febrile 
children under five should be treated presumptively for malaria but that over-fives 
should be tested before treatment. About a half a year after the new first-line drug, 
AL, was delivered to health facilities, only 43% of febrile patients over five years 
were given a diagnostic test, compared to 26% of children under five. Prescribing 
differed little across age groups, however; antimalarials were prescribed for the 
majority of adults and children with negative test results and those without tests 
performed. AL prescriptions usually followed a positive test result. The authors 
conclude that different age-specific recommendations for diagnosis may be 
difficult to implement [216]   
 
Other studies, however, have shown more positive results. A dramatic reduction in 
the use of antimalarials following implementation of RDTs was documented in 
urban Tanzania [217]. In Senegal, where the public health sector is quite strong 
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and in the presence of a small financial incentive to the consumer (who have to 
pay for first-line antimalarial drugs), parasite-based diagnosis increased to 86% 
over the three-year period following the policy change, resulting in a drop in ACT 
prescriptions to roughly the same number as confirmed malaria. This suggests that 
high adherence to an RDTs-based policy is achievable on a national scale [218].  
 
Why do health workers fail to follow recommended treatment practices? An 
increasing number of studies have explored this question. In the Zurovac et al 
study above, only 28% of children had AL prescribed, even when it was in stock, 
with health workers preferring to prescribe AQ. Factors associated with higher 
likelihood of AL prescription were health worker’s pre-service training, in-service 
training including AL use, presence of a positive malaria test, main complaint of 
fever and temperature greater than or equal to 37.5 degrees Celsius. Stock-outs 
and lack of training of health workers continued to be a challenge. Most (92%) of 
children received AL in the correct weight-specific dosage [209]. Interestingly, in 
a study from Zambia, in-service training and provision of job aids did not seem to 
influence AL prescribing [219].  Chandler found that 33% of slide-negative 
patients in a hospital OPD were prescribed antimalarials. The variation among 
hospitals was not apparently related to the transmission level, and patient demand 
was not seen to be a factor driving over-prescription [220] 
 
A qualitative study published in 2008 looked specifically at the issue of why 
health workers do not prescribe ACT when it is indicated. The reasons found 
related either to specific failings in introduction of policy (1) mixed/unclear and 
incorrect messages delivered during training and (2) availability/continued supply 
of AQ; and 2) more general health systems issues (workload of staff and erratic 
nature of drug supply) [221].  
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Treatment in the informal sector is well-documented as often inappropriate 
[182;222]  . Following the change to SP as first-line policy, Kachur et al found 
that, in rural Tanzania, only 17% of clients who visited drug stores to obtain 
medicine for a patient with fever or malaria actually purchased an antimalarial 
drug, while 77% purchased anti-pyretic medications. Of those that did purchase 
antimalarials, education of household head was significantly correlated, suggesting 
the importance of cost. The same study found that patients seeking treatment from 
drug stores for febrile illness were as likely to have malaria parasitemia as those 
seeking treatment in the formal sector, which confirms that the role of the informal 
sector in malaria case management cannot be ignored [193].  
 
Poor drug dispensing practices in the informal sector are being compounded by a 
large market for counterfeit antimalarial medicines in Africa [223]. A nationwide 
survey in 2001-2002 of CQ, quinine and antifolates sold in the informal sector in 
Cameroon found 12-74% of the samples to be of poor quality or containing no 
active ingredient [224]. A recent analysis of drugs sourced from urban or peri-
urban pharmacies in six African countries found that 35% of all samples failed 
quality tests, including 19% of artemether-lumefantrine fixed dose combination 
and 42% of artemisinin monotherapies [33]  
 
Patient use of antimalarial drugs 
 
Definitions of adherence and methodological differences among studies 
complicate the comparison of adherence studies. Some rely on self-reported 
adherence [225], while others combine this with pill counts/bottle inspections 
[226;227] and/or biological methods [228] . To be considered completely 
adherent, most studies considered both number and timing of doses. Studies differ 
in how they treat vomiting of doses in measurement of adherence [229].  
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It is generally believed that the simpler the dosing schedule, the higher the 
adherence. Abuya et al’s study bears this out, with SP used more appropriately 
than AQ although “adequate use” is not well-defined. One of the few studies to 
examine adherence in the informal sector, this paper found adherence to AQ of 2-
12%, and to SP of 46-84% [222]. In rural Senegal, less than a year after the policy 
change to AQ+SP as first-line treatment, 38% were considered strictly adherent 
[230] . Adherence to tablets was better than syrup (45% vs. 28%), which echoed 
previous findings [231].   
 
In research studies, adherence to AL has been found to be high [232;233]. Fogg et 
al found 90% probable adherence to Coartem in a study in a Uganda outpatient 
department. However, this was quite a controlled study and subjects were given 
careful instructions explanations by health workers [67]. In less controlled studies, 
adherence was still found to be quite high: 88% reported adherence to AL was 
found in rural Tanzania, and most non-adherence was due to untimely dosing 
rather than missing doses [225]. In another study from Tanzania, the full dose was 
taken at a satisfactory time in about 90% of cases [227]. However in Malawi, only 
65% of patients were completely adherent according to pill count and dose-recall 
interviews [226] and in Kenya, only 64% were [234].  
 
Adherence to co-packaged or co-blistered ACTs has been found to be lower in 
general. 77% adherence to AS+AQ, assessed by self report and pill count, was 
documented in children under five in Zanzibar [229]. Adherence of 48% to 
AS+AQ was found in a remote rural area of Sierra Leone, where patients had 
relatively little education and the treatment had been implemented for some time 
[235].  Another study found 75% complete adherence to AS+SP (based on self-
report and tablet counts), but with counseling and packaging interventions [236].  
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Several studies assessed adherence in atypical settings, with contrasting findings. 
In a refugee settlement where SP-AS was given at a clinic, without clear marks of 
timing or dosage on the packaging, only 39% probable adherence was found 
[237]. Among internally displaced persons in Uganda, Kolaczinski et al found that 
overall adherence to blister-packed CQ plus SP distributed through community 
health workers was 96%. However, this measure relied heavily on self-reports, 
even when the blister pack was not presented, sampling bias may be a problem, 
and the patient population may not be representative of non-conflict areas in 
Africa [238].  
 
Education level in the patient or caregiver, lack of supervised intake of the first 
dose   [229], poverty level [225], and unclear instructions from prescribers [237] 
are some of the main factors associated with non-adherence. In one study, children 
were found less likely to be adherent [226]. Conversely, improved packaging 
[231] and pictorial inserts and verbal instructions [239;240] increased adherence. 
 
Drawing on the literature review, a set of baseline model parameters is proposed in 
Table 6.2. A database has been compiled with quantitative results of the literature 
search.  
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Table 6.2 Proposed baseline parameters for case management model 
Input variable High or best estimate (Source) Alternative estimate (Source)  
% that seek treatment in formal sector 50 [3] 20 [3] 
% that seek treatment in informal sector 80 [3]  30 [3] 
% not treated 20 [3] 0 [3] 
% that seek treatment on the same or next day 30 [140]  
Formal sector  
 
% tested  35 [31;241] 
 
Of those tested ,% tested by microscopy 20 (Assumption)  
Of those tested, % tested by RDT 80 (Assumption)  
Of those that test positive, % that get antimalarial treatment 95  [213;214]        
Of those that test negative, % that get antimalarial treatment 50  [205]  
Of those not tested, % that get antimalarial treatment 60 [214]  
% of facilities that have ACT in stock  90 [209] 60 [209] 
Of those that test positive, % that get ACT (where ACT in stock) 70 [214]  
Of those that test negative, % that get ACT (where ACT in stock) 30 [214]   
% of AL that is good quality  95 (Assumption)  
% of SP that is good quality  90 (Assumption)  
% AL prescribed correctly 90 [242;243]  
% SP prescribed correctly  34 [208]  
% good adherence to ACT 90 [67] 39 [237] 
% good adherence to SP  95 (Assumption) 
 
Informal sector  
 
% tested 0 [31] 
 
% that get antimalarial treatment 30 [182]  
% that get ACT 6 [31]  
% of ACT that is bad quality  19 [33]  
% of SP that is bad quality  50 [33]  
% that get correct dose of ACT 70 [244]  
% that get correct dose of SP  46 [222]  
% good adherence to ACT 50 (Assumption) 
 
6. Parameterization of case management model  
 
153
Interventions and strategies to improve case management 
 
We reviewed the literature on interventions to improve access to malaria treatment 
by modifying patient and provider behaviour. We did not include wider health 
system interventions, for example removal of user fees in public health facilities or 
improvements in drug and diagnostic quality control or supply chains.  
 
Given the large and persistent share of the informal sector in providing anti-
malarial treatment across Africa, and the inappropriate care they offer, several 
approaches to improve their practices have been piloted. These interventions 
require first identifying retailers and characterizing their practices [245].  One 
approach has involved training shopkeepers to recognize malaria and improve 
dispensing [246;247]. In rural Kenya, the proportion of shop-treated childhood 
fevers receiving an adequate dose of a recommended antimalarial drug (CQ or 
later, SP) within 24 hours rose from 1% to 28%, following training for drug retails 
and community education [248] The estimated annual cost for implementation of 
this programme on district scale was US$ 45,489, or US$ .10 per capita, or a cost 
per DALY averted of US$ 3.85 [249]. Cost-effectiveness was modeled based on 
data from the early implementation phase, assuming that the same level of 
effectiveness would be maintained on a larger scale. This may be plausible, as the 
programme showed a higher effectiveness when it was scaled up [248]. The 
analysis is dependent on assumptions of a district population of about 473,000, 
annual fever incidence of 4.8 per child, that 56% of children visit a shop first for 
fever, and that the programme would have an eight-year life span. Larger-scale 
studies are needed to show whether this type of programme can be cost-effective 
on a large scale, with combination therapies, and whether it is sustainable. 
 
Due to the high cost and difficulty of reaching numerous retail outlets, an 
alternative approach involved training drug wholesalers to educate retailers dosing 
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and distribute job aids/posters. The study design was limited, in part because shops 
were not randomized. Following the intervention, 32% of shops receiving job aids 
(assumed to have been “informed”) prescribed to mystery shoppers the approved 
first line drug (SP), against 3% of those that were assumed not to have been 
informed. The cost of intervention in the first six months was US$ 8300, for a 
district of 900,000 or US$9-11 per retail outlet reached [250]. Many of these costs 
were fixed (such as development of shopkeeper job aids and posters) that could be 
spread over additional districts and annualized, making the average yearly costs 
much lower. 
 
One study was found that evaluated a relatively large scale Ministry of Health 
program to train retail sector providers in Kenya. It found that the program led to 
significant improvements in provider knowledge and practices. About 31% of 
intervention providers sold AQ with correct advice on use to surrogate clients, 
compared to about 5% of control retailers [251].  
 
In Tanzania, a new class of outlets known as Accredited Drug Dispensing Outlets 
(ADDOs) was created to improve access to treatment in the private retail sector. 
The intervention involved a combination of private drug shop dispenser training, 
incentives, accreditation and regulation. Subsidized AL was made available in 
both health facilities and ADDOs in 2007. ADDOs were found to greatly improve 
availability and accessibility of drug shops, and the quality of advice and 
dispensing in these outlets, and the use of the private retail sector increased despite 
much higher prices than in health facilities. However, the low affordability of AL 
restricted its availability, and SP and amodiaquine were still the most dispensed 
drugs. This study highlighted the importance of the private retail sector in 
provision of antimalarial treatment, but concluded that affordability of ACTs must 
be improved if they are to be widely dispensed [252]. A companion study in the 
same area found that contemporaneous health education campaigns aimed at 
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increasing people’s knowledge of appropriate malaria treatment seemed to 
improve care-seeking [253] 
  
To address the problem of limited affordability and accessibility of ACTs, 
particularly in the private sector, a subsidy scheme entitled the Affordable 
Medicines Facility - malaria (AMFm) was recently launched.  Hosted by GFATM, 
it negotiates with drug manufacturers to reduce the price of ACTs to both public 
and private sector first-line buyers, who are expected to pass on the highest 
possible proportion of this price benefit. Countries participating in AMFm must 
also implement “supporting interventions” to ensure the increased availability and 
safe use of ACTs. AMFm Phase 1 is being implemented through pilots in eight 
countries, and data is available from initial pilot projects in Tanzania and Uganda. 
In Tanzania, the proportion of consumers in the intervention districts purchasing 
ACTs rose from 1% at baseline to about 44% one year later, while no change was 
observed in the control district [254]. However, caution should be exercised when 
applying the findings of this small-scale study to the envisaged AMFm.  
 
Only one published study was found with data on the impact of private sector 
ACT subsidies on coverage of prompt effective treatment. The intervention, a 
cluster-randomized trial in Kenya, involved provision of subsidized packs of 
pediatric ACT to retail outlets, training of retail outlet staff, and community 
awareness activities. While there was no significant difference in treatment-
seeking behaviour between the control and intervention arms, at follow-up the 
percentage of children receiving AL on the day of fever or the following day was 
25% greater in the intervention arm. This suggests that the increase in coverage 
was indeed due to a change in the type of drugs dispensed in the private retail 
sector. Furthermore, most caregivers paid the recommended retail price for the 
subsidized ACT [244]. 
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There is virtually no evidence on the feasibility or impact of introducing RDTs in 
the private retail sector in Africa, although a randomized trial is upcoming in 
Uganda [255]. 
 
An alternative distribution mechanism to public health facilities and the private 
retail sector is community, or home- based, case management.  Delivery of 
treatment for suspected malaria through home-based management of malaria 
(HMM) has been discussed and applied in sub-Saharan African countries, with 
various degrees of implementation, for some years [256-259]. These experiences 
resulted in WHO’s development of the Roll Back Malaria strategy for improving 
access to treatment through home management of malaria [116]. This strategy 
consists of four major components: an effective communication strategy, training 
of community-based providers, availability of medicines, and supervision and 
monitoring. 
 
The average net cost of an intervention to promote home management of malaria 
in rural Burkina Faso, including training, purchase of the first stock of drugs, bags, 
labels and packing of drugs, incentives to community health workers (CHWs), and 
supervision and drug distribution, was 1994 US$ 0.06 per resident child [117]. The 
cost per villager, including consumer and provider costs, of design and 
implementation of a strategy based on use of CHWs for near and appropriate 
treatment of malaria was between US$ 1.40 and US$ 1.70 [119]. Both 
interventions seemingly resulted in improved management of febrile illness.  
 
There is some evidence of the effectiveness of HMM, although evidence of its 
cost-effectiveness, particularly with ACTs, is limited [260]. A study at sites in four 
African countries examined the feasibility, acceptability and utilization of ACT 
provided at community level. Results from a post-intervention household survey 
of recent treatment- seeking for febrile illness showed high coverage (52-75% 
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treated with ACTs from a CHW) and adherence (71-87% treated promptly 
(receiving first dose on first or next day) and correctly (dose and duration)). 98% 
of all children were correctly dosed. However, this was a very controlled research 
setting and monitored over a short time period; community health workers were 
not paid but were given other incentives [261] The cost of delivering home 
management of malaria in a trial in urban Ugandan children, including the cost of 
AL was estimated at US$ 33.83 per child per year. Home Management of Malaria 
greatly increased the proportion of febrile children receiving prompt and effective 
treatment with antimalarial drugs. However, the health effects were modest, 
suggesting that most antimalarials were given for non-malarial febrile illness 
[118].  
 
Some studies suggest that CHWs can be trained to effectively use RDTs to better 
target malaria treatment and that adherence to test results is high [262;263]. 
Harvey et al reported on a 3-hour training course together with provision of job 
aids for CHWs in Zambia on how to use and interpret RDTs. The course cost 
approximately 2006US$ 175 per CHW, including supplies, transportation, lodging 
for CHWs and salaries, per diems, and transportation costs for the trainers, 
observers and Ministry of Health personnel. When only supplies, transportation, 
and lodging for CHWs costs were included, the total cost per CHW was 2006US$ 
66 per CHW trained. Following the course, significantly more CHWs conducted 
and read the test results correctly than those who had received only the 
manufacturer’s instructions or job aids [121]. 
 
There is now increased interest in exploring whether CHWs can be trained to 
manage both malaria and pneumonia using RDTs, or integrated community case 
management (ICCM). The WHO and UNICEF now recommend ICCM where 
malaria and pneumonia are major killers. A cluster randomized control trial in 
Zambia found that training CHWs to prescribe amoxicillin to children with 
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nonsevere pneumonia and AL for malaria after use of RDTs results resulted in a 
five-fold increase in the proportion of children with non-severe pneumonia who 
received early and appropriate treatment. Furthermore, use of AL dropped 
dramatically; CHWs adhered well to RDT results [120]. Preliminary evidence 
from Uganda suggests that CHWs can be trained to assess manage malaria and 
pneumonia in children, but this study only assessed performance immediately 
following training and these findings need validation in a real-life setting [264] 
 
The evidence on impact of interventions to improve provider practices in public 
health facilities is mixed. Agyepong et al found improvements in prescribing 
practices in clinics where a training for dispensers was held [240], but it is not 
clear whether this translates into better adherence, and if so, whether these results 
can be sustained over time. One study found that gains in knowledge following in-
service training for medical assistants on malaria treatment had deteriorated within 
a year [265]. It appears that knowledge does not always result in improved 
practice. Eriksen et al’s study suggests that staff with less training did not perform 
worse than others [198], leading her to suggest, as others have, that factors such as 
motivation, job satisfaction, cultural factors and financial incentives are probably 
more important. In a study of clinical practice in a health facility in Malawi, only 
71% of ill children that should have gotten an antimalarial according to gold 
standard clinician actually did, and neither in-service training nor supervision were 
associated with fewer treatment errors [266]. These findings are similar to those of 
Rowe et al, who reported that 50% of children were correctly treated. In this study, 
neither in-service fever training nor supervision was significantly associated with 
correct treatment [267].  More recent evidence from Kenya indicated that in-
service training and job aids were not sufficient to improve provider case 
management practices following the policy change to ACTs as first-line treatment  
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Given these results, it is unclear how providers can be convinced to adhere better 
to current malaria treatment guidelines involving RDTs and ACTs. Mobile phone 
text message reminders are an innovative intervention that was shown to improve 
health worker adherence to case management guidelines in Kenya [268] 
 
In the case of severe malaria, some evidence indicates that improved provider 
practices can reduce in-hospital mortality. Biai et al found that paediatric in-
hospital malaria mortality was reduced from 10% in the control group to 5% in the 
intervention group by providing a financial incentive to staff and better 
supervision [269]. Recently, evidence has emerged that rectal artemisinins as pre-
referral treatment can reduce mortality where patients cannot take medicines orally 
and access to injections will take several hours [270]. 
 
6.4. Conclusions 
 
Treatment-seeking for febrile illness from the informal sector remains high, and 
the influence of the implementation of new treatment policies on these patterns is 
only beginning to be understood. Care-seeking for severe illness remains a 
neglected area of research, although recent studies have shown that, in some 
settings, resorting to traditional healers first is no longer a significant reason for 
delay. The multiple factors influencing treatment-seeking for fever in Africa, both 
on the supply and demand side, are well-recognized. There is a need for a greater 
understanding of the key bottlenecks in different settings, as well as 
documentation of best practices of countries that seem to be performing better than 
most, like Uganda and Zambia.  
 
In addition, descriptive evidence indicates that quality of care is sub-optimal, 
including under ACTs policy. However, a clearer understanding of the multiple 
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factors that lead health workers to treat inappropriately, and convincing evidence 
from well-designed, large-scale intervention studies to address these issues, is 
needed. In addition, more data is needed on the etiology and management of non–
malarial fevers. Another area where information seems to be scarce is on referral, 
and its relation to malaria mortality in severe cases. Finally, more information on 
diagnostic and treatment practices in the formal and informal private sector would 
also be very useful. 
 
Adherence to ACT seems to be relatively high, even under routine conditions. 
However, particularly where education levels are low and patient provider 
communication is poor, adherence has been found to be sub-optimal. The impact 
of the introduction of RDTs on adherence is unclear; studies where patients were 
only treated after receiving a positive RDT test showed both relatively high [225] 
and low [235] adherence. There is still room to improve adherence, for example 
through better communication between providers and patients/caretakers and more 
attention to groups that are thought to be less adherent, in particular children.  
 
There are a number of difficulties which arise when comparing studies on human 
behaviour related to malaria treatment, including methods, sample, types of 
questions asked, and the way the data are presented [172].  In addition, there are 
numerous drivers for the results which are unique to the social, economic, cultural 
and health systems context in which the studies were undertaken. For example, 
epidemiology of febrile illness, level of infrastructure, stage of implementation of 
new policies, and health worker remuneration and incentives are just some of the 
factors that influence patient and provider behaviour. Thus, it is debatable how 
much descriptive or intervention data can be applied across settings. Notably, there 
is a lack of data from vast swathes of Africa where malaria burden is high; studies 
are needed to fill those gaps.  
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7. Discussion and Conclusion 
 
The overall aim of this thesis was to predict the impact and cost-effectiveness of 
P.falciparum malaria case management interventions in different transmission and 
health system settings. In low-transmission settings where policy-makers are 
considering pursuing elimination, as well as in settings of higher endemicity where 
the immediate goal is reduction of disease burden, case management is a critical 
component of integrated strategies against malaria.  
 
An existing integrated set of models was applied to examine the effect of passive 
case detection (PCD) in the aftermath of local transmission interruption, and was 
extended to simulate the cost-effectiveness of another chemotherapy-based 
intervention, mass screening and treatment (MSAT). This work also contributes a 
revised method for estimation of uncomplicated malaria burden and a new case 
management model, integrated with a model of pharmacodynamics, which will 
enable a more precise, finer-grained analysis of the effects of scaling up case 
management and improving diagnosis and treatment practices on health outcomes 
and drug resistance.  
 
This discussion places the case management models in context. It then discusses 
the implications of the studies undertaken and summarizes the strengths and 
limitations of the new case management model and the outlook for future 
modeling.  
  
7.1. Context of case management models  
 
Models of the impact and cost-effectiveness of malaria case management can be 
divided into two broad categories. The first includes models where case 
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management (and economics) is considered separately from the biology of the 
disease. The second category comprises models which bring together case 
management, biology and, in the case of cost-effectiveness, economics. 
 
A number of models have investigated case management interventions to reduce 
malaria burden. Some of these are very simple models which use data on baseline 
case management parameters and estimates of intervention impact to predict 
treatment effectiveness [271-273]. Others use estimates of disease burden, 
intervention effectiveness, and unit costs to predict cost-effectiveness of 
interventions or combinations of interventions in different settings [11;128;274-
276]. There is no within-host or transmission model, and the main effect of case 
management is to reduce mortality from the treated bout. There is no explicit 
consideration of the dynamics of transmission and immunity, the loss of which 
results from reduced exposure.   
 
A few modeling studies consider changes in immunity levels and the dynamic 
effects of case management on transmission [277-279]. To date, the application of 
population dynamic transmission modeling of infectious diseases together with 
methods for economic evaluation has been extremely limited [280].  Several 
previous models bring together aspects of malaria biology, case management and 
economics [281;282]. The Yeung et al model, developed primarily to study the 
spread of antimalarial drug resistance, used variable antimalarial and ACT 
coverage rates and adherence and the simulated level of resistance at each time 
step as the determinants of cure rate. Costs to the provider and patient were 
combined with predicted numbers of cases, cures and failures to estimate cost-
effectiveness of different case management strategies. The predecessor to the case 
management model presented in this thesis [41] was integrated into a set of 
models which combined parasitology, burden of disease, health systems, 
transmission and economics. It modeled care-seeking and costs in the formal 
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sector and self-treatment, based on real data from Tanzania. The work presented in 
this thesis adds a pharmacodynamic model, integrated with a more complex case 
management component, to this already quite comprehensive set of models. 
 
7.2.  Implications of studies on passive case detection and MSAT 
 
The passive case detection study was the first to apply the integrated models to 
answer questions regarding local elimination of malaria transmission. The models 
are well-suited for this purpose for several reasons. First, interruption or re-
establishment of malaria transmission is a stochastic process and is likely to 
depend greatly on random variation in risk, human movement, treatment-seeking, 
and other factors. The stochastic models capture this variation, allowing 
predictions of the probability of re-establishment based on multiple simulations 
with different random number seeds. Second, the use of model assumptions allows 
investigation of the effect of model uncertainty on predictions. The findings 
highlight the urgent need for research into the mechanisms and rate at which 
naturally- acquired immunity to P.falciparum malaria decays in the absence of 
exposure. Many people in sub-Saharan Africa could be in this position in the 
future if current efforts to control malaria lead to reductions in malaria 
transmission without eliminating the parasite, and this is likely to be a key driver 
of intervention impact in the longer-term. 
 
However, our analysis ignores several sources of heterogeneity which may be 
critical in low-transmission settings. Notably, it does not include spatial 
heterogeneity in interactions among people and mosquitoes, or in transmission. 
This may lead to overestimation of the probability of local interruption of 
transmission, as residual transmission is likely to be concentrated in 
geographically-defined foci. A transmission dynamic spatial model with multiple 
7. Discussion and Conclusion  
 
164 
interacting populations would be required to capture this heterogeneity. In 
addition, the models were fit to data from medium or high transmission intensities, 
and have not been validated with data from low-transmission settings. Finally, it 
was not readily possible to simulate immunity differentials between individuals 
importing infections and the simulated population; this may bias the estimated 
probability of transmission re-establishment.  
 
One methodological issue which arises in studies of malaria elimination is the 
difficulty of defining such a concept. WHO currently defines malaria elimination 
as zero incidence of locally-contracted cases [20]. However, until eradication is 
achieved, importation of infection and some degree of onward transmission is 
almost inevitable in most places; under the WHO definition, a number of countries 
currently certified as malaria-free would not qualify [51;283]. Our study 
established a threshold allowing each imported infection to give rise to a 
maximum of 2 secondary infections before classifying the simulation as one where 
transmission was re-established, but this was somewhat arbitrary. 
 
The costs of interrupting transmission and preventing re-establishment must be 
considered alongside the expected benefits in terms of disease burden, potential 
health care savings to caretakers and providers, and other benefits using an 
appropriate time horizon and discount rate, to inform the decision. Cost-
effectiveness analysis is likely to be insufficient to inform decision-making for 
elimination, as many of the benefits of elimination go beyond health outcomes. A 
recent analysis found that pursuing elimination is unlikely to be cost-saving 
because of the high upfront costs need to find and eliminate the last infections, as 
well as the ongoing costs for preventing re-introduction [76] . However, non-
health benefits to achieving and maintaining elimination may be substantial and 
need to be taken into account in making investment cases for interruption of 
malaria transmission. These additional benefits are currently very uncertain. There 
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is a need for further research and methodological developments for economic 
evaluation of malaria elimination.  
 
Surveillance in near-elimination or elimination settings will likely require 
interventions based on active case detection, either indiscriminately or in response 
to a detected case. There is a need for more data from field studies on the costs and 
effectiveness of different surveillance strategies.  The impact of such approaches 
will likely be determined to a great degree by rates of decay of natural immunity 
in the absence of exposure. This information could be combined and used with the 
model to help predict the most cost-effective surveillance and response models in 
different settings.  
 
The MSAT study reported here was a first attempt to quantify the effects, in terms 
of burden reduction, and costs of one variant of active case detection. These 
findings suggest that MSAT may be most cost-effective in settings of moderate 
transmission intensity, and not low transmission, as has often been assumed. The 
appendix presents a methodology for estimating costs which could be generalized 
to other interventions involving household visits. An area of uncertainty is the 
investments in the health system that would need to accompany such an 
intervention to ensure its successful implementation. 
 
The study highlights the scope for extending the analysis of the cost-effectiveness 
of scaling up combinations of interventions. In future studies, DALYs should be 
used as the outcome measure in the cost-effectiveness equation. In addition, an 
alternative method for estimating malaria burden which does not assume a fixed 
three-day duration of uncomplicated malaria episodes could improve the accuracy 
of the cost-effectiveness estimate. Finally, future analyses should consider a 
sensitivity analysis varying the unit cost of interventions, particularly case 
management, at different coverage levels. The current case management costing 
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model does not take account of investments in infrastructure or activities that 
would be needed to scale-up malaria treatment, which are likely to be substantial. 
 
7.3. Case management model integrated with 
pharmacodynamics: strengths, limitations, and outlook 
 
The case management model developed as part of this thesis will enable more 
accurate simulations of case management, including the activities involved in 
changing treatment practices, and the effect of drug treatment. It will also permit 
investigation of the development and spread of drug resistance, which is one of the 
most pressing questions in malaria control today [284;285].  
 
The added complexity of the one-day time step models comes at a cost. Enormous 
computational power is required to fit the model parameters to data; this is 
achieved through the use of volunteer computing through the internet [39]. It was 
difficult to predict how long this would take, and ultimately it was beyond the time 
frame allocated for this thesis. In addition, the models are quite time-consuming 
and computationally intensive to run.  
 
Adding additional detail to an already-complex set of models also makes it more 
difficult to understand the key drivers of results and risks increasing users’ 
reluctance to engage with and trust model outputs. The community of potential 
users for such models is still being defined, and for the time being, may need to be 
limited to those who have considerable experience using and interpreting 
simulation results. For this reason, the current utility of standard tools and 
interfaces for analyzing model outputs is questionable – those with data analysis 
skills and knowledge of the models will want more flexibility to analyse and 
present results. 
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Developing the integrated case management model required harmonizing the 
workflow of a large multidisciplinary team. The core program is now entirely 
written in the general purpose programming language C++; the project therefore 
required interacting not only with developers of other models components (in this 
case, the within-host and drug action models), but also with those developing the 
code. While a complex code base increases the functionality and versatility of the 
simulation platform, it is quite obtuse to non-programmers. This remoteness of 
modelers from the code can inhibit interaction with the models and result in 
mutual dependency of modelers and coders, which can slow down model 
development. Efforts to develop user interfaces for experiment creation are 
challenged by the ever-changing code base.   
   
One of the objectives of the literature search presented in this thesis was to add 
geographical specificity to the case management model by defining parameters for 
particular places. However, data was found to be limited in geographical coverage 
and by study methodology. Also, case management variables are very dependent 
on local context, change over time and can vary substantially within a country 
[173]. This leads to considerable uncertainty in case management parameters, 
arguing for the use of sensitivity analysis.  The costing model should also be 
expanded with additional data from other settings on the costs of febrile illness so 
that the effects of variation in cost parameters can be explored; some of this 
information is compiled in publicly available databases, for example through 
WHO-CHOICE [286]. In that vein, a probabilistic sensitivity analysis varying 
health systems parameters and costs was recently carried out using the five-day 
time step model [287]. 
 
Moreover, the complexity of health systems makes it difficult to characterize 
countries in terms of a few variables related to malaria case management. 
Countries may perform relatively well on certain aspects of case management and 
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relatively poorly on others. Therefore, allocation of countries to case management 
categories was not found to be feasible. Rather, it is considered more useful to 
simulate ranges for each variable, without referring to specific places, or to apply 
the model to specific settings where data is available.  
 
Health systems are dynamic, and interventions to improve malaria case 
management may have numerous effects on the rest of the system. For example, a 
reduction in the end-user price of malaria drugs may modify patterns of treatment-
seeking and self-treatment, prescribing practices and adherence [288]. The case 
management model offers the possibility to combine quantitative modeling of the 
feedback effects in health systems with dynamic models of malaria transmission 
and cost-effectiveness analysis. Whether the models can be useful to answer these 
types of questions, or whether they are best explored outside the models, is still 
uncertain. 
 
Once the one-day time step models achieve a satisfactory fit to data, they should 
be illustrated by applying them to several simple questions. First, the effect of 
drug stock-outs could be simulated by varying case management coverage in time 
and exploring the effect on health and transmission outcomes, relative to constant 
coverage.  Another immediate research question is the cost-effectiveness of 
different levels of diagnostic testing.  
 
In the longer-term, it would be important to fit the parameters of the 14 sub-model 
variants, incorporating different assumptions about decay of immunity and 
heterogeneity in force of infection, treatment-seeking and co-morbidity with the 
one-day time step model. This would enable investigation of the impact of model 
uncertainty, and comparison of the predictions of the different models. 
 
7. Discussion and Conclusion  
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7.4. Conclusion 
  
The rapidly changing malaria epidemiology due to factors such as intervention 
scale-up [26] and urbanization [289] in much of Africa requires that policy 
decisions be taken urgently. Models are necessary to inform these decisions, and 
the results of multiple models should be compared against one another towards 
assessing their validity. A major challenge for the next phase of the project is 
increasing the application of the models to help guide research and policy-making.  
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